var title_f37_30_38368="NuvaRing PI";
var content_f37_30_38368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F81410%7EPI%2F73663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F81410%7EPI%2F73663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    NuvaRing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 246px; height: 246px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD2APYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooqOeaK3gkmuJEihjUu8jsFVFAySSegA70ASUViHxb4c/6GDSOf+n2P/wCKpP8AhL/DX/Qw6P8A+BsX/wAVV+zn2ZHtYd0blFYn/CXeG/8AoYNH/wDA2P8A+KpP+Eu8Nf8AQw6P/wCBsf8A8VR7OfZh7WHdG5RWH/wl3hvH/Iw6P/4Gx/8AxVH/AAl/hr/oYdH/APA2L/4qj2c+zD2kO6NyisP/AIS7w3/0MOj/APgbF/8AFUf8Jd4b/wChh0f/AMDYv/iqPZT7MPaQ7o3KKwx4u8N/9DDo/wD4Gxf/ABVL/wAJd4b/AOhh0f8A8DY//iqPZT7MPaQ7o26Kw/8AhL/DX/Qw6P8A+BsX/wAVR/wl/hr/AKGHR/8AwNi/+Ko9lPsw9pDujcorD/4S/wANf9DDo/8A4Gxf/FUf8Jf4a/6GHR//AANi/wDiqPZT7MPaQ7o3KKw/+Ev8Nf8AQw6P/wCBsX/xVH/CXeG/+hh0f/wNi/8AiqPZT7MPaQ7o3KKw/wDhL/DX/Qw6P/4Gxf8AxVH/AAl3hv8A6GHR/wDwNi/+Ko9lPsw9pDujcorD/wCEu8N/9DDo/wD4Gxf/ABVH/CXeG/8AoYdH/wDA2L/4qj2U+zD2kO6NyisT/hLvDf8A0MOj/wDgbF/8VR/wl3hv/oYNH/8AA2P/AOKo9nPsw9pDujborE/4S7w3/wBDDo//AIGxf/FUn/CX+Gv+hh0f/wADYv8A4qj2c+zD2kO6NyisT/hLfDf/AEMGkf8AgbF/8VR/wl3hv/oYdH/8DYv/AIqj2c+zD2kO6NuiseDxRoE88cMGuaVJNIwRI0u42Z2JwAADySe1bFS4uO6KUlLZhRRRSGFY3jTH/CHa7kZH2Cfj/tm1bNY3jT/kTte/68J//RbVdP416kVfgfoeL6NpOmNpVtLPZxs7J3FW10bScc6fD+VO0U/8Seyyv8FXuXDM3AFfUNu58Q5O5nf2Lpf/AD4Q/lTG0XS/+fCH8q0uexpjZ9aabE5MzP7H0wHH2GLH0py6RpXewi/KrxPbNAAPU1pchS82Vk0nSe2nwn8Kl/sbSD/zD4PyqYbVI71KGHpUO/c1jNkKaJpAHGnQE/SnjRNI76bb/lVhWwOmKeGzWb9TVS7lb+w9I/6Btv8AlR/YWkf9A23/ACq4OnWjPvU382Xcp/2FpH/QNt/ypP7D0j/oG2/5Vdz70Z96L+bFconQ9I/6Btv+VIdD0f8A6B0H5Ve3e9IW9qfzYXsUDoekf9A6D8qjfQ9IzxYQj8K0SR6Uwnn0ql6mbkZzaJpI/wCXCH8qjbRtK7WEP5VoOc/xVGxI6GtFfuZtvuUDo+lj/lwh/KmnSdL/AOfCH8quMW9aibdj71WkzGVRrqVjpOl/8+MP5U1tJ0v/AJ8YvyqwS2OtN3HuaqxDqvuyo2k6d/z5x/lTf7K07/nzi/KrhbNKBmgnnl3ZRtrC0tfEnht7a3RXOpQAkdv3i19E18/DP/CR+G9o5/tKDP8A38WvoGvDzb44+h9TkTbpSu+oUUUV5B7gVjeNf+RN17/rwuP/AEW1bNYvjf8A5EvX/wDsH3H/AKLarp/GvUir8D9DyTRM/wBjWR/6Z1e/velU9B50KxP/AEzFXgPlY19S9z4lrUjpCKkxTSKEKxGw9qTFSkUw1VybABS0AcUGgBytg+uakU7RzzUQI59aI5DGSCN2e1SykyyDlcg4FCDHJIxTEjc/M3yD34FRPc2UZPnXcQI7BxU7miv0LeQOVFNIB5PFUl1fS3fb9rAx6GnnVdIIy13n8amzW6ZS12ZbzkYOMUzBXoeKrpq2lSHaLpQPUmrET285xDdQsO2HFH3ibS0EOD1601hU0iSLxsyv94VGQF4BzVJ3VxNWZCy0zFTkUxlqkyHG+pXYVEVq0VppSrUjGUSiVOaRlq0yc01krRSM3Aq4pRxU/l0mynzE8hTPHiLwwfXU4P8A0YtfQVfP84x4h8L/APYUt/8A0YtfQFeFm3xx9D6nIv4UvUKKKK8g9wKxPHP/ACJPiD/sH3H/AKLatusTxz/yJPiD/sHXH/otqul8a9SKnwP0PKPD/Ph6w/65irwB5HaqfhsZ8PWH/XMVp7OtfTyerPjHG7IdpxSbDVjFG2jmHyFfYaa0dWcUhFCkJwKoQngdetIRhQWHB6/7NWVTc2FG5+yjrWZrWvaZogZ5n8+87woeh9xTTbdo6kSiktSzL5NvAZ7mUJCBnce9c7P4zti5j0q1NzLnAYVlS2mpeK5GvdVc2tkvKRj5Rj3qcahYacqW2i263V1j70YzzXTGlFay1Zyzrv4aaux88HiXVi7XV39ltDyV6YFZjaHpMc4WS8ee4/ujPNbMOka7rEqy6rKbe26lFODiuu0+OLSYkWytoJJB/HKmamWI9mrRWpccLOp/Gqcvktzk7Lwtc3QH2Pw/JIv98yYzV0+CdSVcr4ecn082uqm1TU5cb5kj9BDxTTfagwy11IT/ALLGsfrGIa0t+JusJgo6e+/mvyOB1LQhZoTqeiS2yjuHJrOtdI02aUNpeovDN/dbIwa9UTWNSVMMLeZf+mw3Vk6vYW2uwsLmCO3lHRrddvNXDFVNFNfdqRLB0b3pVJL12/A5i3m8S6U+ZJ/tdqP4R3FXbXxnZmXydRtDZseNx5zWZ/Z3iDSHY2sn2izX+FuWxUJ1bSNXBttQg+yXQ4IlGD9RW/JTqa/kc0qlaju+Zfed0rRzQrNayCWM8jFNyDyDk919K4iAap4ZIm05vtVg3Vepx7V1Gk6zZasn7gGKcf6xH6isJUpR21RvTrxqLzLpcf3ePWl27RhuSeRTSxTMTDr0NNJIIDdRUpcxY4qCaaVFLmjNMLIYVHpTSKkzSUXJ5UZ16MeIPCuP+grb/wDoxa99rwS+/wCQ/wCFf+wrb/8Aoxa97rxs1+OPofR5L/Dl6hRRRXlHtBWJ46/5EnxD/wBg64/9FtW3WJ46/wCRI8Q/9g64/wDRTVdL416kVPgfoeW+GRjw9p//AFzFah4JFZPho48Paf8A9cxWsT81fSy3Z8ffUd+FFNzRmoLuKAGzjt1pMbmCqPvcKfejeAckfKOtU9evxpOg3Fw5AZwRD/vUdRN6eXcpeLvEEPhuxMVvtm1mb5UVOQoNcvpGiwWqNqmtMrXEnzvvP48UzwzprDfquqMZZWBk3P8Aw+1SaXpVx4w1F76+doNFtzwnTfXfCKoRevq/0PNlKWLlaGkURp/aPjW9+z6fvtdHQ7WkI2k12ujaLp2gR+TYxLJKBzMRzmrg8qO3SOziEFuo2qB396SMAjaowT1auWc5T02XY7KNONJWiOYyOgMrls9jTSoOMcCncAlQ27FFStDReQmxewwaTbgYHFPpeKGDRBj1oZckEHGPSpsCmnFFxWuNWR0OQxx6Vk6z4e0vXlZLyEQXD8LcIPmzWvimEYPXaP73rVX6p2E13PMxe6j4O1A6bqaST6aT8kwG44960NSso7uOLU9FlCyHlljP3vrXeyCGWMwX1usts4xyK841+xPgLWIr61YyaRfN+8TqIa6IV+Z2kjjr4b7dJ6nUeHtZGrQC2uFEWpxdV7EVpv8AeK/xj73sa5O+SN4otU0k/wC2XXuPSuo068i1HT0nh/1gGJF96VSHI+aPUKNR1obWaHD3NBdQcc0pAzzwaGYgYC5FSjRLuL2ppNJmkpWE7FK//wCRg8K/9hW3/wDRi175XgN4c6/4V/7Ctv8A+jFr36vGzX44+h9Jkv8ADl6hRRRXlHtBWJ45/wCRJ8Qf9g+4/wDRbVt1ieOv+RJ8Q/8AYOuP/RbVdL416kVPgfoeU+HGB8PWA9IxWjvy1ZHh1saBYf8AXMVohvmNfUOOrPjL6ssb6A+agD+tLvxU8ocxah5cggCMjLMegrgNQu5/FOviFDt021fv3I710HizUWsNCljjJEtzwlZfhrS5ls0tIP8AXT8sx681vh4csZVJHLiqsny0o7sZdM+uakmi2XyWSfNLIvqO1diNlrbQ2tuqrFGMEDoao6dp0ejiWCPBmJ+dvepsgHa3J7ms5vn9DdRjRXJHfqTttBBGcelG8tnPT2qEtnp0pQ1TYrmJh8gxH0PXNLuqIP70u4UrFcxLmjNR7hSb6LBzIm3UhNRb6N9HKHMiXNNfDdegqMvSF6LE8w8nPLdulRXtva6nYTadqUYlt5xggDkemKC9ML7TvHLr90VXLfcXOo6nndqtz4O8RtoF4TLp03NvJ2BPQGuhtJG0fVQV5hfhgOmas+N7Eal4baVVzd2BNyGHU+1Y2lXq61okFyv+sUAyDuDXVR9+LUjhxC9jUVWPzOzkG9gWI554pvGDg1XsblbiyB/iWpQy4xWFnqdUmnqtgPSkpu6kJppGdyld/wDIweFR/wBRW3/9GLXv9fP9yc+IfC3/AGFbf/0YtfQFeNm3xx9D6bJP4Un5hRRRXkntBWJ45/5EnxD/ANg64/8ARTVt1ieOv+RJ8Q/9g64/9FtV0vjXqRU+B+h5BoH/ACAbD/rmK0M8ms/QP+QDYf8AXMVeH3jX1b3Phm9xTkYz3pTkfepCOmTz1pkjnKL3ZgKFqK+hjeLUa4m0xP4VJJFbvhO1a6uL28DbLe3hyrf7Q7VleKXH9pW1ug+aLr+NdNpMosfh5IwXEk8rR0q0pKhFL7Wn3smhBPFylLaKv+H+bMtJGmBlPBc5J9aczkAgLknvUMAKW8SN1ApxanYakSlsHaOnrRn3qINSbqdg5iXdS7veod3NG6iw+Yn3+9N31CWpN1NRFzk+/wB6N/pVfdSFzRyi5yxvpN47mq+40F6OUXOTlx60zzNjq/XHaoi1ISWBFVy6E85YhZdzRSfNHNxJn+7Xn+io2h+Kb/TZMrBcuXgU91rtmf5cjt1rmfG8Hl6rpmpR/wAChCfrV0vdl6kSXPTlF9rnQ6UNkMyqOV+8PSpzJhRx81M8ORedfXMWc+YoP6VFuw8gP8LlamWk3EmE3KlGb6lgt703dUW6kLVVg5yOY58QeFv+wrb/APoxa+g6+eGbPiLwsP8AqK2//oxa+h68HN/jj6H1eQu9B+oUUUV5B7gVieOv+RI8Q/8AYOuP/RTVt1h+Ov8AkSPEP/YOuP8A0U1XT+NepFT4H6HkGgf8gGw/65irw+8aztBbGhWH/XMVeLcmvrXvc+Ebtf1HtliGpeGkQn+FgajzwT3IxT4Dlie4U0mgvsc7rVybnXb6ZP8Alnt4rttSIHgDTCnGZ8mvOLVzJqOp/wB8V1Onakbvw1DYSnLQy+ZiqxEGoU2tbNfkY4apetXT6p/mTEk8tSGkBJGW/CjNNq2hdxaDSbgKTNIQUUmaQmqSBsWkzSE0U7EsKQmkooRIFqTNBpDTsAE0b9vNIaB15FAttQX5SR/erJ8XxF/DZxyyTLg1rYJlwelVtaRG8K3bt0EwpN6p+ZdH4vKxY8FOx1/TwTxKCD+VJdr5eoXaf9NW/nTvAKB9f0r2DfypbzB1K8kHUzMv605v/aH6L82Y0V/ssfV/kiCkzUmBTcCqRNmysP8AkZPC/wD2FLf/ANGLX0VXzuf+Rj8Lf9hS3/8ARi19EV4GcfHH0Prsg/gP1CiiivHPeCsTxz/yJPiD/sHXH/otq26xPHP/ACJPiD/sH3H/AKLarp/GvUip8D9DxrRSBodh/wBcxV1mHNZ+hn/iTWQb/nnVzoSc5FfXtaXPz+Ulr6kmenpTlbbOjfwnioGbGKGfDJnoKTiDexzSqIfF2qRHhGxiodHvXtPFL2z8xSDArQ15ETW7SXobg9fWsPVT9m16zvCcRiUBvpXWvep28jicuTFX/mO7lGyVlHQGm5onZfO81SCko3LURk64HNcsU2tTr5l3JCaSmB9wz0PpRuquVhzLuSijFR7yO9IZKaT7BzLuSYpcUxX9aPMFJphzR7km2kIpnmil3gnrRZhdBil200sMdaaZAByaLMTkuo7bRtAVvWo/OX1oMqkcHnsKaTFzRehMR8v1rG8ZXSQaJHpqn97PIsn4VqJOo/eykBY+SPWuGmun1vxSZlXdFGdqjsBThDmkk+mo1U5IOXkegeCAtvdG5P8Ay7r/ADFQ4Vp7hj0eQv8AnVe2uBbm5hU7dwAOKPtCD5Qc470mm5yl6GcZKFKnTfQsYWkIWqrXMY7iomvYwetUosTqpEzY/wCEi8L/APYUt/8A0YtfQtfOFvcLN4m8Mqp6anbn/wAiLX0fXgZwrVIryPreH5KVCTXcKKKK8c94KxPHP/Ik+IP+wdcf+i2rbrE8c/8AIk+IP+wfcf8Aotqun8a9SKvwP0PDNDmDaPaqzYISrSygAgvXH2Vw62UOGIwMVYNy+QNxxX3caOmp+X1cS1J6dTp2mBYDdStMrfxCuX+1vnO4037S2Sdxp+xRk8TfoaXi0SS6VFdQHMtqcjFU9fiS+0BJ4jlvLBOOzVGl0QCGJZG4I9aboEoSW50q5I2uC8ZPqe1CjyaIbqOpZ21RpeFNTF9oiJK37+2GzB71qNcKoD7vqK4Rkl0nVcp8qdGHatYzFkDqx2ml7FNl16zunBbnStMu/IbGR0o88f365j7QxOWY5o88/wB41XsF3MniZdjpjOuPv0ecv98VzJn4+8aaZz/eNHsF3F9Yl2Oo+0KP4xSfao/WuWMx/vGk85vU0ewXcf1iXY6g3cfrTDdwg8vXM+afU0hk9zT9ikHt5HStqEQ/iqF9TjHAOa58yUmd3TrR7OKF7WZsSaoO1RnU8DcOo6Vk4weadHGZGwCBiq9nEpTm3ZMvXeoP9ml3N99cYqTwlZ+VHJcMNq7Scn1rLSJr+/jt7bhgfmz0ra8S3MVnaR6Tbn94/wAzsvasrr4UbSi4pRb1KEd9LmdnJLE8Gk+1yiPOTk9aqZChFTnHrTicnK9a2UUjnnJtkzXLnuajaZ/U0zOabVJIlN9TR8OMzeLvDm4/8xK3/wDRi19V18peGf8AkbvDn/YSt/8A0YtfVtfK57/Fj6H3PDX+7S9Qooorwz6MKxPHP/Ik+If+wdcf+i2rbrD8df8AIk+IP+wdcf8Aotqun8a9SKnwP0PlqBv9Ejx6VJvPXNRW4xaR9+KkIIUjFfoUfhXofllS3M/Vi7jRk0mDTgpNVoZaB8wXIOWP3RTbkHKzxk+dF82fX2p6KVYk8n+H2oVcN7dcUn2LjLlaZsOIPEOlCWMBbiNcOO5Nc9bSSIGtnyCpqzA8un3gurc7o/44R/F71qXdhHqcf27TWBkPLwjqKxu4OxacV10f4GYe3NGaagMTeXNneOoPapxFvP7n5x3NaRmpEVKUoehFnmjNTLAxzgZx1pwtmI6VV0ZWfYr8UlW1tmPUYp32N/7tLmRShJ9ClS8VdFmx68UosSTycelJziV7OfYo0oGR8vWrwsjnBP6UpsSFLFwoFL2kRqjUfQpoPO+UcGhgV+Rc7vapwP4Y1O7pkVopFFosC3uoKJWf/Vw92NYTq82iO2FFYdXl8XRCx20OiaS1zOQL6UYQd6wEV8ma4JeaTnJ7VoyxTalcC7vmOw/6uL+5TDanc2GqqbS3OacZ7bsphcAmmjK/jV8WjbMZpn2RgMZzWvMjL2c+qKeKSrZtnHao2gcfw5quZCcJLdFjw1/yOHhz/sJW/wD6MWvq6vlXw7GR4v8ADhPH/Eyt+P8AtotfVVfLZ7/Gj6H3HDX+7P1CiiivDPogrD8df8iR4h/7B1x/6KatysTx1/yJPiD/ALB1x/6Larp/GvUip8D9D5btR/ocf0qY4pLRS1pEB1xVhYTnJHFfoEZaI/Kp3c36sg20oRz0FW1hx2qxGntSdSw1QmygkTntTxbtmtJFIP3amCbu1R7VmscL3ZmpCychck8Ee1NFlc2Li70qTLnl4ya11QA85zUix/LlSUb271nOpc3hh4xTv1KM7W2pbTKBBe/xA8A1Uktruyk3OgMX+yK17iyhulUyjy5FOd69ahZr2w+aRftFp6nkgUe69DRe0pKy96PYr21xDKPmXZ65q7HDG3KHIqERWGoAyWzOh7hhjFRGyuIuYZAVHoah3RpCVCeifL5MvC03/wAJpy2xPQGs8tdKOHk/Kl+0XXGMjNTzPqdH1ZvZ3NA2xH3qaI4cFvMXcvas+QXUrYZ5FPqBUkVlJJ8rMF9Sxxmkm3sJ0oU9akrE9xcxRR5O0sfSqMcF3cuXiRiD19MVdWC2s4zJdnzAOgXmpF+33sf7ofZbY8Bl4bFP1Zn7V81sOvn0I4Xt9MUvbxme7PVeoBpsFhPPK17qR37+Ui/ufhWja20dipEOZZD1dutPMRwSXJZutJ1F0FGglJyk7soPGZXDuNqDoKGiGflHWrrJgAEZFNKcFucjoKOYvkZQMZ9KbsOelXyOOhqN42Hamn5icGUniOaRozjnFWwjfxZoeEnpVJk+zbK2lqB4q8NMB11K3H/kRa+m6+arSMp4n8Mccf2pb/8Aoxa+la8DOXepE+myOKjRa8wooorxj2wrE8c/8iT4g/7B9x/6LatusTxzz4K8Qf8AYPuP/RbVdP416kVfgfofNunxA2kBx1WriRjpipNLg/4ltscfw1cEGCM9K+159EfAOi027bspiL2qVI8dquLDjrTyyJ6UnIaplVVGMdD6YqVYz2p32heiR7j9Kkja5f7qBfqKltlqKESJj2p/lsP4alWC4b/WMo+lTi0H8bE/Q1m5x6mig3oiuqHHzLxT1BQbU+YdxVyO1iHTd+JqRIYFOEVgfU1m5xNo0pozZLeGXh48E9gMZqOHSGcN9mBU+5rZjyjEFVJ7HFKruM7eCe4pe2kti1hoy3/IyYNJ1AZErgL64rdtvC1rPZCS41VBKOg21GvnquWfPtSSRGRVLEg+grOdWq/hdvuLhgsOvjpmZdaPeLK0cVyGj7HFQxaE7zg3d15iAcqOK2yrDjccY9aZsO0jn61Xt6ltWH1KjF3hGxSWytYQVitTj+8TmpGAwM+nYVeAKRADBp+CQCqrj6VPte5aoWVomSfLJ54/CkKRMRmTH4VrlVbhox+VNa3iPVKftVbUl0JdjNEUZHDik+z47g1eNlC3qKiawjz8hfP1pqpEl0Zdiv8AZ2PQCmNB8wz1FTPZTKCUf8zUKSzxkqwBqleWxLjy7xGSwg9RiovLA+7V+Jw4+daeYAfujFHO47h7NS2MXbt8S+Fzjrqlv/6MWvomvBL2Pbr/AIWwP+Ypb/8Aoxa97rx80d5x9D3Mqjywl6hRRRXlnqhWL43GfBmvj/qH3H/otq2qxvGv/Im69/14XH/otqun8a9SKnwP0PDdJi/4lVof9irZiG003R1/4lFp/uVZC9a+rctT5BwKMqPj5areWxPz1qlCeBSi1LfeFUp2M3TuVrNY0xxzWhkN0NRC0I+6OKkW3Yd6iU1LqaQptdCQJ0yc0/y6YsbZ4NShWA5rJu2xuovsOEZxTxGaFLYqRd1Q5GqiNEJNPWE+lSKGBzUgLelZuRpGIxYfan+UKcC/pTwDUOb6GigR+SKTyfarAUmjD9hU876lqmupCIh6UvlgdOlS7JD2oKOOvWjnD2a6EHl05UXBzUhhcikFu/OafOHsyLCCo2K5+XrVlbf1oNuoPHWqU0Q6TM59xziofs5Y5IrYaFR2prRqOgqlU7EOkupnx22Oal8rPFTkYpMYpubBRSMrUI8a54Y9tTg/9GLXt1eLakP+J34Z/wCwnB/6MWvaa83Hu7iejgNpBRRRXnnoBWR4vjkm8J61FDG8sr2U6pHGpZnJjbAAHUn0rXopxfK0xSXMmj56sE1e2soIZPDWtsVXHFnJx+lTGTV8bR4Y1vH/AF5yf4V7/RXp/wBqT/lR5n9lw/mZ4AJdWH/Mr65/4Byf4VIt1qg6+FtdP/bnJ/8AE173RS/tN/yof9mR/mPBvtuqDj/hFNe/8A5P/iacL/U/+hU17/wDk/8Aia93opf2i/5RrLkvtHhQv9TB/wCRU17/AMA5P8Kf/aWod/Cevn/tzk/+Jr3Kil/aD/lH/Z6/mPEBql+Bx4S1/P8A15yf/E04avqP/Qpa/wD+Acn+Fe20Uvr9/s/iUsDb7X4Hif8Aa+oDr4S1/wD8A5P8KcNavs/8ij4g/wDAOT/4mvaqKX11fy/ix/U3/N+CPGBrV9/0KXiD/wAA5P8AClGvXv8A0KHiD/wDk/8Aia9mopfXV/J+LH9Tf834I8a/t6+/6FDxB/4Byf8AxNOGv3v/AEKPiD/wDk/wr2Oil9bX8v4h9Uf834Hjv9v33/Qo+IP/AADk/wAKP+Egvv8AoUfEH/gHJ/hXsVFH1tfy/iP6o/5vwPHf+Egvv+hR8Qf+Acn+FH/CQX//AEKPiD/wDk/wr2Kij62v5fxD6o/5vwPHP+Egv/8AoUfEH/gHJ/8AE0n9vX54/wCER8QD/tzk/wDia9koo+tr+X8RfVH/ADfgeMnWdQP/ADKmv/8AgHJ/hTDquon/AJlXXv8AwEk/wr2miqWNS+x+Ingr/a/A8V/tLUv+hW1z/wABJP8ACk/tLUv+hW1z/wABJP8ACva6Kf1/+6T9Q/vHiAbU9R13w+q+HtYt44dQhkkkltZAqqHGSTjgCvb6KK569f21tLWOihQ9jfW9wooornOgKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ring stays inside the vagina for 3 weeks at a time. It delivers hormones into the body that help prevent pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.nuvaring.com. Copyright &copy; 2004 Organon USA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    NuvaRing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This ring stays inside the vagina for 3 weeks at a time. It delivers hormones into the body that help prevent pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.nuvaring.com. Copyright &copy; 2004 Organon USA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38368=[""].join("\n");
var outline_f37_30_38368=null;
var title_f37_30_38369="Vertebral NTM osteomyelitis on MRI";
var content_f37_30_38369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F85856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F85856&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    MRI of vertebral osteomyelitis caused by nontuberculous mycobacteria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MRI: magnetic resonance imaging.",
"    <br>",
"     <br>",
"      Spine MRI of a&nbsp;39-year-old immunocompromised man who&nbsp;developed M. fortuitum spinal infection thought to be a result of paraspinal steroid injections for low back pain.&nbsp;The T2-weighted MRI image demonstrates enhancement within the L4 and L5 vertebral bodies consistent with osteomyelitis.&nbsp;Culture of a biopsy specimen of the vertebral bone grew M. fortuitum.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Dr. Shannon Kasperbauer and Dr. Charles Daley.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38369=[""].join("\n");
var outline_f37_30_38369=null;
var title_f37_30_38370="Radio-opaque nasal foreign body";
var content_f37_30_38370=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86434&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Radio-opaque nasal foreign body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 413px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGdAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5lT5lwDkCuw+G8QOpyHqcYrjY5PlAxj6d67z4axE3E0n8IFAHWsFF+wx0NfQfwQ1c3FrNZuegyBXzxnfqDYOea9D+Fmtf2T4khDHCSHaaAPpeVgg3N0rH8T6BaeIdNeCdVLEfK2Ola86ie2IU5DLkGuNt/E/9mag9lqAO1TgNQB434g+G+p6RdO0MZeLnBFcjNpt59o8ryX39MYr67gvrO9gDLJG6EdCag/sLSzP532SLf1zigD5v0X4d6vqoDCEqp9RiunHwYvTEHMo346Zr3WSe1sYvmaOJR26VnDxLp5fCy5A70AeB3nwt1uCQrHFvX1FRJ8MdfYDbBX0RHrunueLhR9aV9e01GAa7jyeAM0AeNeH/AIO3MxD6rII19O9b2q/BzT2tCbGUiYDv3NelXWr2ttb+fK+I/Wl0vVbXUoy9rIGx1HegD5B8QWU+h6rJZ3SFWU45qpIFZAw719M/E74e23iy2M0G2K/UcN/erwm8+H/iHTpTC9nI4B4KjIoA5vaIkBbrQpknXbGpb1wK7vQ/hbrerSp58f2ePuz8V7T4R+Hej6BaBXhS5nI+Z3GRQB8wPp15Eod7eRUPIO3imwghsE9fzr7EvtD029tjBPaRFCNowoGK+Zfi14Tl8Kax5kILWcp3IfSgDlpo2MoB6UyVvLUg9aRLoSRI6nnvTWlDdRkUAMjy3J4FPHyggU0yrtAxgChZVXPfNAEinpzzTjH5ny5qMuCBj8KmicKvFACN8p2cUjkYJTrTHO+YelPJCH60APhYbcNUTRAzHHSrClPL96YwCkNxg0AOAULgDNRv8vI4pwZScZpCQTt60AMhcEk1Z8wGPB5FVli2Scj5akcYbjpQAPgjjgVCwBI5/CrAUMMGmPGFPynI9aAEkRRH8vWmxnafm5zUkeG4PWnFQXAIoAa4V2G0H3pSuDtqRl8tsLQyrt680AREjGByTSPjcVPpSMmX4+7TpI8MDnmgCBP3Z9qcxB61Z8tWGTxTZEBXoKAGY5HP40xn2N7Vasra4u5RFawvI56BRmr134P1yFPNmsZVTr0oAy4wHYHt60HaGIPaiQvaqVliZWHHIxVe3dZXJb8BQBYDqDwvFDplDzzTsbN3FVyznPpQA5B5Ywec0Z3nnpUkA3DDd+lDoUc+lAEZcL8veg5z0604gA56mlDBm4oAkiTe4QDk19D/AAe8MJpul/bpkBml+7kdBXnHwy8FzazfJc3KEWyHOTX0E7xWFtHbxALhdqKKAGzTNNeCFR8g+8a4v4teJF0bRzbQNiaUY47Cus1C8i0fTZby6IBC5r5l8a+IZvEmtyyMT5QOFHbFAGVbO80rTSZYsc013zJiptpjhG0dKzLiYo+4delAFxTvfiuB+J8Z+zxtjjNdtaSmQ59DXJ/E8A6ap54NAHllFJRQBbjJCjcOO1en/DqIx6fLL0zXlqZ3Ae9eweGU+yaAh4GRQBesIw16xJxzmrnmta6lG6HG1gaq6Z8z7j0qS/OZxjqKAPrnwPqA1LwzZT7tzbApPvXE/Fe08i7iulwAw5q98D7pp/CxRv4G4rQ+K1l9p0DzAPmjNAHkaaxc2xQW8rDHYGut0rxZei1xI7lu1cJpcJ80u43AV2Hh/TZL+XeIyIlPJxQBX1i51bVeYvMKfU1v+GtMgt7LzNSlUMecE9KyfF/i6y8PWpt4djT4xgV5FqPibVNV8wrK6IT0BxQB614m8QaPZyFIZkLL1wa52DxhpKXAkdiWB6Zrxy587zGMspY/WqIjeWQYY/nQB9H6h8TNLubDyCBjGOTWXpXxGsNLbdAx/OvB7m3uFGU3EAVHBDK/UmgD6v0X4yaRORHefI3rnrXVWnxB8OXRAF9GpPZq+L0hlzhc5qxHbXQOSWH40AfbcnifSVi3peROMcBWrKl8WfaCVskBHrmvkWOXU7cfJLJj/erpdE8Xajp8Y3OW9jQB9SeH9ZkvXaK4j2uOh9ao/Ezwwvijw1PbKoNwg3RnHf0ryLw38WI4J1W6UK3Qmvb/AAx4jsNetFltJkLd13c0AfHkmn3OkXstpeRsjISuCMVNFCCfUetfVXjXwFpfieFmljWK7x8sqjv7187+NPDF/wCEL1o7hCYSflkHQigDn54FC/KOTUItwFznnFXo5EmtwR+NV92ScAgUAV0HIB7VNsO8DNOVB1JzUuMdMHNAEDKQCcVGzEttzk1ZHpgdaZ5I8wseaAGwI0nQ02dZGOCTxUsLEOVzjPSnT8DpzQBDE3Y9+hp6/K3vSRqvLEGkX5punWgCcbmHtUcuVKgnjtUwGwYNROytIATQAoUrkjjNI3GNx61OyjZ6nFV5WAwAM0APEWW+U4zUoBjI3fnTIEOAc1JIpdlRec+lADoVe6nWK3Qu7HAAGa9b8G/CZrq3S51tzErciMDnFdD8JfBFrp+nRaneRB7mQZQMOFHrXpc88cCbpCABQBw03ws0B4diI6Nj71cxq3waDZaxux7BhivThq+/JiiZl9R3q5a3gnXOxl+tAHz3e/CnXoGxCiyDPUVp6H8HtQmKnUZliXuO9e7mUL1qnqF+9vAzwwtKw6AUAZvhjwhpXh63VLaFXl7yMMk1tTTWjHypXhP+yxFee674l1honVITAvTIFcZHeztIzySuWznJNAHq+seC9C1hWM9pGCf4kArzbxP8Fhh5tEn56iNqsaX4pvrJvklLr/dbmu10Xxza3LLHer5Lnjd2oA+ctZ8Oavo8pjvrOUBf4tvFZLnC4PHtX2VItlqUGJFhnjYdwDXHa58L9C1NmeOM27n+70oA+aUKkc8Us20J1JNe2yfBWHzsx3vye4rY074R6Rb4+0SPKR1oA+erC3uLqQRxRM5PoK9R8DfDCe+ZLnUQY4s5we4r2DTPCui6SN0FrEpH8TYqtrHi2y08+RbgSy9AF6CgDQi+xaDYx20IC4GAo6mhI1RWvrtsYGeTwKydHtJNRlOoXxIB5CnpivNPjV8RBbRnSdMkBc/KxU0AZvxU8bvq9y1jZSEQKcHB61wNqFTlupqhpIYo002SzetaQZX5oAmdhsPOa5/Uph5uBWjc3QjJQiuY1K6BuAFoA6DTXUL9awPiXGraKzjqMcVs6W26IHHbvWR49YPocuOoHIoA8hopKKALtmpa4iUDvXslqgi0m3jb+6K8o8PxeZqkCkA5YV6/NF8kKKe3SgB9mhVcgdaius/aAPf86vMfJhTj60aTZvqOrQxIpO5gMUAfRfwUszb+F/NcYMhGK2/iLdLb+HJwwyW4FafhjT10vQ7W1UYKIM/WuG+Kd1LPcw2MPIxkgUAcb4D0uTV9V8tV/djlj7V6H46v7Lwf4YcptVypC+pNa/gbQ4dF0ZCVAmkXc7V88/HjxVLrfiJrC2f/AEeA7Rg9aAOAvb+fV9TlubglgWzVwDapCcAjpUVvCLe2A4Jx+tLGXyCelAGbdRv5hJ6GoUjaNx65rTvJQ2Ao5pgtJXQORxQBeto1lt8Ec4qOO3RG5I4qW1R1iKnqOlQTQS7ic5oAnHkwtu4yabNcKxAXArPmt525zxUbwzCMsudw96ANxSRGSMHismW+Ec21wME1SF5dRZXBI96o3cpeQFqANq4ghmBkQ7Wx2qDSvE+q6FeB7G6dNp7GoLOCS7AVH+tWbzSPKg3Hk0AfQHw3+NMV8IrPxBhJeAJa9O8WaLY+MfDckAMcodd0Ug5wa+HreOUSgRt8wr2D4V/EW+0K6isr+RpLNyBhj92gDj9a0+68M6xJZ3SFQrFRkcEVKJFZd6AGvorx34GsfG2lre2hUXLLuRx/F7V84atpeoeHdSls9RiZdpwCR1oAGYbMqMZ4pqFw2OwpAQyBl+7Sjt3PpQBMxDketNOcgGo9x8zngVMx/d5NAEYU7wcDiluVJHGc0yFmc4XmnTbg4Evy0AMjb5SG5NSREFxxihYyFLcYpcAcjigCaZcIfT1qsI+dxP41YkO8BR0FRyRtt4NADzzjrTNoMgHFSQx5HPWoZiFJA60ATBtjdjXV/Dfw5Nr2vRZQ+QjbnJ6VmeEPDV5rV2NqHyQeWI4r1eTXNJ+Hejtkp9oI+73JoA9WaS202zXzZEhhjXALHAAFcDr/AMRNCSUw/aUk2nHBr5u8YfE3W/FWpMguHjts4CKcDFVbS2iKq80xZ+p5oA+hG+Kmm2sR8mPcMcVhT/GgxynybYbe1eVRKpGBytNmto+4UUAeoP8AGaWX/ljgDmtXS/jVZsRHeQbfevF/s0KAHg1X+z28j4BAagD6i03x34c1aIJJLGpYfdYVM2g6LqKu1q6fN02tXy8to0ZDRSspHvVyy8Vato8y+VcuQOcE0Aexat4Zu9OuC0KmSH1FVLayaadRtKk9c1H4R+KEN2I4dUxuPBJr1LTrbS9UiW4tijE85XrQBSh06S00gPBKysBnrXKnxlqlhMVDiVQcYavS54U+yNET8uMV5hqenQnU3jVgcmgDoNH8ftdsEuLba3qOlX73xlBAOw9qxNM8NNGyyBM1U8WaGqBZGBUd6AKfiPxJfaiP9EZxF3xU3gfRxqN5512rEIf4u9bPhm1sXslgQBnPXjrW3rE9p4Y0Sa6bagVSR7mgDmfi14xg8NaM9vauouXXaAD0r5osYptW1B7y7Jbc2eT3q54o1ifxV4iklZmMW44BrRhtxawBVHIFAEjRoFCrgVVb93J6rUsr7Uz0PrVRt0vAPFAFTUB5nzg8VzDHzLzaexxXR6oTFE3OB6Vz9qoe53n60AdLYArEBjis3xhCH0e46jitKB8Qrg1Hrkay6TMGHVTQB4fRTnGHYehooA6XwfGZNbhU8168LfbKpbpXkng5hHrcJPT1r2LeJMYoAj1DBQY4x+tejfA/w+t9qxvJVzHDzz615ndHc4X3r6G+BkCxeHZZAPmZwCaAPRL2dbW1klc4CAmvPvDlrJrfiKa8ulzEhyM/pXWeJ4J7q1WG3zhjzVrQdPXTrFI8DeeWPvQBi/EvXk8OeE7q5ziRl2IPc18eRSvf6hLcytuZ3JOa9g/aP8Rfa9Rh0i3fKQ8vg968osLcQRgk8n2oAsFDu56Cp3WPysDAoXaFy2Kp3UwLlV6UAINiEkjJzxVlLoFQBjFUmUBck5NIhCjJGOaAJnuSJM+lEl3wNnNRS4cgCnoV2c447UASrMGU5/Kn2s6b9jDrVVWzkEcURBRKWz09aANGa1glyQADWDfafgnC55rS80mcYJxVsFHxnkUAc/pkrWU2WBx3rRv9QjmhKg0mqWyspKVzjvsJB78UASxO3n/Kc1t2eZ2BY7XHesG3cCUe1b9g6s6tuoA+jfgr4rE1suk3b/Oo/dkn9K6/x/4JsvFmnskiql2o/dyD19DXzXoWsDTNSgnik27WB4NfRN18QtOsvCp1WRt7JFuKjucUAfOuueGdR8M3clreQsVVjhgMgispHzIQVIr0Dw38b9F8WeJ0stes44beRyiSN0HpmvaZPAXhq9VJorOPawyrxnIPvQB8ryMFkGRwPWpZv9UAOc+leq/GHwFaaPo5v9OO3B5BrzHwXCdS1KK3cZGaAO6+Efgsareme9Q/Z155HWtj42eCrbTtJTUNMj2hThgBXqOlQ23h7RVdUAAUZx3puvrb+JPCtyoHyOh69jQB8n6Xd+bCVYZxxVyQjaOBWZdRjTtamtx0RiKvOQxB9qAHxgbTzzRGx3HPT0piyqDtqeC2uriQJawsxPYCgCIN+8+Wu28C/D+88Q3a3E6mO0U5Zj3roPh38MLi6mS91pfLgByqHq1eq+JNb0zwboZciOPauI4h1Y0Act4u1TRvh7oflRBBOV+Ve5PrXyp4u1u/8SapJcXEjeWWyAT0FdL4w1a88Va3LfXjt5WflBPAFc/qJh8vZEAMdgKAMNYTC2U/OtCzaeRwAx/Cqav8xU9K1dKRtwIHSgDcj82KAMBzWNqepXIIXaQfWt57uOGLD+n51iXU0UzEgDA6UAUF1afbgnmhLuUEEEjvUDxq0hKionZlbBBxQBuw6k2wAtz0qKe63H52zWdGrMu7NPijcnkEigC1HO2/92SD6iu48C+PL7Q7xI5ZnaDODk1wajYc9KmYgpuUc0AfZfhjW7bxFYK8MiliOQDWZP4amXVhKWJjLZzXzb4K8Z3nhy9R4ZGaPPzKTX1L4K8WWPiWwRo5FE+PmTNAGr9qgsYlWQ+1c/4p1C2vbXyYeXPf0rpLzS4rhiWJrldR0cw6igU5jJ5oAv8AgnShbwmeQZZuntXl/wC0j4jaKODSreTBblwK9yt0S1sgBwFXNfI3xKuJNX8cXDMxZA+B7UAZPh20+zxiWTqfWtmU7/mAxnvTGVUjVVGOBikkkYJgdqAKt5yCD0pLZcLu7UHL9ahklaGMr60AZ2sfv3KgjntWTBCUkwT1q8YJZ5mYE0jWjxuCTyTzQBoxIFi6dqZeusmnypnBweKlIItvTFZpzJE+emD9TQB5FeIUupVPBDGiptYXZqdwvo1FAF7RpxDqELtwAwr3HT132kcg7rXgUTbdjLnI74r2bwdfm70mIA8qMGgCe9JWcHnrX0T8C7yOTw68GR5itmvn6+jDSDjnNe4/A3TytnJcbjgCgD1tgM5rP1+/GmaPc3RIHloSPrV/GK82+OOsjT/C8kCvh5O1AHznq902t+Jbi5lYsWkJ5qa4iEaHOapaFGXmaRuSeau6szIhwKAMmaY8jP0FIiZwxJJqBR5pJPQVah7A547UABy59AKimTZyTxUjNiT5QaSUFh+tABAdwORT2QYBFMX5cYqRySMKPpQAZHCgc+tRtHg89aljQry5pki7gG9KAEVPmy3FSp9z5Mmojg1JFlOAKALEQ3gqw5965zWIDHLla245CsmOTUWpW5dC2MigDmQC3fmtC0SZIsgn86hit2ebAGa0rtfs1t746UAZbXU8lwsSElicACvQfFs0uj/DN47mT97KgUAnnJrjvBsCTaubiYfJHz+NY/xT8WPreoLYQt/olscDHc0AcIjtG4dSQwOQRXtvwn+N+seGZLex1CRrrTs7cOclRXinCg8cmnxj5FbPNAH3B8RL648X+EYrrTCGtym8qpzmvH/BFwNN1pDIMMGxzVj9nnx25ibw7fNuRgfLLH9K6bxh4Mmt9Re9sx+6Y7iB2oA9tlKar4bXYc7kB4ptnGth4UmVjjCE81i/C+eS40byJuSgxV74gS/2f4buNvygrigD5c11luPEVw6nILn+dOcYAA5PTAqqkbzX7yKpJLZrcP2bSrJ7u9OCBnmgCbwro4vNSj+2OI4M5JJr3Ual4M8KafHLLc2gcKO4Jr4v1/xvqF3dN9ikMMOfl21zd5qV5eEm5uJHPuxoA+7ZPiUurWEreGTFKyDHJ6V4T4r13UtW1dhrsrq4P3SeAK8j8CeML3wrrCSwyloGYCRT0Ir1rxxcQeIdMg1SxwG25OO9AGbqVzbx2gSNh0xXLNKCxJOQaLbdOyo7EnNbMukKLEuOGx3oA56NgJwR0zzXV6c0YhDYAJrlFhKT7T+tbkbCK2AJ4NAEesM0k2F6dqW1sZHhHU5q/ZQrcruI4HrW1BAkMQAoAwIdJk6MOT3px0wDIINdNGyEfypjKvmYxyaAOc+xLGo45Bx0p8tp+644reuoI1UYqB0Vl254xnNAHKSpsbHOantdrhgRzWndWSspK1kxwsk5HIoAa1uRcZ7V0vhbWrrQ7+Oe1kZQDkgGsd4yxFXoIFaMc4oA+r/h/wCL7fxNYDDAXKD519a6K7thK4bHIr5a+HOuvoXiCFg52MwBGeK+p7S5S7tI54zlXXdQBFqm5NJudv3hGf5V8iamQ3iS6L9fMNfXGsXKW+lXMkhAAjPX6V8g6swl8Q3MingyHpQBdkHeomwOCM1OiEx5qFyGBxwRQBFIOM9BWZfTqCBnNaT8IxbgYrmLyQvc7QeM0AbNrcRAc46darzTLNN8nNUpwsUIyTk03TAxkJ7djQBtOP8ARiO+Kxi4UP2rWuvkty2cA1hSYKSkHsTQB5jrDb9UuW45c0VFfndeTEdN5ooAljJCAkjB7V3/AMMtTVZpLZm78V5uCQB6VpeHb42GrQy9s4NAHuN8cOCOvWvVPgt4ljtLk2Nw4VJOBn1ryuJlu7FJVOcrmsqHUZrO9BgcqQaAPt15EWIyFhsAzmvmD41eIX1zXGtYDmCJscd62ND8bX1xpJgnnb7uOtcLqkXm3kkp6k5zQBU02EQQoDwRzRqrqVx681NCoLdeagv4w59u+KAMNAFY9qlfIO4d6dLGA3T8aQDdjrkUACqch/0pUYNkmlZ8UIgPTpQBHznA6U52CAe1SZQN05pvBf5vwoAcRvQHdgUjMqoR39aQZ3ADGM06YDdgdKAIwn7vcTxUqspjyByO9JKNsajipLYDyzu6UAQxFRJz1qxcZa3OKhIXzBtGakckwt1oAq6Nbrvdm9ai8QMuwqvbrV7SFBZhiqmvqAW460AReH42i0u8lTIwpIP4V5NIxe4lZ+TuJNetT3DWPg67kSNizKV4HrXjysdxP50ASlsqNw/OpYWz1HHaq5J53c+mansl86VYgcbiBQB1Pw6vjY+L9PljJ/1gBxX0z8RvGK6Xo0TnALqBk14H4T8KXGn67Y3V2R5IYNmuo+Pcjvoti8ZOwNg4+lAHunwB12LWLKZlbc3eup+K8DT6CyAgA9Sa+b/2TPEDweKH06RzsmHANfQfx21BdM8DXVwTggHFAHlWiPoVmgt3kiNw55JIzmvNvj7L9nSzitziKXOcHrXlsWq313rMcqTOZGkG0A+9en/GaAnwzpktwf8ASFIz+I5oA8diJ6jrQ3XDd6YnX0xQRkk0ADc17X8O0N14IkUncUyB9K8SPGOtem/B7XVt7ifTJ2+SYZXPrQA/R13avsYYwx4rtr+MC2CgZ4rClsPsviNmQfIxyK6O6KlFB64oA4XUYPLuQRnGamLEqozxV/V4ecj86o2ybnxmgDodBVRHgr171ozlUwAKq6eoSEAU9pezAUAJJKUUFRTVlDuDnmmXB3IR2qGABOvU0AWbmQgjdyKFkDA9OaqEF5MZPFMuCY8AGgC5GC2VI4qpd2v7zKrV20bEWX6055AW5FAFHyCqDIzxSoNox05q6OSSOlQsockgcCgCukpiuFdeqnNfT3wl1g6poKI2cxivl9gWmXH0r6e+DVkLfwur4wXPWgCf4uakuneFJ/mAeTgV8vaXm4unkfkk19HfGzSbjUdEV4MlY+oFfPmmW5gnZZBtNAGmAwUgCqefmPqe1W2c7iBVOUAyZ6UAVbpnEbcVzxjLzkjqK6O9kVYSM81z/nBJGYk0AU9RZvtKLk/StKwXYAKy8m4vFI6Z5ro7WDEY9aAF1MZtB3rmrsNFYTM57Guj1KQCIKOtcn4pnMOkS+pGBzQB5xKd0jH1JoptFACg+tAJHOcd6CeB1oJyaAPY/htqgvdKNs5+dB0JpusxNb3xxwDyK8+8Faq2maxHk4jc4Ir2G9tEvYknTB4zQAmg3DbBu64rSncMDk1lWZ8iMkjGKbFctLPgnjNAFjBWb2p0mGBAqeWMFQwNQKOT3FAFCZQMjH1qCJQrZJq3cgsSOapsp/KgAmj67aLXgHNNjkz1PSpIyD9KAGyIN24dTSBmY4I6UrkB8VKgATnmgCIKdwI6U5h84LEDvQjDLD3qOUHdQAtyxbBHNOjDFMHpilXAiGTzSq/HAoAgHyScc5q6yEwEkYqmn7yYA9O1aNw4SIL7UAR6WmwsTVPxFJGVVR1zzVuCVRGcYrDum+0amkfO0sKAPaPhl4Zs7/wjK+oRq0ZU53DtXy74/jsYPFd/DpaBLZJCoC9M19ZL4g03QvATwCaNZTCQBnGTivjS/l87UbiU/NvkZvrzQBARgYzn3qawV5L2BIgS5cAAeuahbrgDk1618G/As93fLrWqRtHaw/NGGH3j60AVfiJrV3p66daL+7YKGJ78V0PjFm1D4XxXU4LN5atz1zXDfFfUY9W8bPFagGOHEKkdzmvRfHqiw+FcEBH/ACzRaAOD+Bd+bD4g6c+4gFwtfRf7WeuCHwPb20R5nbBINfLHw3l8nxlpr5PEq9PrXsP7Tl88+laVGTld39KAPHPhzaLeeL9PjcZUSAmva/jZpSz6JAuQu3pXkXwj2jxvZFsda9F/aK1OWKLTreIkLJkkj2oA8LljeCYo4IIpvXPpXW3MFlqPhJLkMBfQjkDqa5EdKAAdetaXhy7+w63bTZwFcZNZoPPtQpIII654oA+iLyNJlt7pQCGAOamlIEIbHasvw288vhC1kuFYAL1IrQjlElvx6UAZOpqrxkr1rKs42Mta0rDcVIzVWPENxkDGaANq1IWEDv3qvIDuNWIPnXcOtQTOVkIoAhmdlAGMU5I8puPQ0Fd3zEZpZZiI9qjpxxQAhIxxUFwmcN/FT0yAT3qSBTI3Jx6ZoAWzOU2t1q0ygdBUZVYmPNSK24e1ACswKkIecUyPAOG4pY0KnINUbyfbIuemaAL9pbb7tFHILcEV9X+CbQWfhmyjxglNxr5q8FwJf61aRAjJcDFfVkMYgtY41HCKAKAGXdul1A8UqhkYYINfO/xO8OHR9ULxJiJzkYr6Lhbjmuf8XeG4/ECIkhAC96APmi2SSQ/KhJ+lamn+FtR1OcLBC3zd8V7lpXgGwsgNyhj9K6ix062sVxBEq++KAPDLr4P381ju3jzMfdrxnxZodz4d1Bra7Uhs9fWvuQOCcDrXgH7TOkoYYL2NAr4wSKAPGdKs0YLIO9bkSCNTxWT4azJb7W7VtzDCnPagDn9SkzckL0zzXD+O7k7IoB3OTXZX3+udgenNea+K7r7TqRUdE4oAxaKDRQAZNFHtQOtADgxVlZeCORXvHw9uWvNEj83kgV4ZZW7XVykKDljivffCNqumaXHG3B20AJqceyVlQYFZyrslBNbF2fMkLZqjLEByDmgC0JCYhnpRCVBOKpeaQMZ6VathkZY8UAPuI9yl+MAVmMwOQelajTDdsHQ1WurQhCyUAZuPmOelGQnIPPpTkDLu3DnpzScY5oAcmDyxpSx4K9KiYZ6A1LGPl5oAcoyeOtDkLkMM0oIQZ71ECZOaAIl5frx1qfcowV6jrTJFIb0qSGMsQe1ADIPmmwB35p+ottUmpgiwjf3FZGqXW4jnigCNblgCB+lO02Iy3bSOMbeQaqREDkde1TahcvYaPPcdG2kA0AcX401m5vdWmiM7mGM4C54rBSIvEz9CO9RyO80jSMcuxyakjcqhUDk+tAHdfB3w5Dr3iFWuk3xxHdtPQ17V8WPEEXhfwk1vYARyuvloBwRXNfALQnsdPm1O6+RXHy59K4H42+J11zxI1vatm3t/l47tQBjfDPRZfEXjG2jcF1D+ZITXqnx9ZbTw/BbKcfMBgVZ+BGgf2Ro0mq3KBZph8pPYVxXx01Y317DGp+QMTigDifh+C3i3TgBk+av869V/aQVhZ6STnGT/ACrgPg9afavG1lxkI2416x+0rZFtBsp1XIicc+lAHjHw2l8vxdYn1avXfj/p/n+GLW8VeYXGT7GvC/D14dP1m0uc/ccH9a+lfFIXxH4AlCfMXi3DH0oA+XEkdQVViAeoFJnBNK6GOVkbhlODSH659qAG5p0bbJFYjOCDimjrycUe9AH0n4c1nT9e8ExwWoVJok2svoa56K9+yM6SHoTxXC/Cm/a21xrct8ky9Peuy8SQNFfEheG5oAjjujPddMA1BezMl2BzSWv7uZSwzmpNQxJJuA5oA3dNlBTGetOuV+Yt+lUNIlGQDx2rYmQOcjGaAM6aQJGFp0Y3Rg4p1zbk/MafAR5YXrQBCp+U5Ap0IK/Njv09KkkXJ4H40BCF4oAe4MmDTtu1D60sQJB45qCZymd3agC1bOvIY9KydYKsflNQz3mH+U1Xupw8RY9aAOp+GF55Hiuy3HjeP519hKwaMMO4zXxT8P8Ac/iayI5+cV9qW/8Ax7R/7o/lQBSfULaBissiqw7E1NBeQTD93IrfjXz5428R3J8Y3UEchCK5UDNX9H8Vz2MihnJoA958wdTgVBeXUcMeS45964ix8StqdoSjbXAriPEPifUIr/yHYkA4oA9r0/LgvnINeS/tJSKuhwKepNeoeEpHm0K2llB3MozXjH7TFxiW0gB/hyRQB5H4dG2IbehrQ1SQRxZB61V0dU+yKeh9ar6rMSdnWgDGvJCkEshPQE5ryy+m8+7kkPc16L4qk8jR5NvcV5n1oAO1FFFABRRVrSrU3l/DABnc2KAO4+Hegbwb2dcY+7mvQWkJO1T8o4wKrQxrp+lwwxgDgDipYhmJmJ7UARmYlioNMZ27HNV0OZ2ANOmJVuKAK+8+fntmtMSgR4Q81SUKw+UcmmPvic5yBQBaEwU5PrV6O7VkAJ4rBnyVyDSRSsABnpQBrXdsZBvT7vtVNEOMdhVqO72wgHk9xRbMkhPGCTQBTcjcMUSseBjirUsEfnYJxTngTaORQBnksx/pVmJQB71PHbooy3SnRrGmScGgCqEZzkjAqYSpEvbPpUNxdqGITjFUHl5IY9aAJbq6aR8AnFZF0C569anllBY44qqrF5h60APs42lkVMfMa6zxP4bd/BUp2/vNm4VY8B+Hn1LUUdl/dqc12XxW1Gz0Hw46Oy79uFUHnpQB8n+U0MjLMNrDtW74O0VtZ1aMOCLdDudu2PSs+2t7nX9XEVuhaWVu3avRNY8rwR4fS2iIN5KuMjrn1oA0PHvjz+ydNXRdFYKwTa7L/CP8a4z4deF5/EWspcXKsbVW3uzfxGo/A3hW58U6p5k24w7sux/iNfTPh7wzb6RpSxwxqgC4JxQBgaxqkVhYLYWo27VxgdhXz78Qroz6wEJztFe1eILNkvJJBlhk14R4z3f29PvGPSgD0P8AZ4shJr0k7rkLgCvW/jvYfbfB0oUZZVyPwrh/gDCken+dwWLda9U8eQ/bNAlX/ZP8qAPikZDe4r6Z+FFx/aPhCNH5ABXn0r5x1WH7NqNxD/ccivoP4CI40D94DtJ4oA8X+IelNpPii7j24R2LrVKfQrgaVHqEAMkJGWx2969t+OXhA6hbjUbNMyxDkDuK8z+HuvRWcr6ZqQHkSnau4dD6UAcPxg+tIK7Px54Sk0ib7dZqXsJTnI/gNccME9MUAaHhy8NhrVrPnAVxn6V7X4iCz2MNzHzkA5rwRshgc89q+i9A0O7vvhpBfOhJCZz7UAcLDMSxBPOasSOSoI49qo2zAXLo/DA8VcnkQfKPSgC1ZymNiTWjDeO0o54rJtlLoPX1rRs7VpDhc8UAaokWXAB5qRYlXnNZTwzQHdzilS5mcYxQBobkMmCanaP5OMZzzXOedItyDg4BrchuA0AP6GgCeJhGrM9Yt/MW3EHjNWbmbcpxkVgXNy3mGM9CaAGBiZCOpqO6bcMZ6dqlQ7GLNjNVJnDyE4oA6v4aMR4oshj+MV9qQ8QIP9kfyr4y+FEfneLLMejivsuVvLtHb+6mf0oA+Y/ifbR2ni2eWJwSz1jpeIMbz81UvG+pyXniq75Jw5AH41kXErR4LggGgDrrXxO9jIPLOBV3Tb86/rsIZc5IzXOQWUdxYearDcRXd/CHwvcz6ol06/uk5NAHv+kwi206CIADagFfNH7Q18LnxWIQeEGK+n3IihY9Aq5r41+KN/8A2j42uiDkB8UAQWo2Wa7D2rHvpCZRurZgXbaEe1YV+37zgd6AMTxo/l6Tkj73Fec16Z4xg8zQ2fHIGa8zoAD1opKKAFrqvh7Zm51reRlUFctxjkc16P8ACy0xHNcHvQB1upufPROwrSSMC0JH92sS5mDagfr3raiJeDA6YoA5wu0U7ZPBNXbaVJeGHNUtRBW4x2pYflYFaALjwNFKHXlfanSt5oGeoqxD86DPNQT7Y5cL070AUZFKFgw4pI1+UletWbuRGGABVU4RcKaAJYJVL7Wq7DHtfKtkGsnODkdKtWlwc+1AFiVZDJnnFSLDIRkHp605bhXwOKtrgoAp4oApMWXALcVE7ep4qedCSRiqV1BNxszigCreyeWhKjJrLSSSSQ5zitAxsuRIDTNihsqOaAIhF8u41o+G9FutY1KOC2iZiTzgVveE/Ct94juEitoWKE4LYr6X+H3gOy8L2at5avdnlmI6UAclZeGh4T8LSXMi4kRNzGvkP4keJ7nxHr85eRjCjFVXPFffHxCtDf8Ahi9t0PzNGQK+GdF8C31140NtcREQJMS7EdRmgDuPhJ4UTSNBl1zUEAkdMruHRa8t8TahN4l8WMM/I0mxB2AzXvPxGvl07ws1haYGI9uB2FfOWh3ItNZhmlGQH5oA+mvh5pVrpNnDEoVWwOa7u+v4VQQjG5uK8ss9VD2UdxbSBgFB4NWF113YSSk5HrQB12uadbrp7yEAnGa+W/iNs/4SGTy8cDBFe+aj4j8+zdHYbdtfOfiu5F5rs7ryudooA9m+DKsmghgMc165zd6Y6SdSteYfDZRY+G4S3cZrq18RqIjGo59aAPm34h2X2HxXdpjCs24V9F/AtbWbwlD5eN4HzH3rx74s6Y08g1FMnbw30q78EvFD2Mz2DuQG+7k0AfQ99aR3XmwMAykYIr5q+LXgltEvmvrJcRE5YDt7177bazHahpJWyW5rkfFdxHrsU6MBsIOKAON+GOt2/iPS5dE1ba8mzapbuK858beHZPDetSWjqfKJ3Rt2IqpZ3Mmg+JvMt3wYZsZHpmvd/HugR+LPBEWo2y5uY4xIp/DkUAePeB/B8nibUIVjnjSIuNwPXrX3r4W8NWFr4LttJVFMQh2E471+eWi6ve6FfCW1kaORDyM19J/Bv42g3EdlrT4VuNxNAGb8VPhle+H72W9tUMloxJBUZxXmDh8/MOR6196SCw8QaWRujnt5VzxzXgfxE+EjRSS3GlKSuSdoFAHjdnuEIOMmtjSrnyM7+lU5tPutLdoriNlI9RTIsyIR0oA6eC4inQlgCaZtg2MQBXPRu8I6nFTLec4ByTQBqQwxOxJXGKYyKrkDp2qL7QqR/eG41WkuwRkkZoAlu9qk5rEuogX3Dr1qxc3OVODwartnbu9aAIrhgVHTOKqoM5XGeak2lnwT1q0lsyqWI60Ad58ErPzfFtsQM4YfhX1dq7rFpd07cKsbZ/Kvnn9nXTHk12S6dTsjHWve/Fkby+G9QSL75hbGKAPkXUwl14kuZI+RvJ/WjV0Dwqu3kVjm5ks9Xn80EMHIOauLqQnYqe/SgCW18/yRHExxnpX0r8GI5I/DX75QHyOa+d9GCtNycYPc9a+mfhfn/hHl4xzQB0HiO6Fnod7Ox4WI18Q6zMbvxHPKuTukJ/Wvr34s3gs/Bl4ScFlxXyDpgEuouz9M96AOhiIFsSeK52/GZdwPy5rpJ4x9mIB5xXLXjFZNo/WgCHXsTaFMuf4TXlVesXq79ImA5+UivKGG1iPQ4oASikooAcR04617D4Cg+z+H1JHJFeQQgtKgHPIr3HRo/J8PxhQMlaAM/P8ApZZvXrXQ2HzpnFc5nLGuh0QjywCcmgDL1eHExOKghQ4GB0rc1e3DAkcVgrujYjmgCRJpQ5APfFMui5OSTWjpNmbu6VF6k16Xp/wym1KAMFxkdaAPGGmzgGkcswAr1nV/g1qsIL2oD1weseF9U0lmW7tJFA74oAzFgHlgk846VE0TDBVvrUoJHXj1FIx+UgZNAELTGM8GrthfqBh24rNkjZgd1RLAxOFyaAOne+gIByCaRbpJFO3k9qh0PwvqeqyKlvbyEHvivVfDvwqNpELjVGxgZK0AeTxadeandCO3hZiTjgV6b4O+EU1yUn1U+XHwdveruo+L/C/g1igaIyr2XBP51wXiv9oS8nge30SHyR03mgD6V00+HPB9isXn29vgckkbjWdefEzR3YxaZMtw/TKmvhjW/FOr6zM0t7eyuWPTccV6r8B9KuJS97d7vJz8u6gD6es9Rk1O0bzVxuFcNrfh9rC5mu4Isk5yQKvHxTa6fKsBIBFdrpF1Z6xYkgq2RyKAPl3xGTe3cyXGR1GDXi/ifR5tNvnIQmFjlW9K+jfi1pK6ZrbNCMKx7VxlxYQanaGO4QHIoA8k0XxLfaZhUkLRf3Sa7vS/GNndRAXJ8uTvmuS8VeFZtLczQAvAT+VczwR156DFAHofinxRCtsYbJ97MMZFcDYW8l9fRxoNzO3NQspUfNzmt3wRPHb6/AZQNpOOaAPcdLiNpokMJ4wgH6UxIwoz3NXZyGt1ZemKrxjjnk0AZ+q2a6jZS28gyrDHNeK3cN14a13jKmNsqfUV73IoVgcV558V7SA2cdxgCYHj3FAGxpvjWx1LT41uJQkqjnccc1S1vxjZWVq62z+ZMwIGK8kQMWATJJ9K6jRfBWp6lteRPKiPdupoA5wvJd3pdvmkkfP4mvqf4ey+T4XgtLkgnZjafTFed6F4FsdOxLN+9lHIJrqbA3D3kSQA7QcYHpQB5J8VtD/sjxHLLCuLec7hjpmuOinaN1eNirjuDXunxy00poMcrp86kHce1eDr0oA9i+Gfxk1Pw8yW95K0luMDk9BX0PpPxX0rUrRHeZG3Dnmvhb+E+1WLW/urY/uZnUfWgD7Q8Rz+HtZhMheHee+cGvOr7w9A0rfYZQfQZrwM6/qY+X7S+PrWvoXjXVdNukd5WeMHlTQB6HqWlXlsxEkTY9ccViuroeVINeu+C/FWjeJNMQXJjEmMMretbE3gCw1lWayZQx6YORQB4LLNKWPOMDpTGkYjrzXoXir4b6lo7FyhZD3Argry1lgfDKRg0ARKJGAz0q/bpuXaRTIDiLkc1IsuzHFAFeaB0lDDpXQeHLCbWb2C0jQncQDxWZAWvbhIo1yScDFfR3wj8DpYWsd9dx4c8rmgDuPA3hq28OaPFDEgErKC7Ve1jVrWzzDcsAXGMGtUGvEfi3rIs/FUELPheKAHeJvhfY69JLc2B2SudwI6GvJvEPw91jw/KZJImeEH7wFfQ2jXskekx3Fr+8XbnFJc6/aayq2FxCS0hxyO9AHzdo8bvfRKwIJIBr6w8CWhs/D8CkYLDNYFp8MtJiuVuOd+d2K7y2hWCFY0GFUYFAHmHx/vRD4aEOeX7V8w2Lfvsr0Jr2f9obV/P1JbKNshBg4ryGxhChcjk0AbMjbbUsT2rk7uTdOT710l4rC2wSa5yRBvoAuBQdPkBHG2vIroAXMo9GP869ltkDWrq3UjpXkOsJs1O5UHOHNAFKiiigCxYjddwj/aFe524K6LGO+2vDtOx9ug/wB6vcxldFiJ/uj8KAMJ2G/B/StnS5goGPrWE4JZiOTV+xfa680AdRc4lhyB2rnriLZIcj8a2Y5sxde1ULpjIcAUAXvCM8cWqxbsY3CvrHwy0T6TC0WMEdq+M45GtZ1ccc5r6C+EfjOKaJLG6cKeikmgD2CqOpaZZajC0d3AjgjHI5q6DkZHINVL8S+RI0WdwHGKAPI/Gfwjtbh3n0w7GPO0V5fffDvWLSVgIi4B616rqHjm/wBO1dre5TegOMEV3nh++TV7RZngwD6jNAHzjpnw41a/lCmIqD3Ir1Twj8IrKzCS6iBI/Xaea9XSKKNflUKfanwnJPpQBh3MWi+FtNe4kSKCKMZ3EYr5m+Lvxsm1CSbT/D5McAypcd69A/azkvYPC9s1sziFm2uRXyEmTyaAFu5572RpbmVndjkkmq3lhGGW4PerRHBz+dV3U7yGJx2oAu6NbfbtVtrVASHcLX1VDFB4b8MRJCoXYg/E183fDa287xdYrj+LNe+fEqdrfTEjzzj+lAHmfiPxZs1Mh5CWzzg16l8KfElw8sfzko3FfMOrRXMuouWR8k8V738FI3jFskoO444NAHUfF12uriOQjjjmuHs1Gwepr2T4oaGp0VbgDDKK8WicqSo7GgCHWYllt3jkGQVrw+/i+z6hLEBgKxr6J0/SJtVkCxqzZ44rF8Q/BDU726aexyGbnBHFAHhjc8557570RSvBOkqcFTkV33ij4U+I/D9s1xPbmSMcnaO1cA6kkqwww4oA978G6mmq6NGcguqgGtNFZWOa8g+HWtNp+pLDI37t+K9mnZXhWUdxQA1x8uT0rxj4kaobrVPs6n5I+or2C7nCWEspP3VNfPuou17rExJyXkx+tAHZ/Czw0NRuze3SZhT7uRwTXrd2iwqI4lAC+lVfCVimm+GYAqgEoCad5plc7jigBY/nTbn5q9N+GHhUSqbqdMqOmRXnGlRfaL+ONRkbsV9K+EbNbDRYUOAcZNAHg/7Q2jPPpksUKHCr0Ar5K2lZSh4YHFfop42sdP1C3likZC7DGM18UfFrwfLoGtSXMSEWkrZBA4BoA4LBGenFJggZ7HpToyNpByD60pxgAnigCM8NxnHvVmPng8+9QEgsMDp+tPjOSR0/rQBdstQutPINrKy/SvVvhD8Tr/StbhivpmkhcgHJrx5Tg5JIzU9u7RMjrkEHINAH39rXiDT9T0QOCrB1z+leOah4fttVnc22N1c/8Odak1LTVgkkY4Xua6mHzrPUIxGcnIoA5fUfBGpWyl44WdfYVjDwzqk7hFtpM/Svr/QbaGTRoWniU5X5siqyw6RHOxRIcg0AeMfCr4bXJ1CO71CPCKc8ivoiKNIYkjQAKowBXJ654s0/RodsZUv2UU/wjrlzrAeV0IjzwaAOsyBzXzN8ekmn8QCeMHapxmvpVxxXmHxL0iG5gkcoCcUAVfg/qC3PhtUunG9RjBq3ppsbfxiBK67Cx2/WvEbbxFdaJcyQwMVQHBGafZ67eajrMJVjvLDGOtAH18MEAg5FVdVuxZWE87fwKTUXh7zho1p9oyZPLGSayviLcC28J30hP8NAHyx471M6r4iuJHbPzYFZUCHevtWcsrXGqSMSfvGtyxHJ3CgB17IFtjmuYG55WOehrb1lyMqOBWRbgZOTigC/Y8qyng4ryvxMnl61cj/ar1S0BycdMV5h4uOdcn7nvQBi0UUUAWLE/wCmQnOPmFe5xNv0SMA87a8IiO2ZD6EV7lpZMmgQlf7lAGQ2F6jvTo+X+U0yXO/nnmljfY4GetAHRWQPljPpSXnyLkVlrftGflJxVs3Qkgy/WgCqZN7/ADDNW7PUZdOuUmgcqVOaoPgycfXiopjnvk+lAH038LviFBq0EdlfSKJgMKxPWvUeGH19K+EtN1CfTrpJonKspyCDXtvgL4uSBorbUyCvAyaAPYtW8LaZqVwJp4FMg71ciittLtQi7URRgVJpep2up26y2squCM4B6VX8Q6Y+p2LQxPsYnrQAkN9FcE+W4I9jWhCQFGK88h8M6zp7loZS4z2NdNoUepkkXvC9qAF8e+GLbxd4butMugP3inY3oa+FfHngrVfBWryWmowOI8/u5sfKw+tfe+ravb6MiyXbgITjk1m+ItC0Tx5oTQ3KRzxOPlkHVTQB+enDdOKbswck816z8Rfg1rnhu+mfT4JLqxySrIMkCvNxoupGfyfsc4kPG3YaAOq+C2nyX3jqySIZwcnHpXvPxn0aS3ggfYcY54qt+zV8P59Jd9X1OIpMw+QMORXuXibRbfXNOe3nUHjg+lAHyNY6bbzhS8Slx3xXe+AraO11SI8AA1a17wn/AGFcNkHb2rH0q+MV2Np6GgD1L4k38TeHTGCMkV4Vptm1zdBVHBNdr4r1Vrq1WLd26VT8GWIe6DEd+KAPRvAWiw2UCyOozjvXZTX9tB128e1YIcW9kB04rl9W1Bhu2tQB3N9PZ6vaSQSqjKwwQRXyT8cPh+uh376hpyEQO2WUDp717xpF/MJQcnb3qz4r0yHWtLliuFDKV70AfEVrKYbhHU4INfQHheVdQ0WJyd3y14p4y0r+x9eubZPuKx2/SvSvhVdl9L2E5A/SgDa8Tf6No1yAeAhrw/w/EJ9dt1PIMle2eNFMuiXQXuhrxnwswj8RWxP9+gD6F3+VpkcY7LismZwBweTWjcHfaRtnHFZ7RhgrdOaAO0+Hdkpl+1TLkL6+tS/ED4vJpE/2C0lAYfKSDVvw1LHDob7cbgpr5X+IEs0niy9aUn7/AB9KAPdbHxTfaiVulnLAnPWui8WaXD4n8GXCuitMYyQcdDivB/hlr3k3YsbljsbpmvoHw9KEspYt2Y2BxQB8e3ETW9xLDJkMjFT+FIM9sY962PG8Sw+LNTRPu+cTWUFBAxkUAIDtxj5iaXkkZ5PoO1OC5PI/GnxxPPKkUClncgAAc0ARpkHrVuIFlAPWtbU/C19pdmlxdIVDDgGsuEfMB0PpQB1Xg3xC2iz5/hNez/D7XoNd1qIScgEV87bc969H+FU0ttfo0XJ3fnQB9uxqn9nLHERt2YGK871nR72J5XiYgEkjFdR4Le5uLBJLnIBHANbd7bh0PGRQB4ha+Fb/AFbVB57Ptzkk17ToWnx6Vp0VvGAAo596wLjUodNkYjaCKSy8ZWc0nlvIu7p1oA64ndWD4it45LZ965GKZcawZP8Aj1G7NT6ekl5A4uu/rQB4Vr/g6DUryV7UhZM/dFdL8Nvh2LfUY7m7U4TnBrZ1TRprHxBC0OTHI3H516hZQLFboFGDjmgCygCqAOg4FeWftBaobHwp5Stgy5zXqfQV8z/tGa79t1BbKNspHxgUAeQaMxmnY/jXUwL5a5Nc/oNsY1DDvXQTNiI/SgDF1iTc+RVFoyyjbVm6YM2OM1FEeevA7UAXtNOIju54ryjxSwbW7kj1r1y2CrbMT/drxvWpBJqlyynILmgCjRRRQA5Thga9w8Lyeb4fi7fLivDq9p8Evv8AD0f+7QBVkX962ORmmMVDDJp1w5EzKMdardTyeaAJiQOTTkl5+tRTcAYNRs+PxoA1UCsoAPzetLJBhc9fWqMDksMfjW5bgMg3YoAyJIcjLdBTIVKNleo6VqzxoRhapiEhsntQB1PhDxxqWgzrtlZox/CTXtnhz4r2d5Gi3Yw2OTXzaId+NvFW7cGJx82OaAPrFPHWjFNxnwKx9V+KOjWSEqxYj0rwaAM8Q+c1VvLISKSWJNAGz8R/iHceJJ1jtyY4V6AVsfCXxrPpVylreOzQOe5ryu4tzFOQBVxLg28auvysOc0AfasEkF9apIoWSJxkZ5rB1nQdGija5eyhVxzuVRk15Z8F/Hkk1wumXj5U8KSa9wu7aO6iKSDKmgDP0GSOSzBgTYo4ArVAOKrWdtHax+XEMD0q12oA8v8AjOwhsAw+8R1rx7wqv2i8+avWPjqWXTo2H3TXkvhCXy7oH1oA0PFEHlTDB4NdB4BQGVM1i+K2LBWHao/C2uW2nXEP2u4jh3uETzHC7mJwAPU89KAPZtTizbDb6VxOpQ75NoHNd9aSRXtooDAkism+0giTcFzzQBgWNt5cY4561V8Rav8A2Zpsrv0ANdI8Agi3SgKAK8U+M/iu1XT5LO2cGZuOKAPDfGupf2tr1xcD7pbArv8A4Rqxs3GOpxXmVpaTXlyscSMzE19DfCPwtI3kwBee5oApa/EXtpIsfeBrwyaF9N14842SZB9q+zPGfgAwaY1xFy6jnFfLnxF0r7LdrMV2tnDUAem6PL9v0iFlOTtGaeyDAjAwaxPhdeC40jys5KjFdKqgagNw4zQB1nhjSJ5NNctkKQa+fPjFpBsdc87BCvwa+vfCoifSQMY4rxD45aTHPFOVUbl5H4UAfO1tM9rcRzQkgqQc19JfDzVhqfhwS7gXVSD+VfNbLg496+gPgXo9xN4Vv58HZztoA8R8Vy+f4lv3PeU1nBCByBntVzWYyNevg2MiVs/nUYUMNuOaAK5BBznivWP2dvCaeIvF6y3CbooOenevLWi5zX0p+yPAwurtwvfrQBp/tD+FzbaSGtosRqOcdq+X1G0kHjFfod490KHXtKe1lA+YYFfKvjH4J6vaXLyWCGSJm4AFAHkBbAx39K9p/Z50wX2rAypmMHvVTwj8D9b1G9j+3QmKLIyTxxX054K8AaZ4UsVFug81R8zY60AdYjW9hZjJCRotefeJfiRZ28r29qwZhwTVrxxNeXemTRWhOMHpXzxf2tzbzSmfcXzQB1fifxXNesRExG70pfBemX9/fIwDkE1x+kRPLfxiUHaT3r6j8BadbW2jxOsa72AOcc0AaOhaUtrZoJAC+Oc1R8Qa3b6YRGpG/wBK6ZvukCvNfEPhm91DWGdWPlseDnpQB0WjXMesbJSBuT9K6pOBj0rE8L6Guk2oUndIetbhIRSSQAOSTQBkeKtWi0fR57iVgCFIWvjfxbqL6xrU07cgtXqnxw8Ym7vDp9nJ+7Xg4NeT2lvvG9upOaAJbGPaqgdanu5dkBA+961KqeUhJrKvLnfuHSgDOdmZzxk0sTeo5oXh8kZFTRgeZ0PNAFq6k8nR5nPGFJyPpXjErF5GY9WJJr1fxpcC28PyDoWG365ryagBKKKKAFr1v4Zz+bo5jzkrXklegfCy72TywE+4FAHQamoS6cDrmqu0ls1p65Ftud471n5xmgBspAXJ/E1AcGny88k5HpSA8dKALlkFUjJrUd1CjDcisaA4Qkdf5UqTHdjOTQBqxgzfLzg8cU6SJg2TUVtdLEPmxmpTexyA9KAJ4Iwwz0NJJE33vSm25LsNvSty3tlaP5h1FAFPT7oqQrc1qzoWhJU1VaxRPmXg1PbykqUP0oA53VZPKbpz61TVxMuN3Fbmr2qbCetcwhKykDpmgDW0G4k0vVYLmIlSrA8V9heENVXWNCtrkHLFQG+tfH9pCZR7ivffglqhEL2TtxjjmgD1O4YxZftVaz1BLicoODV24TfGRXLKfsWo7j90mgDK+M1kbnw6zgA7Oa+cItXi0llaQOdzhFxgKCT1ZiQqj3YgV9ceIbVNV0SaEYO9eK+XX8M6rdeMn0TSIlN39+SRwfLtoycb3/XC9WP4kZV60KFOVWpLlit2+g0m3ZHd6R4E1PxJbQXWq6pa2lhINyx6cwnkdf8ArqRsH/AVb2auS+L1v4d8HXmkaVpFlDHcRf6fdXMhMk7dVjUyNk4J3tjOAUXitCw+IPhr4f8AiLS/CmgiGbTvtRXV9UkYDdM/ylgRxw2Cx+6ANo6HHhXxC8TS+LfFmqapkiG5mJhU9REo2oP++QM+5NfGZXTzLHZiq+Lk/Ypc0VblTu2o3ivv1u9u50TcIwtHc96+FnjhdTvUgMvfHWvflaI2odivTNfnz4V1ubQtSS4hY/KecGvZn+MkzaOVRyX24r7g5jtfjP45t9IsZYLZwZm4ABr5itGuPEGsgTMzmRsn6UeJ9budbvnnuZCck4HtXT/CjTTLfNcyL8o4GRQB6F4a8J20JhSCBd7YzxX0J4C8Nx6VapKyASEVyPw/0X7TdrOy/ItesXM0dlZs7EKqLQBQ8SXlvFp8qTsvI6E18dfHPyROTbjCl+cV6b498Xz3urSQQOdgOODXjnxNuQ9okbNuc880ASfCGX5pU9K9AuGxdZHavLPhXdCLU3iJ+8M16pcHdLnsaAPRPCmvQR2IjkbaQK5nx+sOpRylCGyCKwd0kYyhODSSXZWNhIScjpQB8/6lYSprctuqHPmYAx719wfA/wAJrpvw7t4rhMS3CEnPuK8d8CeC49f8UxTvECA24nFfV9jAlpaRQRABI1CgCgD87viRpEmj+OtVtZVKsszEfQmsAqMBQMV9cftHfCmbxGo13Qo919GuJolHLj1r5RutL1C1uDbT2kyTA42shzQBW8sM4VBlicV9m/sy+FZdE8Jm9u49kt0dwB6gV5D8EfhBfa1qcGp61A0NlEwYKw+/X1tM0GkaX8ihIYlwABQBJeqCNxPSo7We2l+UlCR614/4x+KsMAkgt2G8GvOpPiXe7maKQg/WgD6wMsEY5eNR9QKgmuLedTEsyZPHBr5Dv/iHq9wpzcOPoao2Pj3WbecMly5we5NAH2OdMhMBTGc+tYVz4C0i7ffcRbmzXjGh/GjUbaNVu4xJj1rqbf442rKBLbYagDvE+HuhxkGO3wRXS2dlHaQLFCMIvAFeWr8Z7BgMQY+ppZPjBaLgiIEUAer7D60KozkjmvMrL4t6dOQJIwnvmpL74nWKDMDKfxoA9LZlRCzEADqTXl3xU+IEGl2L2lhIHnfKkg1xXi34m3l5GYbViqnjivMtTklvX82ZyzNzzQBnXTz6hePPKSxJzk1p2abFG4ioo02R9MCoWuPLyGoAsahONuBWGx2vkdas3NwCOmazmYs/GTQA52y4zVq0XzJVweBVONeSD3NadmgjBfsB1oA5P4lXn7u3tlPGckVwNbXi67N3rMvOVT5RWJQAUUUUAFbXhO9+w6zC5J2scGsWnxsUkVh1BzQB7tqSC4tFlA7ZrCdcsPWtTwlerqeiqAcsFwfWqNxEYbggjoaAIJE2kY60yVMj39qlfOaj55GKAG8iPiiIHccjBqVOSOKHAB+XrQAEZHWpbeNQcnmoApLYFSg4yM8dKANvS3AkAFdMoAQEVyOnuIyD+NdAl4vk5zzQBYuJQoIJ61TM6oOKp3NyXY85x3qm9wSaALV7cNICDWZFB8+T060+WYsCKfa7m6gYoAvWYKLhTzXoPwrvGt9eiB6Ma8/syFfB+ld14IQLqkLr/eGKAPpInKZ9RXN6xAXfKjmt62bdaoe5UVx/i7X5YL1NG0KKO516dN4D5MVpHnHnTY7dcL1cjAwASMq1anQpurVdorVtjSbdkUdT8SXlo6aHosUdzrk6bwJMmK0jPHnS47ZzherEYGACRxr6VfarpOpaX4RuJvsrO39q66x/fX8/R0iYdhjaWHCgbF5B26/h7Q21w3Wm6RdXH9kmYnWNbLYn1KYcNFEw6AY2sy4CgbEwQSvpVpaWuj2sFraxRwWcKiOOJF2qijgAAdBXhUaNTN6ixOJVqK1hB9f70v0XzZo2qatHc+FPGngm+0i5aN4CEHAAHGK5B4pISRIuPwr9BvE3hDTfEdqRNGu8jhsV4t4o+Cs0ZdreMSL2wK+iMj5eZRgEU9FwOM16xd/C25t3YNbyAA1Xh+Gl08nEEpB7YoA8uWFpZ1RFJJ4GK9t8DWK6fp8EeMO2M1FD4FbSgsklq2RzkitGy3RypwQFPSgD6L8BQpHpMewfMRyaxPitrT6dpzRo2Nwq78OLo3Gn4HQAVwHx3+1FTtB2AcYoA8J13xIlrdtzulJrh9Y1SbVLvfMflHSjVY5jfyGUHk96rqn+yfrQBJpN3Jp96k8JwVP6V7BpniSzvrWNmkCuByCa8eWIsD8pz6AVPbWV5K4W3ikJP90GgD26PU7eQbY5FY+gqez0241S7SKBGYsew6Vzvwz8CazeXkct1FIkR5+YV9Q+EfDVlo0CySKvmAZJNAEvw98LR6BpqF1H2hhycdK6yRtvXpWJfeJrC2coJQzegNc/rXi3dFstxgmgDtRewAlXkUH3rndW0bw5f3yzT21s9wD1AGa4a4vLuS3aQSNz6Ve8EQS3V+ZJmY7fU0AenWMUUECx26KkY6ADFcb8VtWGn6DKobDMK7ZQEjHsK8S+M2ofame3VuAMcUAfPOsM9xeSPuJyTUEMLdMk/jWpf2hRvu1DEoA560AQvCFGc5plrGrP0q5NFuXANPs4ArKT1oAjeIqPlBGaIojIM81vLa+amSvFRtb7cgKBQBQRAi4JNSR7mYDnFKyndyKtWqohyT17UAE8RSLIJzUMAlcgZNXJJFbqRimwssbYH1oARoyvDUku0KD0NSzSqcZrPuZcnCnigCUXIK7SOaz7p92RilL7Bn1qCVi/OMUARbGHXmmMQOKk34j/AK0wZLUAEKF2/GtDVpVsdHlkZsYWk0+EtKM4rnPiZqBjgjs0PLHJHtQB55PIZZnkbqxJqOiloASiiigApaKB1oA7f4b6x9kvjbSNhX6V6Fq1qHImTp3rwq3maCdJYyQynNe3eENUj1jSlDH5wMGgDMmwGxR8pWrWpWxhuCO3WqjDIyvX0oASUbcbe/Wk5zyKV88U7bleTwKAGnODjjFMzngU+V8KePaolUgZFAF+A8D0qx556bqzwxCU2OUnIOaAL6SFjz0zUsi5TcOBUUA9OuKnLBV+YGgCK3jPJI5q9CVVcVAhyBinKSG5oAtW4BlGPXmvRPAEBmv4gPWvN7PJnFd/4av7m21GzsNIjifWL0N5BnOIowoBaRu7BQQdo5PsMkZ1qsKMHVqO0Urt+Q0ruyPYfE3iGawMOiaCkdz4guIw6q+THaR9POmx267V6uRgYAYrx+g6Odbe603Srq5OkmYnWNbLYn1KYcNFG46AY2sy4CgbEwQSr/D+itrr3WnaXdXB0kzE6xrZbE+pTDhoomHRRjazLgKBsTBBK+q2FjbWNnDa2UEdvawII4oo1CqigYAAHQV4NGjUzeosTiVaitYQfX+9L9F82aNqmrR3G6db29jZwWdlBHb20CCOKKNQqooGAAB0FQa4heyfHUDitBUA+tRX0RltZEHUivojI4bRvFItbg29y2RnAzXZwala3CArIuD614N4l8/T9ekSTIG7IrsvD5a5iTy5Dzg8UAelta2k+C0UbfhQmn2iEbbeIf8AAaxLdbmxUMzFkP6VsWN6lyox96gBbrS7K6iKT20bA+1ebeLvh1CJDc6cNo6la9OmkMfNVrq9jFuSehoA5rwJYf2faeW3DdK0fEPhu210BblQVqPTpg0zbOla0moxW4/eHAoA81vvghol05dsAn0FZU/wF07P7lkxXssGoRTKGjOR7VKbpQhY8AUAeM2HwL0+NsylfwFdfovwx0LTCGFujkdyK6M+JLMXBhDZcVM9+JxtQgA0AVJ1sNMh2xqiAdgKxpZzqiskUpUdsGoPFNpMyAxliTTvCOkTx5llzz2NAHnfiGxnsdUGWZlJ6mta4aL+zo3X7+BXXeMNLg8oyyYyB3rzcTNLN5aE7AaAOl0H9/FtkHy123hmwSB2dBgGsfw7pyyWi4xmuy022+zR4NAEmpzi3spHPGFr5v8AGl2bzVpWz8uele1ePdXS10+SMHDEV4Ldt9ouHc9Sc0Ac9qsQKEjIPascw4j3Dk10V+mfl7e1Yl8TFGccUARIvyhh2qW3O6RRiqdvNxz1NXLU4fd0NAHUWkY8peKoasRAxK96s2Vyvl8msjWboOSAelAEIkVhubA9ahdtx+RselUGkOz5c1LC52nOc0AXW3IoJOaEl+Yk1EJNy85IqFjg4oAlmm5BPSq7TZzxSTAkd8VBuGeOtADnJAOTx2qLeeBjg0SngA004zQAsqHgqetWI0yvJwaWPDR89adbRtJMB/DQBdtyLaBpnIGBmvJfE+pHU9XlmzlAdq/Su38d6qLOw+zRH95Jxx6V5kaAEooooAKKKKAClzSUUALXReC9cfSNRXLHynODz0rnKUeueaAPf5lj1K1WeIg8VjTL5ZwRzmud+HfiMRkWN23H8JPeu31KzEq+dFyDQBhOctmmyk7RipG+9tpZFwMelADI/mUFhxSHPT9KlUDZTQQ56igBoU7eBmlWPn5uuaeSFBOORUYYkjFAF2M56VKckjAqKE4A5qUdQR0oAsxLgYp6Q8evvS2ylx0Na1ta8DPSgClY25E6nHFeo+CvDlh4gi+y6rAZYMhwVdo3Rh0ZXUhlPUZBHBI71xsVsqgYwTXsXwstR5BcjGBSaTVmB6BYWlvY2UFpZQR29rAgjiijUKqKBgAAdBVjtQBxTZXCISaYDhQetNjIZQQeDTsUAeX/ABb0PzIUvYE5U/NgVV+GO5m+f+GvSNetVvNMmiYZyOK5PwPpb2sspIwM4oA7K4CmAhumKw7BhDf4B4Jrdu4S0R25zXKu0lve9+tAHV3Yzbk+1cnrM5FsypnNdZat59uM9xiuL8byJp0RYkfNQAeGZ8yFXre1ay+1W/y5yK4nwldieUMG4Jr06FFaAY6EUAcrossdlMYrlwD1GTVnW9YtIrdgsq5I7GuL+IJubLUgULBSOMVzccN1epuZmK+pNAFi+1SMXxaFuc812/hu4kvRGBmvOhoshfcCSa9E+HkU0DMsqHb2JoA7X7GroA4zj1qzBCsShVGBUgp1AHIePLZ5bFivAryrT8QXhVxkk4r3XWLQXdm8ffFeR6nppstSywxzQB3nhaNhbq2ODXRTzLFCWY4wKzfDpVrCPA7VX8TyyQWbunpQB5P8RNWM186BsjPFcI823kHg1o+IpzPfSFjzmsZzldvagC5CI5lyQM1i6zab9wUcdqvQMyHA6VPJD5i88mgDio4SjHdkCrUXBHpWld2Jyx7g1Q8louGHNAFuGQhD83NULrLk80/zDkgdahO4NyeaAERAQBjFTW8PHXNRMWXoODRHI2euKALpVFUjiqMkg38cmnyuSM54qKFN2W70AJJJkEHNVwoU571OF+Zs1BOjKaAFkw/Wgx5GR6U5E3x5zzUsC9uvagBbVCxx3NXZ3TTrR55cYAJ5qTT7fYS78AetcL8Q9eFxJ9htnyg++R/KgDlde1F9T1GSZj8mcKPQVn0lLQAlFFFABRRRQAUUUUAFLSUtADopGikV0JDKcivWvA3iNdQtfs1ywMgGOa8jqzYXktjcrNAxDL+tAHtOoWfkuZE6GqBGTkirXhPWodbsVV2Hm4wR71Jqdo1uxIB20AZ8rDAApqDaD+dKiF+T0p2zB5NAARlCMZ96SIYIHPFPJ49BSqA3NAEinJq9bxlyARVeCPoelbNnH04zQBctLZUjyRzWhBEWIqOAZUDPFaMCgYoAkgg+Yd69s+HUIi0rjGT2rxyNSOa9P+Gl+8zNAc7VFAHodZ+uyGLTJnH8IzWhVPV4TcafPEOrLQBX8OXIutMjfOSODWpjisbwtaNZ6d5bjB3E4rZNAEMoyhB71DZwLFnavWrJGaUDHSgAbGOawdRs98+9RW+eRUDx5NAFXSSfLKntXm/xvkkjtoSh+XPNepQxhGJFeW/G25jFokRILGgDhfB2vi2lVJGxg19AeH71L7To5UbPFfJMW9WDJkc17r8HtaMlqbWZuR0yaAO38R6HFq+zzBytVU8OQQWvloozXTZprAHvQBx9p4e23BZl4zXUWdqlvGAqgVZCgU6gAXpS0g60tACEZrlPEegC+nWRODmusprigDD0+EWNuiNxgYp+sxrcadIOD8pqxdqJDt71V1FGisJOei0AfOPie2aLWJAOATVNrHK7uvet7xBibU5CeSGqrJ8iY46UAYuwo3IqeDJPSrRi3nOPepI7c43CgBjWwdCSBmuc1KPDMAOneurByu2sPU4cEsO9AHMFMPzQVyeKszrjNQqT+AoAhk+RTmmQ/jmpphz/ADpFC8AHrzQA1gRxmmJuGRT58hQe1Mhck8jFADhy3PTFLPH8gORzTiBtz0NJKTwM0AVlBVcAVo2Fv5hBPSi1t/M5PSqviXWbfRbEhWBkI4A65oAoeNPES6batbWzAzuMDHb3ryl3Z3LOSzE5JNT393Le3TzzsWdjn6VWoAKKKKACiiigAooooAWkoooAKKKKAFoAzSUtAGn4f1WTSr9JUYhM/MBXt1jew6zpqshDEryK+fq6vwPr7aberDKxMLnA9qAO/nhe3cqRgVEMnqOK6O6jS9shLEQSRkEVzrKyOd3A9KAFKgjHf2qTbhelNgG45qbOGwKAJrf3/CtqyHGBWPGemOTW1p5AwfUUAWwfL+tW7WYuwyaSOHzQOKkS38ts0Aa8Jylem/CmJAly4HzdK840yzlmP7tSSR2r034a2s9qbnzlIBHGaAO8pCMjFKaKAGqu3gU49KKKAIw3zkU+ohzIeKloAU00nmmSyLGhZjgCsK98S2dsSGkGR70AbzEKpY4AAr55+LN219rZVWyinGK7/wAQ+PIUt3jtzliMZryK8ma+vGlfksc0AVUttsHK84rp/BF39gvEfOBmspVG3FEQaN8qcUAfQdnr9tLAGZxnFPh1iCWXarg14L/bE8K7Ec4+tWdO164inDM5oA+hUlVgCDwakBya8y0jxcNqLI3auy0vXbe6UAuATQBuE0tVobqKeXZE4YgZ4qyaADvSdR70tHegDB8SR3MFubq0yxj5KiuFuvH8FzbPbMu2blSD616xgMMEZB6ivnH4saG2heK/PgBFvcnevpmgCtcwmW4eVujHIrOush8dRWzAwltFYdxVS4hU9qAIoU/dA4pHkCHHapgQqbc81TmcBjzQA5iDz61m6gCM56Vog7gMCqmpjMRIHagDk7yT94cdKgcgR/KfrUt1GQxPaq5+6RQAhG5QM0kS4O0YJ7GnqmV5ohGyXOaACdcqR3qFGAIHWrFwwb7tVvKKsGoAlbpzUsEJlIB6CpLa3a5OegFQ69qttotozSMC+OB3JoAbrur2+i2TMzDdjAA65ryLVdRm1K6aadicnhfSn6zqk2qXLSyk7c8L6Vn0AJRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAtKCVYEHBByKSigD1P4feJBPCLO6YbgMD3rptWted6jjrxXh+n3b2V3HPGSCp7V7b4Z1KPWNMUlgWxg80AUYmCAg9qTzSX4xVrUbRonO0ZFZ8YO/B4INAGtaMMdK17JuR2FYNvuz14rWtWKfyoA6S1fAHNWWdcj1FY0Erdjg1O8rAZ/OgD0XwHqFtHdKk+3njmvY7WOJYw0IG0jORXynFqMkEgaNirCvbPhR4uTVbY6fdSAXMY+TcfvCgD0f8AlRRTXdY0Z5GCqoyST0oAdwBz0rI1fXrKwXZ5yyXB4WNTk15t8Q/G09xO1jpExSFeGkXqTT/hhoj3tyb6+ZpNvI3HOTQB6bpbTTQrLKpUtzircxIQkdhmpVUADsKq6pdw2NlLNcOqoqnkmgDzHxb41MUslqp2kcV5rqGqSTuXMhwfeuW+JHiuD+3p5InBUE4xXn9741nc7YjxQB6y10pb53yPWnQ3cIfAda8Om8VX7k4cgVV/4Si+VsiU/SgD3+bUIU5LjiqE/iKzhOGdc/WvEpfFV/KuC+OOtZUuo3E0mWlY5PrQB9D2uqWt2w2yKW+tXgwD8fnXztY6zd2ThopWwOxrr9M8fyIircA5oA9lhmIIAODWxa308S5Vz+deMw+P4twIzgVvaf4+tZAAzgHHegD2Dwj4iltPEETXDkxOdrAnsa9sR1kQMhypGQRXyfZ+JLO4dSsgB7YNeu+BfGqpAltcSB4xwCTyKAPVO9JTLeaO4hWSJgyMOCKfQAtcH8YtJTUPDYuNuZLdtwPtXeVgePZEj8K3xcjG3A+tAHgumT7bXYeq0sr5yOtVLH5mbHTNXPLwDn8qAK27bkntWZcFppzjp6Vddf3hGaRECNuNAEltFsQAdar3sfB5q5EcnnioNQIWFqAON1QFXxnjNU1yAWNT6i/mSHHUVCuNmD1oARGLMaSRCGBzUY+Vjtp+SetACBSThRVy2gMh+boO9LZwF+WHHWqHiTXoNHtWAYGUjgUAO13W7fQ7VsMDIRwvc15LrOqT6rdtPcMTz8q9hUep6hPqNy01w5Yk8D0qpQAUlFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUvakooAWul8Fa0+m36xlv3bnpmuapVJUhlOCPSgD6IbZf2SyRnORmsOSDDnAwe9YHgDxMHQWlyfnHHPeu2vYA6+bHjn0oAoWmA4FbtrEsi571z0efMFbti+MdzQBZx5bkZqwXHlgnFQupZgcU90O0CgCpIm5yR0NOs7250e7iu7Z2R4zkEVOkJxzmq98CIyGoA9c0b4y2zWYGox/v1HJHGa5Pxd8XW1NjbW8ghgPBAOM15DrUMiwSPCxDYNeY3N5dC4be7Ag460AfQi69Z43M4LZyTXqHgD4g6RZWXl3UyRjHPNfFo1O72/wCubI96Z/al6Qf37jPbNAH2r4t+PegaRGy2QNxN29K+f/HXxs1nxGzxiQxQHoi8CvIXkaVz5khb3JqLPJz0+tAF69v5ryRnmcknrVTzNp681ESCvQnmkZuB9KAHs57nFMOd3PBxSBiV7YpDnI3CgBwPqaUMd2R0FMBJIx2pD1+XOKALAfJGef6U5SC+O3aq4IGD+dPRskFjnmgC0CeCOtSRyELwSMGqeTkdvSn+ZnI9etAGpaXk8ZBSRge3NdRpHjPULBx+8LYriYZfU9KsiUY5GCaAPpT4T/HD7NqUOn64T9klbbv7ofWvp+CWO4hSWFw8bqGVh0IPevzJMpVw6naR6V9cfsy/EyLVNMXw5q84W8gH7h3P319KAPoGvKfjp4iSy06HTInHnSncw9BXpuqX1vptjNd3UipFGpYkmvkPxhr03ibxXc3ZJMe4hPpQBu6U+IAxPLVf88DrWJZz4UAdAMVb3hhnNAFibG4kd6rXLYUY71LE25cHqKgkIPB6UAPtZTjJqvqkn7ps81YiQBeKzdabbEe5oA5W6f8AfHNRF+Peo5n3TEHjFP27lGDwaAHLjnmrtnAZDlh8tVLa3ZnyR8tGt6zBpNkxZhvIwBQAzxJrsWk2zKGAcjivJdU1CbUbpppmJyeBnpTtX1GbUrppZWJGflHpVGgBKKKKACiiigAooooAKKKKAF7UlFFABRRRQAUUUUAFFFFABRRRQAUUUUAFKKSlBoAmtZ3tp0ljOCpzwa9e8HeIY9RtVikPzAYOa8c6gnFXNL1CXT7lZYmI55FAHuU9vtk3J0PpV2wYBgDzXN+GfEltqMAWVlEnoa6GHaJN8ZBFAG4ihh9KR8gY/wAmobe6UjHQ1OzCTpnNACBuKpagQ61YdeOKqXAIU5oAyXh81WBHFeVeMdPa11EsEKo3evYY1y3Peq2saNb6hbMsqA8cEigDwYtzjOAKcSeMDitnxHoE2l3DbQWizwQOlYwACE5IY9aAGtgn1HSozjbgA596s7AOSeO4phjzkluPWgCvyD6Ucj0qUrk9PxpTFn8PSgCE/rihc59amCkHkc4xRtJJAHOKAIQeQQeaOo4NShcDpTSORx0689aAGg4/GnDqT2FKyfd7gClYFuWGKAGoRj5h070o+XPc0u3Kk9aMMBgcetAApyOanVxgkCo8dBnNHAwB370AS7sLyM1veDLe/l1WKfT3eN4jkOpxWHaW8t5cxwRAszHHFe5eDNATSdNRmUeYRkmgC5rfiPXr6wSzv7qV0C4OT1qro9ooiJI+c1dv0WY5HWltAI1A6UAPSIxnkcGpwSOo5o3bsYpSpOTmgB9tJgsCaUoWJ54NQwjPSpo2OcGgCRMxr8xNc/rtxnIFaupXXkp15rlLyf7Q5HSgDNwTISeQTV22gMjDjin29mTyelR6xqsGkWzMzDOOlADNc1SHSrNiWGQOPevJdV1GbUbhpJmOM8Cpdc1WbVLtpJG+TPyrWbQAGkoooAKKKKACilpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAHZ7UdabS0AT2tzLayh4WIIr0Hwp4t3Yiumwe2a84zxxTlYqQVJBFAH0JaypcorxvkegrVgk2Lh/zrxfwj4qks5UiuHyuepr2DSbuK+gV42BzzxQBfjw5BxTZ4RjpxUsY8tiD3qVgH4B5oAyhEA/SiZCeFNXhCd3I4p32bJHFAGBf6TFew7ZVByK898Q+C5YXaWzBOecV7Olrz0q1Fp0cwxIgI96APnTQ/CGt65qK2WnWMsspPOBxXq9n+zR4pntlkmntonIzsPWvo34TaTp9lZzy20aC4JG5scivQjigD4M8UfA3xjoMTS/YTdwqMloOf0rze7sbqykMV1BLC44KupBr9O+oOelcx4p8B+HPE9vJHqumwOzD/WKu1h75oA/OeOMMcdPSneTg5zzX0r4u/ZpvI7l5fDV8kkBORHLwRXB3/wK8a2m5hp4lA/uNmgDyPywR0IPem+SR0711Gr+FNb0SVk1LTriD3ZDg/jVW20TU7j5oLG4k91jJoAwVhJXkY+lBj7HoK6M+HNX3Bf7Oust28s16p8NvgFq3iONbzWS2n2Z6Bh87D6UAeDY9OtKsUjthEZiewGa+2tJ/Z08IWYU3P2i5YddzYFdxo3w08JaPtNno9vuH8TjcaAPztkgmhP72J0/3hin2VjcX04S2hZ2JxwK/RDxP8N/C/iK0MN7pcCnHDxrtIrE0z4R+G9FtSLS2G5RkMw5oA+ZvBPghtPVbu7X96ecEdK7KebI8tRwOOK6bxSgtbx7aLARTgYrmTbtu3UAVjGSPm6VLFB+7JFDBgamtmONpNABEuOvX0pw28rUUrfPkVVa5CvkmgDSVVB4xUd0wiG4VSN3z1xRPMJYiM5NAGLq175rlfwqjb25ZtxGB61dntgrmRzgd65nxN4khsYmjgYGXHQGgDS1zXLfSrUguN+OleVazqs+qXLSSk7M8LVe/vZr6YyTsSew9Kq0AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAtKDwKbSjrQA4HnIru/h94le1ukt7hztPQk1wnTntSxs0bq6HDDkUAfU0MiXVsjxkE4zVaSQxvzmvPPhx4tDqlrdOd445NekXSrNHvTvQBLbTCRsVoxIDyRWDaMUc59a3raZSoz1oAkKgc09ZMcdKC67elQSOAeD+FAHVeD9efSL9TI37l+GFeyWd1DeQLNbuGQjPFfOQmDKOa19H8WXmiSK0blo88qTxigD36krkfDvjvS9WRVeQQTd1Y100F7b3DYhmRz6A0AWc0Z96SigCte6fZ3ybL21hnX0kQGmW2lafbptgsreNfRYwKuUUAQfYrXdn7NDuHfYKnAAGAMD0FBooAM0UUtACMQqlmOABkmuF1fxzZ7pre2cMRlc1B8TfFqafYSafYvuuZVwzA/dFeK2iSoTIzEknvQB0Gszi7u2lxyTWZNtCnGM00yljk1GWJxQAzyifSkZNucAVOGAHvVW4uAqn0oAo3zlFJHWsaWQs3XIq7dzF8gVWt7YyMaACIM5GT+dSTXEdpCWkIGOajv547GEs5AwM15X4t8Ty3kzQ2zkIDgkUAaHizxczu8FoT6E5rg5ZHlcvIxZj1JppJJyetFACUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUALSr1GTj3ptLQBPaXMlpcLLCxDKe1ey+BvFaX9usUzYkAwQTXiYq3pl7NY3KSwMQc0AfSMq8B4+lOtLoo2CeM1i+ENSkv7BGmUZxzzW3JEiscDGaAL8dyDzmkMm49eKpJgKOKsQAMeRQBKCdw5OKLhTJEBUioCcVbSNNnSgDnGjmgkyjEH2rovDPiG+0+9il81iFPIJqOSGMk5Wq4RFb7ooA+hPD3iWy1e2QrKqTY5Qmt3IxnI+tfMIu5rV90DshAzwa3bTxbqvkrF9obb060Aexa54ktNLljjZwzMcHB6VtW08dxAksLBkYZBFfO89zJdSCSdmdsnkmtPSPFOoaU4WCQlP7rHigD3uuO8a+NLfw5JFGAJJCfmAPQVyN1481Ke32hVQnuDXCeIJWvyZbglnJ6k0Ae7aV4y0jULRZxcohIyVJ6VzXi/x6kcLwaY2WPG+vEbfdFIVR2A9M1qoQQNwJPqTQBaYyX07T3DFmY5yetRsgLhRUkMn+z+tCOPNyVGaAK8kRUd6jA9B0rQmlHTYKqSSBRwtAFSZiBWVclnYkVpzSA8baqbhuHy0AQQ226Mk1BcTR2SszkACtR5tkTEKOB615T8RdcnQmGJdgbjOaAMrxv4me8uGt7ZsIDyRXFHmhiSck5JpKAClpKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This coronal computed tomography image shows a radio-opaque nasal foreign body (yellow arrow) in a child with suspected sinusitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38370=[""].join("\n");
var outline_f37_30_38370=null;
var title_f37_30_38371="Staphylococcal folliculitis on leg";
var content_f37_30_38371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Staphylococcal folliculitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple follicularly-based inflammatory papules and pustules are present on the leg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38371=[""].join("\n");
var outline_f37_30_38371=null;
var title_f37_30_38372="Glimepiride: Patient drug information";
var content_f37_30_38372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Glimepiride: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=see_link\">",
"     see \"Glimepiride: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F176236\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amaryl&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F176237\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amaryl&reg;;",
"     </li>",
"     <li>",
"      Apo-Glimepiride&reg;;",
"     </li>",
"     <li>",
"      Novo-Glimepiride;",
"     </li>",
"     <li>",
"      PMS-Glimepiride;",
"     </li>",
"     <li>",
"      ratio-Glimepiride;",
"     </li>",
"     <li>",
"      Sandoz-Glimepiride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to glimepiride or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Acidic blood problem or type 1 diabetes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697009",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could be more sensitive to low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696699",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful if you have G6PD deficiency. Anemia may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698422",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check your blood sugar as you have been told by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022552\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022547\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be used alone or with other high blood sugar (diabetes) drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695917",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with the first meal of the day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696502",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been more than 2 to 3 hours, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12510 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-109.230.63.219-AC07DF7577-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38372=[""].join("\n");
var outline_f37_30_38372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176236\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F176237\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022545\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022544\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022549\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022550\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022552\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022547\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022548\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022553\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022554\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8823?source=related_link\">",
"      Glimepiride: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_30_38373="Acid reflux (gastroesophageal reflux disease) in adults";
var content_f37_30_38373=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acid reflux (gastroesophageal reflux disease) in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/30/38373/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38373/contributors\" id=\"au6515\">",
"       Peter J Kahrilas, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/30/38373/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38373/contributors\" id=\"se5165\">",
"       Nicholas J Talley, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?37/30/38373/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38373/contributors\" id=\"de8151\">",
"       Shilpa Grover, MD, MPH",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/30/38373?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      GASTROESOPHAGEAL REFLUX OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Gastroesophageal reflux, also known as acid reflux, occurs when the stomach contents reflux or back up into the esophagus",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     mouth. Reflux is a normal process that occurs in healthy infants, children, and adults. Most episodes are brief and do not cause bothersome symptoms or complications.",
"    </p>",
"    <p>",
"     In contrast, people with gastroesophageal reflux disease (GERD) experience bothersome symptoms as a result of the reflux. Symptoms can include heartburn, regurgitation, vomiting, and difficulty or pain with swallowing. The reflux of stomach acid can adversely affect the vocal cords causing hoarseness or even be inhaled into the lungs (called aspiration).",
"    </p>",
"    <p>",
"     This topic review discusses the symptoms, causes, diagnosis, and treatment of adults with gastroesophageal reflux disease. A discussion of gastroesophageal reflux in infants, children, and adolescents is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/50/32547?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"      \"Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      WHAT IS GASTROESOPHAGEAL REFLUX?",
"     </span>",
"    </p>",
"    <p>",
"     When we eat, food is carried from the mouth to the stomach through the esophagus, a tube-like structure that is approximately 10 inches long and 1 inch wide in adults (",
"     <a class=\"graphic graphic_figure graphicRef79301 \" href=\"mobipreview.htm?8/28/8642\">",
"      figure 1",
"     </a>",
"     ). The esophagus is made of tissue and muscle layers that expand and contract to propel food to the stomach through a series of wave-like movements called peristalsis.",
"    </p>",
"    <p>",
"     At the lower end of the esophagus, where it joins the stomach, there is a circular ring of muscle called the lower esophageal sphincter (LES). After swallowing, the LES relaxes to allow food to enter the stomach and then contracts to prevent the back-up of food and acid into the esophagus.",
"    </p>",
"    <p>",
"     However, sometimes the LES is weak or becomes relaxed because the stomach is distended, allowing liquids in the stomach to wash back into the esophagus. This happens occasionally in all individuals. Most of these episodes occur shortly after meals, are brief, and do not cause symptoms. Normally, acid reflux should occur only rarely during sleep.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Acid reflux",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acid reflux becomes gastroesophageal reflux disease (GERD) when it causes bothersome symptoms or injury to the esophagus. The amount of acid reflux required to cause GERD varies.",
"    </p>",
"    <p>",
"     In general, damage to the esophagus is more likely to occur when acid refluxes frequently, the reflux is very acidic, or the esophagus is unable to clear away the acid quickly. The most common symptoms associated with acid reflux are heartburn, regurgitation, chest pain, and trouble swallowing. The treatments of GERD are designed to prevent one or all of these symptoms from occurring.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Hiatus hernia",
"     </span>",
"     &nbsp;&mdash;&nbsp;The diaphragm is a large flat muscle at the base of the lungs that contracts and relaxes as a person breathes in and out. The esophagus passes through an opening in the diaphragm called the diaphragmatic hiatus before it joins with the stomach.",
"    </p>",
"    <p>",
"     Normally, the diaphragm contracts, which improves the strength of the LES, especially during bending, coughing, or straining. If there is a weakening in the diaphragm muscle at the hiatus, the stomach may be able to partially slip through the diaphragm into the chest, forming a sliding hiatus hernia.",
"    </p>",
"    <p>",
"     The presence of a hiatus hernia makes acid reflux more likely. A hiatus hernia is more common in people over age 50. Obesity and pregnancy are also contributing factors. The exact cause is unknown but may be related to the loosening of the tissues around the diaphragm that occurs with advancing age. There is no way to prevent a hiatus hernia.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      ACID REFLUX SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     People who experience heartburn at least two to three times a week may have gastroesophageal reflux disease, or GERD. The most common symptom of GERD, heartburn, is estimated to affect 10 million adults in the United States on a daily basis. Heartburn is experienced as a burning sensation in the center of the chest, which sometimes spreads to the throat; there also may be an acid taste in the throat. Less common symptoms include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Stomach pain (pain in the upper abdomen)",
"      </li>",
"      <li>",
"       Non-burning chest pain",
"      </li>",
"      <li>",
"       Difficulty swallowing (called dysphagia), or food getting stuck",
"      </li>",
"      <li>",
"       Painful swallowing (called odynophagia)",
"      </li>",
"      <li>",
"       Persistent",
"       <span class=\"nowrap\">",
"        laryngitis/hoarseness",
"       </span>",
"      </li>",
"      <li>",
"       Persistent sore throat",
"      </li>",
"      <li>",
"       Chronic cough, new onset asthma, or asthma only at night",
"      </li>",
"      <li>",
"       Regurgitation of",
"       <span class=\"nowrap\">",
"        foods/fluids;",
"       </span>",
"       taste of acid in the throat",
"      </li>",
"      <li>",
"       Sense of a lump in the throat",
"      </li>",
"      <li>",
"       Worsening dental disease",
"      </li>",
"      <li>",
"       Recurrent lung infections (called pneumonia)",
"      </li>",
"      <li>",
"       Chronic sinusitis",
"      </li>",
"      <li>",
"       Waking up with a choking sensation",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      When to seek help",
"     </span>",
"     &nbsp;&mdash;&nbsp;The following signs and symptoms may indicate a more serious problem, and should be reported to a healthcare provider immediately:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Difficulty or pain with swallowing (feeling that food gets \"stuck\")",
"      </li>",
"      <li>",
"       Unexplained weight loss",
"      </li>",
"      <li>",
"       Chest pain",
"      </li>",
"      <li>",
"       Choking",
"      </li>",
"      <li>",
"       Bleeding (vomiting blood or dark-colored stools)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      ACID REFLUX DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Acid reflux is usually diagnosed based upon symptoms and the response to treatment. In people who have symptoms of acid reflux but no evidence of complications, a trial of treatment with lifestyle changes and in some cases, a medication, are often recommended, without testing. Specific testing is required when the diagnosis is unclear or if there are more serious signs or symptoms as described above.",
"    </p>",
"    <p>",
"     It is important to rule out potentially life threatening problems that can cause symptoms similar to those of gastroesophageal reflux disease. This is particularly true with chest pain, since chest pain can also be a symptom of heart disease (see",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"      \"Patient information: Chest pain (Beyond the Basics)\"",
"     </a>",
"     ). When the symptoms are not life threatening and the diagnosis of gastroesophageal reflux disease is not clear, one or more of the following tests may be recommended.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Endoscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;An upper endoscopy is commonly used to evaluate the esophagus. A small, flexible tube is passed into the esophagus, stomach, and small intestine. The tube has a light source and a camera that displays magnified images. Damage to the lining of these structures can be evaluated and a small sample of tissue (biopsy) can be taken to determine the extent of tissue damage. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"      \"Patient information: Upper endoscopy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      24-hour esophageal pH study",
"     </span>",
"     &nbsp;&mdash;&nbsp;A 24-hour esophageal pH study is the most direct way to measure the frequency of acid reflux, although the study is not always helpful in diagnosing gastroesophageal reflux disease or reflux-associated problems. It is usually reserved for people whose diagnosis is unclear after endoscopy or a trial of treatment. It is also useful for people who continue to have symptoms despite treatment.",
"    </p>",
"    <p>",
"     The test involves inserting a thin tube through the nose and into the esophagus. The tube is left in the esophagus for 24 hours. During this time the patient keeps a diary of symptoms. The tube is attached to a small device that measures how often stomach acid is reaching the esophagus. The data are then analyzed to determine the frequency of reflux and the relationship of reflux to symptoms.",
"    </p>",
"    <p>",
"     An alternate method for measuring pH uses a device that is attached to the esophagus and broadcasts pH information to a monitor worn outside of the body. This avoids the need for a tube in the esophagus and nose. The main disadvantage is that an endoscopy procedure is required to place the device (it does not require removal, but simply passes on its own in the stool).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Esophageal manometry",
"     </span>",
"     &nbsp;&mdash;&nbsp;Esophageal manometry involves swallowing a tube that measures the muscle contractions of the esophagus. This can help to determine if the lower esophageal sphincter is functioning properly. This test is usually reserved for people in whom the diagnosis is unclear after other testing or in whom surgery for reflux disease is being considered.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      ACID REFLUX COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     The vast majority of patients with gastroesophageal reflux disease will",
"     <strong>",
"      not",
"     </strong>",
"     develop serious complications, particularly when reflux is adequately treated. However, a number of serious complications can arise in patients with severe gastroesophageal reflux disease.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Ulcers",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ulcers can form in the esophagus as a result of burning from stomach acid. In some cases, bleeding occurs. You may not be aware of bleeding, but it may be detected in a stool sample to test for traces of blood that may not be visible. This test is performed by putting a small amount of stool on a chemically coated card.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Stricture",
"     </span>",
"     &nbsp;&mdash;&nbsp;Damage from acid can cause the esophagus to scar and narrow, causing a blockage (stricture) that can cause food or pills to get stuck in the esophagus. The narrowing is caused by scar tissue that develops as a result of ulcers that repeatedly damage and then heal in the esophagus.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Lung and throat problems",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some people reflux acid into the throat, causing inflammation of the vocal cords, a sore throat, or a hoarse voice. The acid can be inhaled into the lungs and cause a type of pneumonia (aspiration pneumonia) or asthma symptoms. Chronic acid reflux into the lungs may eventually cause permanent lung damage, called pulmonary fibrosis or bronchiectasis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Barrett's esophagus",
"     </span>",
"     &nbsp;&mdash;&nbsp;Barrett's esophagus occurs when the normal cells that line the lower esophagus (squamous cells) are replaced by a different cell type (intestinal cells). This process usually results from repeated damage to the esophageal lining, and the most common cause is longstanding gastroesophageal reflux disease. The intestinal cells have a small risk of transforming into cancer cells.",
"    </p>",
"    <p>",
"     As a result, people with Barrett's esophagus are advised to have a periodic endoscopy to monitor for early warning signs of cancer. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/39/2676?source=see_link\">",
"      \"Patient information: Barrett's esophagus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h2\">",
"      Esophageal cancer",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are two main types of esophageal cancer: adenocarcinoma and squamous cell carcinoma. A major risk factor for adenocarcinoma is Barrett's esophagus, discussed above. Squamous cell carcinoma does not appear to be related to GERD. Unfortunately, adenocarcinoma of the esophagus is on the rise in the United States and in many other countries. However, only a small percentage of people with GERD will develop Barrett's esophagus and an even smaller percentage will develop adenocarcinoma. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/39/2676?source=see_link\">",
"      \"Patient information: Barrett's esophagus (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H17\">",
"     <span class=\"h1\">",
"      REFLUX TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Gastroesophageal reflux disease is treated according to its severity.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h2\">",
"      Mild symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Initial treatments for mild acid reflux include dietary changes and using non-prescription medications, including antacids or histamine antagonists.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h3\">",
"      Lifestyle changes",
"     </span>",
"     &nbsp;&mdash;&nbsp;Changes to the diet or lifestyle have been recommended for many years, although their effectiveness has not been extensively evaluated in well-designed clinical trials. A review of the literature concluded that weight loss and elevating the head of your bed may be helpful, but other dietary changes were not found helpful in all patients [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/30/38373/abstract/1\">",
"      1",
"     </a>",
"     ]. Thus, these recommendations may be helpful in some, but not all people with mild symptoms of acid reflux.",
"    </p>",
"    <p>",
"     For people with mild acid reflux, these treatments can be tried before seeking medical attention. However, anyone with more serious symptoms should speak to their healthcare provider before using any treatment (see",
"     <a class=\"local\" href=\"#H5\">",
"      'Acid reflux symptoms'",
"     </a>",
"     above).",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Weight loss &ndash; Losing weight may help people who are overweight to reduce acid reflux. In addition, weight loss has a number of other health benefits, including a decreased risk of type 2 diabetes and heart disease. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"        \"Patient information: Weight loss treatments (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Raise the head of the bed six to eight inches &ndash; Although most people only have heartburn for the two- to three-hour period after meals, some wake up at night with heartburn. People with nighttime heartburn can elevate the head of their bed, which raises the head and shoulders higher than the stomach, allowing gravity to prevent acid from refluxing.",
"       <br/>",
"       <br/>",
"       Raising the head of the bed can be done with blocks of wood under the legs of the bed or a foam wedge under the mattress. Several manufacturers have developed commercial products for this purpose. However, it is not helpful to use additional pillows; this can cause an unnatural bend in the body that increases pressure on the stomach, worsening acid reflux.",
"      </li>",
"      <li>",
"       Avoid acid reflux inducing foods &ndash; Some foods also cause relaxation of the lower esophageal sphincter, promoting acid reflux. Excessive caffeine, chocolate, alcohol, peppermint, and fatty foods may cause bothersome acid reflux in some people.",
"      </li>",
"      <li>",
"       Quit smoking &ndash; Saliva helps to neutralize refluxed acid, and smoking reduces the amount of saliva in the mouth and throat. Smoking also lowers the pressure in the lower esophageal sphincter and provokes coughing, causing frequent episodes of acid reflux in the esophagus. Quitting smoking can reduce or eliminate symptoms of mild reflux. (See",
"       <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"        \"Patient information: Quitting smoking (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"      <li>",
"       Avoid large and late meals &ndash; Lying down with a full stomach may increase the risk of acid reflux. By eating three or more hours before bedtime, reflux may be reduced. In addition, eating smaller meals may prevent the stomach from becoming overdistended, which can cause acid reflux.",
"      </li>",
"      <li>",
"       Avoid tight fitting clothing &ndash; At a minimum, tight fitting clothing can increase discomfort, but it may also increase pressure in the abdomen, forcing stomach contents into the esophagus.",
"      </li>",
"      <li>",
"       Chew gum or use oral lozenges &ndash; Chewing gum or using lozenges can increase saliva production, which may help to clear stomach acid that has entered the esophagus.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H872169141\">",
"     <span class=\"h3\">",
"      Antacids",
"     </span>",
"     &nbsp;&mdash;&nbsp;Antacids are commonly used for short-term relief of acid reflux. However, the stomach acid is only neutralized very briefly after each dose, so they are not very effective. Examples of antacids include Tums&reg;, Maalox&reg;, and Mylanta&reg;.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H872169148\">",
"     <span class=\"h3\">",
"      Histamine antagonists",
"     </span>",
"     &nbsp;&mdash;&nbsp;The histamine antagonists reduce production of acid in the stomach. However, they are somewhat less effective than proton pump inhibitors (see",
"     <a class=\"local\" href=\"#H23\">",
"      'Proton pump inhibitors'",
"     </a>",
"     below).",
"    </p>",
"    <p>",
"     Examples of histamine antagonists available in the United States include ranitidine (Zantac&reg;), famotidine (Pepcid&reg;), cimetidine (Tagamet&reg;), and nizatidine (Axid&reg;). These medications are usually taken by mouth once or twice per day. Cimetidine, ranitidine, and famotidine are available in prescription and non-prescription strengths.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Moderate to severe symptoms",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with moderate to severe symptoms of acid reflux, complications of gastroesophageal reflux disease, or mild acid reflux symptoms that have not responded to the lifestyle modifications and the medications described above usually require treatment with prescription medications. Most patients are treated with a proton pump inhibitor.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h3\">",
"      Proton pump inhibitors",
"     </span>",
"     &nbsp;&mdash;&nbsp;PPIs include omeprazole (Prilosec&reg;), esomeprazole (Nexium&reg;), lansoprazole (Prevacid&reg;), dexlansoprazole (Kapidex&trade;), pantoprazole (Protonix&reg;), and rabeprazole (AcipHex&reg;), which are stronger and more effective than the H2 antagonists.",
"    </p>",
"    <p>",
"     Once the optimal dose and type of PPI is found, you will probably be kept on the PPI for approximately eight weeks. Depending upon your symptoms after eight weeks, the medication dose may be decreased or discontinued. If symptoms return within three months, long-term treatment is usually recommended. If symptoms do not return within three months, treatment may be needed only intermittently. The goal of treatment for GERD is to take the lowest possible dose of medication that controls symptoms and prevents complications.",
"    </p>",
"    <p>",
"     Proton pump inhibitors are safe, although they may be expensive, especially if taken for a long period of time. Long-term risks of PPIs may include an increased risk of gut infections, such as Clostridium (C. diff), or reduced absorption of minerals and nutrients. In general, these risks are small. However, even a small risk emphasizes the need to take the lowest possible dose for the shortest possible time. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/52/19267?source=see_link\">",
"      \"Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h3\">",
"      If symptoms are not controlled",
"     </span>",
"     &nbsp;&mdash;&nbsp;If your symptoms of gastroesophageal reflux disease are not adequately controlled with one PPI, one or more of the following may be recommended:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       An alternate PPI may be prescribed or the dose of the PPI may be increased",
"      </li>",
"      <li>",
"       The PPI may be given twice per day instead of once",
"      </li>",
"      <li>",
"       Further testing may be recommended to confirm the diagnosis",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       determine if another problem is causing symptoms",
"      </li>",
"      <li>",
"       Surgical treatment may be considered",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H25\">",
"     <span class=\"h2\">",
"      Surgical treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prior to the development of the potent acid-reducing medications described above, surgery was used for severe cases of GERD that did not resolve with medical treatment. Because of the effectiveness of medical therapy, the role of surgery has become more complex. In general, anti-reflux surgery involves repairing the hiatus hernia and strengthening the lower esophageal sphincter.",
"    </p>",
"    <p>",
"     The most common surgical treatment is the laparoscopic Nissen fundoplication. This procedure involves wrapping the upper part of the stomach around the lower end of the esophagus (",
"     <a class=\"graphic graphic_figure graphicRef72609 \" href=\"mobipreview.htm?39/45/40671\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Although the outcome of surgery is usually good, complications can occur. Examples include persistent difficulty swallowing (occurring in about 5 percent of patients), a sense of bloating and gas (known as \"gas-bloat syndrome\"), breakdown of the repair (1 to 2 percent of patients per year), or diarrhea due to inadvertent injury to the nerves leading to the stomach and intestines.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H261\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11444085\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/2/24610?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?39/11/40114?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?23/42/24226?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) during pregnancy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/24/43394?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in babies (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/41/33426?source=see_link\">",
"      Patient information: Upper endoscopy (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?5/53/5971?source=see_link\">",
"      Patient information: Peptic ulcers (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/33/37393?source=see_link\">",
"      Patient information: Hiatal hernia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/29/13778?source=see_link\">",
"      Patient information: Barrett's esophagus (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?19/50/20258?source=see_link\">",
"      Patient information: Achalasia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/6/22625?source=see_link\">",
"      Patient information: Hiccups (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/0/43011?source=see_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/19/10546?source=see_link\">",
"      Patient information: Esophageal stricture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/54/39778?source=see_link\">",
"      Patient information: Eosinophilic esophagitis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?38/25/39314?source=see_link\">",
"      Patient information: Bronchiectasis in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11444207\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/50/32547?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux disease) in children and adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/16/16643?source=see_link\">",
"      Patient information: Acid reflux (gastroesophageal reflux) in infants (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/9/43157?source=see_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?21/0/21506?source=see_link\">",
"      Patient information: Upper endoscopy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/39/2676?source=see_link\">",
"      Patient information: Barrett's esophagus (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33876?source=see_link\">",
"      Patient information: Weight loss treatments (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?18/52/19267?source=see_link\">",
"      Patient information: Antibiotic-associated diarrhea caused by Clostridium difficile (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H28\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/18/17706?source=see_link\">",
"      Approach to refractory gastroesophageal reflux disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1879?source=see_link\">",
"      Clinical manifestations, diagnosis, and treatment of non-acid reflux",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/41/22168?source=see_link\">",
"      Clinical manifestations and diagnosis of gastroesophageal reflux in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19253?source=see_link\">",
"      Complications of gastroesophageal reflux in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25688?source=see_link\">",
"      Endoscopic therapy for gastroesophageal reflux disease: Sewing and full-thickness plication techniques",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/56/39816?source=see_link\">",
"      Gastroesophageal reflux and asthma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/46/9959?source=see_link\">",
"      Helicobacter pylori and gastroesophageal reflux disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/10/33960?source=see_link\">",
"      Laryngopharyngeal reflux",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/53/42840?source=see_link\">",
"      Medical management of gastroesophageal reflux disease in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/28/25034?source=see_link\">",
"      Overview and comparison of the proton pump inhibitors for the treatment of acid-related disorders",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/38/13928?source=see_link\">",
"      Pathophysiology of reflux esophagitis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42905?source=see_link\">",
"      Surgical management of gastroesophageal reflux in adults",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/gerd.html\">",
"        www.nlm.nih.gov/medlineplus/gerd.html",
"       </a>",
"       , available in Spanish)",
"      </li>",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://digestive.niddk.nih.gov/ddiseases/pubs/gerd/\">",
"        file://digestive.niddk.nih.gov/ddiseases/pubs/gerd/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The American Gastroenterological Association",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.gastro.org/patient-center/digestive-conditions/heartburn-gerd\">",
"        file://www.gastro.org/patient-center/digestive-conditions/heartburn-gerd",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The American College of Gastroenterology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acg.gi.org/patients/patientinfo/gerd.asp\">",
"        www.acg.gi.org/patients/patientinfo/gerd.asp",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?37/30/38373/abstract/1-5\">",
"      1-5",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/30/38373?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38373/abstract/1\">",
"      Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38373/abstract/2\">",
"      Hirano I, Richter JE, Practice Parameters Committee of the American College of Gastroenterology. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38373/abstract/3\">",
"      DeVault KR, Castell DO, American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38373/abstract/4\">",
"      Fass R, Sontag SJ, Traxler B, Sostek M. Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial. Clin Gastroenterol Hepatol 2006; 4:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38373/abstract/5\">",
"      Salminen PT, Hiekkanen HI, Rantala AP, Ovaska JT. Comparison of long-term outcome of laparoscopic and conventional nissen fundoplication: a prospective randomized study with an 11-year follow-up. Ann Surg 2007; 246:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f37_30_38373=[""].join("\n");
var outline_f37_30_38373=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           GASTROESOPHAGEAL REFLUX OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           WHAT IS GASTROESOPHAGEAL REFLUX?",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           ACID REFLUX SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           ACID REFLUX DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           ACID REFLUX COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H17\">",
"           REFLUX TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/28/8642\" title=\"figure 1\">",
"           GERD PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/45/40671\" title=\"figure 2\">",
"           Nissen fundoplication PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f37_30_38374="Polysomnography in obstructive sleep apnea in adults";
var content_f37_30_38374=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Polysomnography in obstructive sleep apnea in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38374/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38374/contributors\">",
"     Richard P Millman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38374/contributors\">",
"     Naomi R Kramer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38374/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38374/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38374/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38374/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/30/38374/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polysomnography (PSG) is a diagnostic test for obstructive sleep apnea (OSA), a disorder characterized by repetitive episodes of apnea or reduced inspiratory airflow due to upper airway obstruction during sleep. During PSG, the patient sleeps while connected to a variety of monitoring devices that record physiologic variables. Patterns of physiologic abnormalities during sleep may be diagnostic of OSA and other disorders.",
"   </p>",
"   <p>",
"    PSG is considered the gold standard diagnostic test when it is performed overnight in a sleep laboratory with a technologist in attendance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Its indications, contraindications, and complications are discussed here. The variables that are measured and the information that is derived are also reviewed.",
"   </p>",
"   <p>",
"    In some patients, the diagnostic evaluation may be performed at home without a technician in attendance. This is described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumption of alcohol or caffeine prior to PSG may alter the nature and severity of the underlying sleep disorder that is being measured by PSG. As examples, alcohol may exacerbate OSA and alter sleep architecture, while caffeine may contribute to insomnia and sleep fragmentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients should abstain from caffeine in the afternoon and evening of the day on which PSG is planned. Alcohol is a more complex issue because the absence of alcohol on the night of PSG could yield a false negative result if the patient habitually consumes alcohol in the evening. However, it is clearly not safe to have patients drink and then drive themselves to the sleep laboratory, or to allow them drink in the laboratory. The danger could be reduced and the PSG may give a more accurate picture of a typical night's sleep if someone drove the patient to and from the sleep laboratory, but this creates the liability of having a potentially intoxicated patient in the sleep laboratory. Taking all of these concerns into consideration, it seems advisable to have patients avoid alcohol on the day of PSG. Portable monitoring may be an option for some patients if alcohol is felt to be a significant factor in their clinical presentation and the use of alcohol is unlikely to change. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17734?source=see_link\">",
"     \"Portable monitoring in obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients should continue their usual medications on the night of the PSG, including sleep aids. The medications should be recorded by the technician so that the results can be optimally interpreted. This is particularly true if a benzodiazepine is among the medications, since benzodiazepines may exacerbate OSA.",
"   </p>",
"   <p>",
"    For patients who have a history of insomnia, especially when sleeping in a new environment, we may prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    to take the evening of the PSG. Zolpidem is a sleep aid that improves sleep continuity and quality, thereby improving the quality of PSG without exacerbating sleep apnea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients who have never taken zolpidem in the past should try the medicine at home during one of the nights prior to PSG in order to assess their response to it. If it is effective, patients may bring it with them on the night of the study. Sleeping medication should be taken once the patient is in the lab and not prior to coming to the lab.",
"   </p>",
"   <p>",
"    Any patient who consumes a sedative and then wants to leave before the completion of the study should be encouraged to remain in the laboratory until the morning, even if the patient insists that the monitoring equipment be removed. The patient should not be allowed to drive home in the middle of the night under the influence of the sedative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Protocols",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient is connected to a variety of monitoring devices during PSG. The sleeping room is usually equipped with an infrared camera and audio system that allows the technologist to see, hear, and communicate with the patient without entering the bedroom.",
"   </p>",
"   <p>",
"    The technologist periodically documents relevant information in",
"    <span class=\"nowrap\">",
"     his/her",
"    </span>",
"    notes. This usually includes the heart rate, respiratory rate, oxygen saturation, presence or absence of snoring and its volume, and body position. When the study includes a CPAP titration, the technologist also documents which masks are tried and the reasons for changing. The pressure changes and mask leak can also be documented.",
"   </p>",
"   <p>",
"    Physiologic variables are also recorded digitally on a paperless computerized system while the patient sleeps and during any intervening wakefulness. Following collection, the data are scored manually by a technician who identifies physiologic events, stages of sleep, and wakefulness. Modern systems provide computer assistance by tabulating and collating the scored data. Newer software integrates video images of the patient onto the polysomnographic recordings.",
"   </p>",
"   <p>",
"    Synchronized digital video allows parasomnias and other movement disorders to be detected. The technologist should have a way of recording any abnormal movements using video or digital recording devices if such synchronized recording is not available. Abnormal movements during sleep should be documented, including the exact time, so that the stage of sleep during which the event occurred can be assessed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Split night studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a growing trend to perform split night studies. During a split night study, the diagnosis of OSA is established during the first portion of the study and the amount of positive airway pressure that is necessary to prevent upper airway collapse during sleep is determined during the remaining portion.",
"   </p>",
"   <p>",
"    According to the American Academy of Sleep Medicine's (AASM) practice parameters for PSG and related procedures, a split night study is a valid alternative to full night diagnostic PSG followed by a second full night of positive airway pressure titration, if the following three criteria are met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An apnea hypopnea index (AHI) of &ge;40 events per hour of sleep is documented during &ge;2 hours of sleep. Alternatively, an AHI of 20 to 39 events per hour of sleep is documented during &ge;2 hours of sleep and there is strong supportive evidence of OSA (eg, repetitive long obstructions with major desaturations).",
"     </li>",
"     <li>",
"      Positive airway pressure titration is conducted over &ge;3 hours, since obstructive events can worsen as the night progresses.",
"     </li>",
"     <li>",
"      Elimination or near elimination of obstructive events with positive airway pressure is documented by PSG during rapid eye movement (REM) and non-REM (NREM) sleep. This should include REM sleep in the supine position, when apneas are most likely to occur.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A second full night PSG should be performed for titration of positive airway pressure if the second and third criteria are not met [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This approach provides accurate appraisal of disease severity and establishes the correct positive airway pressure in a single night in the majority of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/6-9\">",
"     6-9",
"    </a>",
"    ]. Overall, split night PSG appears to be cost effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. It decreases health care costs, minimizes scheduling delays, and does not adversely affect compliance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Daytime studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daytime PSG may be used for night shift workers or other individuals who are usually awake at night and sleep during the day. The protocol and duration of the study are the same as those performed at night.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for PSG include diagnostic evaluation of suspected OSA, titration of positive airway pressure, and assessment of the adequacy of therapy that is already being used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of PSG in the diagnostic evaluation of suspected OSA is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"       \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Titration of positive airway pressure during PSG is also described elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=see_link&amp;anchor=H10#H10\">",
"       \"Initiation of positive airway pressure therapy for obstructive sleep apnea in adults\", section on 'Determining the amount of positive airway pressure'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      PSG can assess the efficacy of therapy when there is concern that the patient is not adequately treated with the currently prescribed therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/2\">",
"       2",
"      </a>",
"      ]. For patients who are receiving positive airway pressure therapy, PSG is performed with the device in position and the pressure is titrated if breakthrough OSA is detected. For patients who are being treated with an oral appliance, PSG is performed with the oral appliance in position and the patient is awakened if breakthrough OSA is identified. The patient is then asked to adjust the oral appliance to move the lower mandible further forward. Once the patient returns to sleep, the efficacy of the oral appliance in the new position is assessed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Significant weight loss may also be an indication for repeat PSG. The purpose is to determine if the patient has residual OSA and to reevaluate the positive airway pressure level for those patients receiving positive airway pressure therapy.",
"   </p>",
"   <p>",
"    For patients treated surgically, PSG is performed after postoperative healing is deemed complete. The presence of upper airway collapse despite therapy (eg, apneas, hypopneas, respiratory effort-related arousals) indicates that the surgical intervention was inadequate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PSG may also be used to assess Cheyne-Stokes breathing, hypoventilation, periodic limb movements during sleep, delta (slow wave) sleep parasomnias, and rapid eye movement (REM) sleep behavior disorder. Nocturnal seizures may be identified by PSG, but they are generally not considered an indication for PSG. A 24-hour (or longer) video electroencephalogram (EEG) allows more complete evaluation of suspected nocturnal seizures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no contraindications to PSG. Pacemakers and defibrillators are usually not a contraindication to PSG, but clinicians should check with their sleep laboratory. For inpatients, the risks versus the benefits of transfer from the hospital ward to the sleep laboratory should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of PSG are rare. The most common complication is skin irritation caused by adhesive used to attach electrodes to the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/1\">",
"     1",
"    </a>",
"    ]. Drawbacks include inconvenience, difficulty sleeping in the laboratory setting, strange surroundings, and discomfort related to the monitoring equipment or bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEASURED VARIABLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measurement of the following physiologic variables is required during PSG, according the American Academy of Sleep Medicine (AASM) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep stages &ndash; Global neural electroencephalographic activity (EEG), eye movements (ie, electrooculograms), and submental electromyographic activity (EMG) are used to identify the stages of sleep. The EEG is generally measured from the frontal, central, and occipital regions of the brain. The submental EMG detects hypotonia, which is typical of REM sleep, and is helpful in detecting involuntary clenching or grinding of the teeth.",
"     </li>",
"     <li>",
"      Respiratory effort &ndash; Esophageal manometry measures intrathoracic pressure swings. It is the gold standard for assessing ventilatory effort, but it is not routinely used because placement of the esophageal manometer is invasive [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/15\">",
"       15",
"      </a>",
"      ]. Respiratory inductive plethysmography and electromyography (EMG) with the leads spread across the chest wall and abdomen are alternative, noninvasive methods that can evaluate ventilatory effort [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/14-16\">",
"       14-16",
"      </a>",
"      ]. Strain gauges, piezo electrodes, or impedance devices spread across the chest wall and abdomen are also options. Respiratory inductive plethysmography is the noninvasive method recommended by the American Academy of Sleep Medicine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Airflow &ndash; Nasal prongs connected to a pressure transducer detect inspiratory flow and may be the most accurate method to identify subtle inspiratory flow limitation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/17\">",
"       17",
"      </a>",
"      ]. An important limitation of nasal pressure transducers is that they cannot detect mouth breathing. To overcome this limitation, a thermistor is usually added. Thermistors detect airflow at the mouth by sensing alterations in heat exchange. Thus, nasal pressure transducers are necessary for the diagnosis of hypopneas and thermistors are necessary for the diagnosis of apneas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A snoring microphone at the neck or end-tidal carbon dioxide (CO2) monitor is an adjunctive method used to identify airflow limitation. A limitation of end-tidal CO2 monitoring is that it measures exhaled gas mixed with room air, which underestimates the true exhaled CO2 tension. As a result, it is best to follow trends in the measured end-tidal CO2, rather than absolute values. Hypoventilation is suggested when the measured end-tidal CO2 is elevated. There is no high quality evidence that use of snoring microphones or routine end-tidal CO2 measurement is helpful for detecting apneas or hypopneas [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oxygen saturation &ndash; Pulse oximetry is used to monitor the oxyhemoglobin saturation during PSG. The signal averaging time should not exceed three seconds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/14\">",
"       14",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17734?source=see_link\">",
"       \"Portable monitoring in obstructive sleep apnea in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrocardiogram &ndash; Electrocardiography is performed to detect arrhythmias during sleep. Lead II alone is preferred, which can be obtained from a single torso electrode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following physiologic variables are recommended during PSG, according the AASM [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/2,14\">",
"     2,14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body position &ndash; Some patients only have abnormalities when sleeping in certain positions. Therefore, body position (eg, supine, left lateral, right lateral, prone) is monitored throughout the test using a position sensor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      video monitor. The technologist also documents the patient's position and when the patient changes position.",
"     </li>",
"     <li>",
"      Limb movements &ndash; An EMG of the anterior tibialis of both legs is generally monitored during PSG, in order to detect leg movements.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DERIVED INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;PSG can provide tremendous amounts of data that need to be analyzed and integrated. As a result, it should be interpreted by a specialist trained in the diagnosis of sleep disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/2\">",
"     2",
"    </a>",
"    ]. Patterns of abnormalities identified during PSG are often diagnostic. The following information is normally derived from an attended, in-laboratory PSG. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Total sleep time &ndash; The total sleep time (TST) is the total duration of light sleep (stages N1 and N2), deep sleep (stage N3), and rapid eye movement (REM) sleep [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sleep efficiency &ndash; Sleep efficiency (SE) is the TST divided by the total recording time (ie, the time in bed).",
"     </li>",
"     <li>",
"      Sleep stage percentage &ndash; The sleep stage percentage (SSP) for a particular sleep stage is the duration of that sleep stage divided by the TST.",
"     </li>",
"     <li>",
"      Sleep stage latency &ndash; The latency to any sleep stage is the duration from sleep onset to the initiation of that sleep stage.",
"     </li>",
"     <li>",
"      Arousals &ndash; Arousals range from full awakenings to three-second transient electroencephalography (EEG) shifts to a lighter stage of sleep (alpha, theta,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      frequencies greater than 16 Hz, but not sleep spindles, with at least 10 seconds of stable sleep preceding the change). During REM sleep, there should also be an increase in submental electromyography (EMG) activity lasting at least one second [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/14\">",
"       14",
"      </a>",
"      ]. Arousals are generally counted and then divided by the TST to give the number of arousals per hour of sleep (ie, arousal index). EEG arousals are an important measure of sleep disturbance and they provide a baseline from which to assess treatment response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Apneas &ndash; Apnea is the cessation, or near cessation, of airflow. It is typically characterized as being obstructive, central, or mixed. Precise criteria for scoring an apnea are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H3#H3\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypopneas &ndash; Hypopnea is an abnormal reduction of airflow to a degree that is insufficient to meet the criteria for an apnea. Precise criteria for scoring a hypopnea are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H7#H7\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Hypopnea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Respiratory Effort Related Arousals &ndash; Respiratory Effort Related Arousals (RERAs) are arousals that are associated with a change in airflow that does not meet the criteria for apnea or hypopnea. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H8#H8\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory effort related arousals'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Indices &ndash; Indices derived from polysomnographic data describe the frequency of abnormal respiratory events during sleep. These include the apnea index (AI), apnea hypopnea index (AHI), and respiratory disturbance index (RDI). It is helpful to report these indices at baseline and at each level of positive airway pressure during titration. These indices are described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=see_link&amp;anchor=H10#H10\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Summary measures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Snoring &ndash; The amount and intensity of snoring can be determined with a small microphone attached to the neck, under the chin. Some centers calculate a snoring index, which describes the number of snores per hour of sleep.",
"     </li>",
"     <li>",
"      Body position &ndash; With observation of body position, it can be determined whether obstructive apneas, hypopneas, or snoring are dependent upon body position.",
"     </li>",
"     <li>",
"      Oxyhemoglobin saturation &ndash; The baseline oxyhemoglobin saturation, mean oxyhemoglobin saturation, frequency of desaturation episodes, duration of desaturation episodes, severity of desaturation episodes, duration spent at an oxyhemoglobin saturation &lt;90 percent, and nadirs of oxyhemoglobin saturation can be determined from the oximetry recording during PSG.",
"     </li>",
"     <li>",
"      Limb movements &ndash; Limb movements may be counted both as isolated events and in association with arousals. Patients who have frequent periodic limb movements can be classified as having periodic limb movement disorder. As with the other variables, the number of events per hour of sleep can be used to quantify severity. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=see_link&amp;anchor=H16#H16\">",
"       \"Restless legs syndrome\", section on 'Periodic limb movements of sleep'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     VARIABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Night to night variability makes it possible for a single study to underestimate the severity of OSA. One study evaluated 11 patients who were suspected of having OSA on the basis of obesity, hypertension, or a history of observed apnea while asleep, but had negative PSG [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/19\">",
"     19",
"    </a>",
"    ]. Six of the eleven had positive repeat PSG, with a marked increase in the mean AHI from 3 to 20 events per hour. Nasal patency, body position, or disruptive environmental factors may all be important factors in producing such variability. Therefore, it is reasonable to repeat the baseline PSG if there is a strong clinical suspicion for OSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38374/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/5/35921?source=see_link\">",
"       \"Patient information: What is a sleep study? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/25/26003?source=see_link\">",
"       \"Patient information: Sleep apnea in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attended, in-laboratory polysomnography (PSG) is considered the gold standard diagnostic test for obstructive sleep apnea (OSA) and other sleep disorders. During PSG, the patient sleeps while connected to numerous monitoring devices and a technologist records physiologic variables. Patterns of physiologic abnormalities during sleep are often diagnostic. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic evaluation of suspected OSA, titration of positive airway pressure therapy, and assessment of the effectiveness of therapy are the most common indications for PSG. There are no contraindications to PSG and few complications. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H8\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physiologic variables assessed during PSG include the sleep stages, respiratory effort, airflow, oxyhemoglobin saturation, electrocardiography, body position, and limb movements. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Measured variables'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      From these physiologic variables, an abundance of information is derived. This includes sleep architecture, the frequency of abnormal events (eg, apneas) during sleep, and various diagnostic measures (eg, apnea hypopnea index). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Derived information'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/1\">",
"      AARC-APT (American Association of Respiratory Care-Association of Polysomnography Technologists) clinical practice guideline. Polysomnography. Respir Care 1995; 40:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/2\">",
"      Epstein LJ, Kristo D, Strollo PJ Jr, et al. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med 2009; 5:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/3\">",
"      Scrima L, Broudy M, Nay KN, Cohn MA. Increased severity of obstructive sleep apnea after bedtime alcohol ingestion: diagnostic potential and proposed mechanism of action. Sleep 1982; 5:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/4\">",
"      Lettieri CJ, Eliasson AH, Andrada T, et al. Does zolpidem enhance the yield of polysomnography? J Clin Sleep Med 2005; 1:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/5\">",
"      Kushida CA, Littner MR, Morgenthaler T, et al. Practice parameters for the indications for polysomnography and related procedures: an update for 2005. Sleep 2005; 28:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/6\">",
"      Sanders MH, Black J, Costantino JP, et al. Diagnosis of sleep-disordered breathing by half-night polysomnography. Am Rev Respir Dis 1991; 144:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/7\">",
"      Iber C, O'Brien C, Schluter J, et al. Single night studies in obstructive sleep apnea. Sleep 1991; 14:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/8\">",
"      Yamashiro Y, Kryger MH. CPAP titration for sleep apnea using a split-night protocol. Chest 1995; 107:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/9\">",
"      Khawaja IS, Olson EJ, van der Walt C, et al. Diagnostic accuracy of split-night polysomnograms. J Clin Sleep Med 2010; 6:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/10\">",
"      Deutsch PA, Simmons MS, Wallace JM. Cost-effectiveness of split-night polysomnography and home studies in the evaluation of obstructive sleep apnea syndrome. J Clin Sleep Med 2006; 2:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/11\">",
"      Kapur VK, Sullivan SD. More isn't always better: cost-effectiveness analysis and the case for using a split-night protocol. J Clin Sleep Med 2006; 2:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/12\">",
"      Fleury B, Rakotonanahary D, Tehindrazanarivelo AD, et al. Long-term compliance to continuous positive airway pressure therapy (nCPAP) set up during a split-night polysomnography. Sleep 1994; 17:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/13\">",
"      Patel NP, Ahmed M, Rosen I. Split-night polysomnography. Chest 2007; 132:1664.",
"     </a>",
"    </li>",
"    <li>",
"     Iber C, Ancoli-Israel S, Chesson AL, et al. The AASM Manual for the Scoring of Sleep and Associated Events, American Academy of Sleep Medicine, Westchester, IL 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/15\">",
"      Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an American Academy of Sleep Medicine Task Force. Sleep 1999; 22:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/16\">",
"      Redline S, Budhiraja R, Kapur V, et al. The scoring of respiratory events in sleep: reliability and validity. J Clin Sleep Med 2007; 3:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/17\">",
"      Montserrat JM, Farr&eacute; R, Ballester E, et al. Evaluation of nasal prongs for estimating nasal flow. Am J Respir Crit Care Med 1997; 155:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/18\">",
"      Bonnet MH, Doghramji K, Roehrs T, et al. The scoring of arousal in sleep: reliability, validity, and alternatives. J Clin Sleep Med 2007; 3:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38374/abstract/19\">",
"      Meyer TJ, Eveloff SE, Kline LR, Millman RP. One negative polysomnogram does not exclude obstructive sleep apnea. Chest 1993; 103:756.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7696 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38374=[""].join("\n");
var outline_f37_30_38374=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Protocols",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Split night studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Daytime studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEASURED VARIABLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DERIVED INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      VARIABILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10296?source=related_link\">",
"      Initiation of positive airway pressure therapy for obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/25/26003?source=related_link\">",
"      Patient information: Sleep apnea in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/5/35921?source=related_link\">",
"      Patient information: What is a sleep study? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17734?source=related_link\">",
"      Portable monitoring in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_30_38375="Cardiovascular effects of caffeine";
var content_f37_30_38375=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cardiovascular effects of caffeine",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38375/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38375/contributors\">",
"     Elsa-Grace Giardina, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38375/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38375/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38375/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38375/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/30/38375/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The methylated xanthine derivative caffeine (1,3,7- trimethylxanthine) is widely distributed in nature as a plant alkaloid. Consumed in coffee, tea, and soft drinks, caffeine is the most widely used pharmacologically active substance in the world, and its exposure dates from ancient history to the present.",
"   </p>",
"   <p>",
"    Exposure to caffeine is generally of long duration, virtually throughout the life of most consumers, and the prevalence of exposure is very high (more than 80 percent) in most countries. The main sources of caffeine and the amount found in typical sources in the United States are listed in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef61405 \" href=\"mobipreview.htm?27/27/28092\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The effects of caffeine on the cardiovascular system are the subject of this review. Non-cardiovascular effects of caffeine are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17498?source=see_link\">",
"     \"Benefits and risks of caffeine and caffeinated beverages\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine is absorbed after oral, rectal, or parenteral administration, and maximal concentration is achieved in one hour [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/1\">",
"     1",
"    </a>",
"    ]. Oral bioavailability is almost 100 percent; food slows the rate of absorption but does not limit the extent. Any effects on the cardiovascular system should return to baseline after about 10 and 60 hours, as the half-life is 2 to 12 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Effects on the heart'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The apparent volume of distribution is between 0.4 and 0.6",
"    <span class=\"nowrap\">",
"     L/kg,",
"    </span>",
"    and less than 40 percent is bound to plasma proteins. Caffeine is distributed into all body compartments; it crosses the placenta and passes into breast milk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=see_link&amp;anchor=H25#H25\">",
"     \"Principles of medication use during lactation\", section on 'Social substances'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Metabolism primarily occurs in the liver by demethylation and oxidation, with less than 5 percent excreted unchanged in the urine. The major metabolic pathway in humans is through the formation of paraxanthine (1,7-dimethylxanthine), leading to the principal urinary metabolites, 1-methylxanthine, 1-methyluric acid, and an acetylated uracil derivative. A minor pathway involves the formation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    and theobromine, and their subsequent metabolism. In most patients, the drug obeys first-order kinetics; zero-order kinetics occur at higher concentrations because of saturation of metabolic enzymes.",
"   </p>",
"   <p>",
"    The average half-life in plasma is five hours (range three to seven hours), but is somewhat shorter in children (three to four hours). The half-life may increase twofold in the last trimester of pregnancy. However, there is marked interindividual variation in the rate of elimination.",
"   </p>",
"   <p>",
"    The main determinants of plasma caffeine concentration are the elimination half-life and time since last consumed. Since the half-life is about five hours, and it is usually consumed in separate doses throughout the day, the plasma caffeine concentration is normally highest in the late afternoon and lowest upon awakening in the morning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Overnight abstinence of 8 to 12 hours leads to significant depletion of systemic caffeine by early morning, rendering the subject sensitive to its effects when reexposure occurs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an association between plasma levels of caffeine and toxicity and the activity of hepatic cytochrome CYP1A2. A study of 120 normal healthy volunteers found that CYP1A2 activity, gender, and smoking influenced the toxicity of caffeine; in particular females and nonsmokers who experienced toxic effects had a lower caffeine N3-demethylation index (a measure of CYP1A2 activity) compared to females and nonsmokers who did not experience toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFECTS ON THE HEART",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine can affect cardiovascular hemodynamics as well as the electrophysiologic properties of the heart.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Molecular mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of molecular mechanisms have been detected in vitro for methylxanthines, but only some which take place at reasonably low concentrations are involved in the responses observed in vivo. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inhibition of phosphodiesterase, which results in an elevation in myocardial cyclic AMP and a positive inotropic action on the myocardium",
"     </li>",
"     <li>",
"      Inhibition of adenosine receptors, possibly preventing the negative inotropic effect elicited by adenosine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/6\">",
"       6",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Facilitation of norepinephrine release from sympathetic nerve endings [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increase in intracellular calcium, mediated at high doses of caffeine by inhibition of calcium reuptake into the sarcoplasmic reticulum, and at low doses by calcium release from the sarcoplasmic reticulum [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/8\">",
"       8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Increase in sensitivity of the myofilaments to calcium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/9,10\">",
"       9,10",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the methylxanthines have a positive inotropic effect, they are not used as primary agents in the treatment of heart failure, since their stimulatory effect on the nervous system and potential adverse effects on cardiac rhythm outweigh any potential benefits of increased inotropy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a widespread belief that caffeine, particularly at high doses, is associated with palpitations and a number of arrhythmias, including atrial fibrillation and supraventricular and ventricular ectopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=see_link\">",
"     \"Supraventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Electrophysiologic studies have demonstrated that caffeine has some effects that might promote arrhythmogenesis. Caffeine can directly increase the transmembrane calcium current that is responsible for the oscillatory afterpotential (ie, triggered activity) in in vitro and in vivo experimental models, in part via release of calcium from the sarcoplasmic reticulum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/9,12-15\">",
"     9,12-15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is no evidence that caffeine in doses typically consumed can provoke a spontaneous arrhythmia, or enhance the ability to induce an arrhythmia in the electrophysiology laboratory [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/7,16-20\">",
"     7,16-20",
"    </a>",
"    ]. As an example, in a prospective study, 22 patients with a history of symptomatic ventricular tachycardia or fibrillation underwent electrophysiological testing before and one hour after coffee ingestion (275 mg of caffeine). The ability to induce an arrhythmia was unchanged in 10 patients, increased in six and reduced in six, and rhythm severity was unchanged in 17 patients, more severe in two, and less severe in three. Furthermore, among patients with arrhythmia, caffeine restriction has not been of benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, there may be a relationship between intake of unusually large amounts of caffeine and arrhythmia in selected patients. Case reports of ingestion of large quantities of caffeine suggest that caffeine toxicity can be associated with arrhythmic events, especially in patients with underlying cardiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Thus, patients susceptible to cardiac arrhythmias should probably avoid ingesting very large quantities of caffeine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Caffeine can acutely raise the blood pressure (BP) by as much as 10 mmHg in patients who are infrequently exposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. There is little or no acute effect on blood pressure in habitual coffee drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Caffeine can also potentiate (by about 5 to 10 mmHg) the rise in blood pressure induced by stress, such as that occurring in the workplace, but this appears to occur mostly among non-habitual coffee drinkers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. The increase in vascular resistance associated with these changes also involves the cerebral and coronary circulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The acute elevation of blood pressure caused by caffeine is more pronounced in hypertensive patients; compared to subjects with optimal blood pressure, those with hypertension had a &gt;1.5-fold greater increase in blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/2\">",
"     2",
"    </a>",
"    ]. The hypertensive effect may be more prominent in elderly patients with hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effects of chronic caffeine ingestion are less clear. Coffee intake was not associated with elevated blood pressure or an increased incidence of hypertension in several studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/33-36\">",
"     33-36",
"    </a>",
"    ]. As an example, examination of data from the Nurses' Health Study demonstrated that daily intake of up to six cups of coffee or black tea was not associated with an increased risk of hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the risk of incident hypertension related to intake of caffeinated soda beverages was increased; the authors hypothesized this was the effect of an undefined compound other than caffeine.",
"   </p>",
"   <p>",
"    However, there is some evidence that chronic caffeine use can cause a small elevation in blood pressure in some individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/37\">",
"     37",
"    </a>",
"    ]. A meta-analysis of 18 controlled clinical trials found that coffee ingestion increased systolic and diastolic blood pressure by 1.2 and 0.49 mmHg, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/38\">",
"     38",
"    </a>",
"    ]. Consistent with this observation is that similar",
"    <strong>",
"     reductions",
"    </strong>",
"    in blood pressure may be seen when habitual coffee drinkers either abstain from coffee or switch to decaffeinated coffee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/34,39,40\">",
"     34,39,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of coffee may not be solely explained by caffeine. In a study of 15 volunteers (six habitual and nine non-habitual coffee drinkers), intravenous caffeine increased muscle sympathetic nerve activity and blood pressure to a similar degree in both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/27\">",
"     27",
"    </a>",
"    ]. Caffeinated coffee raised the blood pressure only in non-habitual drinkers, despite similar plasma caffeine concentrations and a similar increase in muscle sympathetic nerve activity. Furthermore, non-habitual drinkers had similar elevations in blood pressure and muscle sympathetic nerve activity with caffeinated and decaffeinated coffee.",
"   </p>",
"   <p>",
"    By comparison, ingestion of tea does not appear to have a significant effect upon blood pressure. A meta-analysis of five studies of tea ingestion among 343 subjects reported that blood pressure was unchanged at a median duration of four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute caffeine-induced pressor effect is probably related to vasoconstriction due to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in sympathetic activity and circulating catecholamine concentrations mediated by central nervous system stimulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/27,30\">",
"       27,30",
"      </a>",
"      ]. However, the above observation that, in habitual drinkers, muscle sympathetic nerve activity is increased in the absence of a pressor response suggests that increased sympathetic activity alone is not sufficient [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antagonism of endogenous adenosine&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/42\">",
"       42",
"      </a>",
"      ]. Subsequent upregulation of adenosine receptors probably explains the tolerance to chronic caffeine ingestion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The likelihood of a pressor response is in part determined by the pharmacokinetics of caffeine in each individual. This was illustrated in a study of normotensive habitual coffee drinkers who ingested coffee after caffeine abstinence of 4.5 individual caffeine half-lives; the ensuing increase in blood pressure was inversely related to the baseline plasma caffeine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/43\">",
"     43",
"    </a>",
"    ]. Thus, rapid metabolizers of caffeine are more likely to have a pressor response after drinking coffee, despite the phenomenon of adaptation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been controversy about the effects of coffee intake on coronary heart disease (CHD), with most studies showing no relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Health Professionals Study prospectively followed 45,589 men over a two year period [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/44\">",
"       44",
"      </a>",
"      ]. There was no relationship between coffee, caffeine, or tea intake and the incidence of CHD or cerebrovascular disease.",
"     </li>",
"     <li>",
"      A later report, which included data from the Health Professionals Follow-Up Study and the Nurses' Health Study, prospectively monitored over 44,000 men and 84,000 women who were free of cardiovascular disease or cancer at baseline; coffee consumption was assessed every two to four years and the total follow-up was 14 to 20 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/46\">",
"       46",
"      </a>",
"      ]. After adjustment for other cardiovascular risk factors, there was no increase in cardiovascular risk with coffee consumption (caffeinated or decaffeinated) or tea consumption, even in those drinking six or more cups per day. There was also no effect across quintiles of caffeine intake. Adjusting for risk factors was important because coffee consumption was strongly associated with smoking. The participants primarily consumed filtered coffee.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A later study from the same epidemiologic studies suggested that coffee consumption was not associated with an increase in all-cause or cardiovascular mortality and, at least in women, might be cardioprotective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'All-cause and cardiovascular mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These observations do not preclude the possibility that heavy coffee consumption increases the risk of cardiovascular events in selected patients. A case-control study of 117 patients with an out-of-hospital sudden cardiac arrest (all with a prior clinical history of CHD) and a group of unselected age- and gender-matched CHD control patients found that the consumption of more than 10 cups of coffee per day was a risk factor for sudden cardiac arrest after adjustment for accepted risk factors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of caffeine metabolism may be an important determinant of the effect of coffee intake on CHD risk. This was suggested in a study from Costa Rica that analyzed outcomes according to alleles of CYP1A2: individuals homozygous for the CYP1A2*1A allele were rapid metabolizers of caffeine, while carriers of the CYP1A2*1F allele (55 percent of the study population) were slow metabolizers of caffeine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/49\">",
"     49",
"    </a>",
"    ]. Among rapid metabolizers, there was no association between coffee intake and nonfatal myocardial infarction. In contrast, slow metabolizers had a dose-dependent increase in risk (multivariate adjusted odds ratio 0.99, 1.36, and 1.64 for consumption of one, two to three, and four or more cups of coffee per day, respectively). These observations suggest that caffeine plays a role in the coronary risk associated with coffee intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Aortic stiffness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic stiffness and wave reflections are important determinants of the efficient performance of the cardiovascular system and prognosis of cardiovascular risk. Caffeine acutely increases arterial stiffness, and the effect is synergistic with smoking [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/50\">",
"     50",
"    </a>",
"    ]. The ingestion of 200 mg of caffeine (equivalent to two cups of coffee) increased pulse-wave velocity and augmentation index by 0.33",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"    and 4 percent, respectively, an effect that was augmented when combined with smoking (increased by 0.85",
"    <span class=\"nowrap\">",
"     m/s",
"    </span>",
"    and 17.4 percent, respectively). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26823?source=see_link\">",
"     \"Increased pulse pressure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have shown no adverse effects of filtered coffee intake on plasma lipids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/46,51-54\">",
"     46,51-54",
"    </a>",
"    ]. In the prospective cohort study cited above of over 132,000 men and women from the Health Professionals Follow-Up Study and the Nurses' Health Study, there was no association between the intake of filtered caffeinated coffee or filtered decaffeinated coffee and serum concentrations of total cholesterol, LDL-cholesterol, or HDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there may be a hyperlipidemic effect of non-filtered coffee [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/51,55\">",
"     51,55",
"    </a>",
"    ] which contains coffee lipid compounds (such as cafestol) that are removed by a paper filter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/56\">",
"     56",
"    </a>",
"    ]. In one study, the daily ingestion of four to six cups of boiled, but not filtered, coffee for a period of nine weeks increased serum total cholesterol by 18.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.48",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and LDL-cholesterol by 15",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.39",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    with no effect on HDL-cholesterol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/51\">",
"     51",
"    </a>",
"    ]. A similar intake of filtered coffee had a similar effect on serum lipids as drinking no coffee.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4862113\">",
"    <span class=\"h1\">",
"     STROKE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coffee consumption has been inconsistently associated with the incidence of both stroke and mortality. The following are representative studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The Swedish Mammography Cohort prospectively followed (mean follow-up of 10.4 years) 34,670 women without a history of cardiovascular disease at baseline in 1997 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/57\">",
"       57",
"      </a>",
"      ]. After adjustment for other risk factors, coffee consumption was associated with a statistically significant lower risk of total stroke, cerebral infarction, and subarachnoid hemorrhage, but not intracerebral hemorrhage. The multivariable relative risks of total stroke across categories of coffee consumption (less than one",
"      <span class=\"nowrap\">",
"       cup/day,",
"      </span>",
"      one to two",
"      <span class=\"nowrap\">",
"       cups/day,",
"      </span>",
"      three to four",
"      <span class=\"nowrap\">",
"       cups/day,",
"      </span>",
"      and at least five cups a day) were 1.00, 0.78 (95% CI, 0.66 to 0.91), 0.75 (95% CI, 0.64 to 0.88), and 0.77 (95% CI, 0.63 to 0.92), respectively.",
"     </li>",
"     <li>",
"      These findings for coffee consumption and stroke incidence are consistent with those of the Nurses&rsquo; Health Study (NHS) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/58\">",
"       58",
"      </a>",
"      ] and the Alpha-Tocopherol,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/50/21283?source=see_link\">",
"       Beta-Carotene",
"      </a>",
"      Cancer Prevention (ATBC) study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/59\">",
"       59",
"      </a>",
"      ]. The Nurses&rsquo; Health Study found that women who consumed at least four cups of coffee per day had a significant 20 percent lower risk of total stroke than those who seldom",
"      <span class=\"nowrap\">",
"       (&lt;1/month)",
"      </span>",
"      drank coffee [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/58\">",
"       58",
"      </a>",
"      ]. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study results suggest that high consumption of coffee and tea may reduce the risk of cerebral infarction among men, independent of known cardiovascular risk factors.",
"     </li>",
"     <li>",
"      One small observational study found that, in patients who drank one or less cups of coffee per day, the risk of stroke was significantly increased in the hour following coffee consumption compared with periods of nonuse (relative risk 2.0, 95% CI 1.4-2.8) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ALL-CAUSE AND CARDIOVASCULAR MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between coffee and all-cause mortality was assessed among 41,736 men identified in the Health Professionals Follow-Up Study (followed for 18 years) and 86,216 women from the Nurses' Health Study (followed for 24 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/47\">",
"     47",
"    </a>",
"    ]. Based upon self-reported drinking habits, there was no increase in mortality with caffeinated coffee consumption and drinking six or more cups of coffee per day. There was also a suggestion that drinking two or more cups of coffee per day was associated with a significant reduction in all-cause mortality in women after multivariable adjustment, primarily due to a reduction in cardiovascular mortality. Such an effect was not statistically significant in men. Similar findings were noted with decaffeinated coffee, suggesting an effect from a component other than caffeine. The authors concluded that more study was required to confirm a possible beneficial effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Consumed in coffee, tea, soft drinks, and small amounts in chocolate, caffeine is the most widely used pharmacologically active substance in the world. The main sources of caffeine in the United States and the amount of caffeine in these sources are listed in the following table (",
"    <a class=\"graphic graphic_table graphicRef61405 \" href=\"mobipreview.htm?27/27/28092\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Concerns regarding deleterious cardiovascular effects of caffeine have largely not been supported. Caffeine can acutely raise the blood pressure by as much as 10 mmHg in patients who are infrequently exposed. However, there is little or no effect on blood pressure in habitual coffee drinkers, nor does it appear to increase the risk of incident hypertension. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Blood pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is no evidence that caffeine in doses typically consumed can provoke a spontaneous arrhythmia in individuals with or without a history of cardiac arrhythmia, nor is there any protective effect of caffeine abstinence. With respect to coronary disease, the risk may be increased in individuals who are slow metabolizers of caffeine and drink two or more cups of coffee per day [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38375/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ingestion of large quantities of caffeine may be associated with arrhythmic and cardiovascular events, especially in patients with underlying cardiac disease. The available evidence, albeit weak, leads us to suggest that individuals with a history of cardiac arrhythmia or at increased risk for cardiovascular events moderate their caffeine intake from all sources.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rall TW. The Methylxanthines. In: Goodman and Gilman's Pharmacological Basis of Therapeutics, 9th ed, Hardman J (Ed), McGraw-Hill, New York 1993. p.1663.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/2\">",
"      Hartley TR, Sung BH, Pincomb GA, et al. Hypertension risk status and effect of caffeine on blood pressure. Hypertension 2000; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     Gilbert RM. Caffeine consumption. In: The methylxanthine beverages and foods: chemistry, consumption, and health effects, Spiller GA (Ed), Alan R Liss, New York 1984. p.185.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/4\">",
"      Robertson D, Wade D, Workman R, et al. Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest 1981; 67:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/5\">",
"      Carrillo JA, Benitez J. CYP1A2 activity, gender and smoking, as variables influencing the toxicity of caffeine. Br J Clin Pharmacol 1996; 41:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/6\">",
"      Scholz H. Inotropic drugs and their mechanisms of action. J Am Coll Cardiol 1984; 4:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/7\">",
"      Wennmalm A, Wennmalm M. Coffee, catecholamines and cardiac arrhythmia. Clin Physiol 1989; 9:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/8\">",
"      Konishi M, Kurihara S. Effects of caffeine on intracellular calcium concentrations in frog skeletal muscle fibres. J Physiol 1987; 383:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/9\">",
"      Hess P, Wier WG. Excitation-contraction coupling in cardiac Purkinje fibers. Effects of caffeine on the intracellular [Ca2+] transient, membrane currents, and contraction. J Gen Physiol 1984; 83:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/10\">",
"      Eisner DA, Valdeolmillos M. The mechanism of the increase of tonic tension produced by caffeine in sheep cardiac Purkinje fibres. J Physiol 1985; 364:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/11\">",
"      Mehta A, Jain AC, Mehta MC, Billie M. Caffeine and cardiac arrhythmias. An experimental study in dogs with review of literature. Acta Cardiol 1997; 52:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/12\">",
"      Nieman CJ, Eisner DA. Effects of caffeine, tetracaine, and ryanodine on calcium-dependent oscillations in sheep cardiac Purkinje fibers. J Gen Physiol 1985; 86:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/13\">",
"      Vassalle M, Di Gennaro M. Caffeine actions on currents induced by calcium-overload in Purkinje fibers. Eur J Pharmacol 1984; 106:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/14\">",
"      Ishida S, Ito M, Takahashi N, et al. Caffeine induces ventricular tachyarrhythmias possibly due to triggered activity in rabbits in vivo. Jpn Circ J 1996; 60:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/15\">",
"      Paspa P, Vassalle M. Mechanism of caffeine-induced arrhythmias in canine cardiac Purkinje fibers. Am J Cardiol 1984; 53:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/16\">",
"      Chelsky LB, Cutler JE, Griffith K, et al. Caffeine and ventricular arrhythmias. An electrophysiological approach. JAMA 1990; 264:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/17\">",
"      Newcombe PF, Renton KW, Rautaharju PM, et al. High-dose caffeine and cardiac rate and rhythm in normal subjects. Chest 1988; 94:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/18\">",
"      Myers MG. Caffeine and cardiac arrhythmias. Ann Intern Med 1991; 114:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/19\">",
"      Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr 2005; 81:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/20\">",
"      Graboys TB, Blatt CM, Lown B. The effect of caffeine on ventricular ectopic activity in patients with malignant ventricular arrhythmia. Arch Intern Med 1989; 149:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/21\">",
"      Newby DE, Neilson JM, Jarvie DR, Boon NA. Caffeine restriction has no role in the management of patients with symptomatic idiopathic ventricular premature beats. Heart 1996; 76:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/22\">",
"      Cannon ME, Cooke CT, McCarthy JS. Caffeine-induced cardiac arrhythmia: an unrecognised danger of healthfood products. Med J Aust 2001; 174:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/23\">",
"      Chopra A, Morrison L. Resolution of caffeine-induced complex dysrhythmia with procainamide therapy. J Emerg Med 1995; 13:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/24\">",
"      Curatolo PW, Robertson D. The health consequences of caffeine. Ann Intern Med 1983; 98:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/25\">",
"      Freestone S, Ramsay LE. Effect of coffee and cigarette smoking on the blood pressure of untreated and diuretic-treated hypertensive patients. Am J Med 1982; 73:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/26\">",
"      Sharp DS, Benowitz NL. Pharmacoepidemiology of the effect of caffeine on blood pressure. Clin Pharmacol Ther 1990; 47:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/27\">",
"      Corti R, Binggeli C, Sudano I, et al. Coffee acutely increases sympathetic nerve activity and blood pressure independently of caffeine content: role of habitual versus nonhabitual drinking. Circulation 2002; 106:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/28\">",
"      Jeong DU, Dimsdale JE. The effects of caffeine on blood pressure in the work environment. Am J Hypertens 1990; 3:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/29\">",
"      Sudano I, Spieker L, Binggeli C, et al. Coffee blunts mental stress-induced blood pressure increase in habitual but not in nonhabitual coffee drinkers. Hypertension 2005; 46:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/30\">",
"      Nehlig A, Daval JL, Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992; 17:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/31\">",
"      B&ouml;ttcher M, Czernin J, Sun KT, et al. Effect of caffeine on myocardial blood flow at rest and during pharmacological vasodilation. J Nucl Med 1995; 36:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/32\">",
"      Rakic V, Burke V, Beilin LJ. Effects of coffee on ambulatory blood pressure in older men and women: A randomized controlled trial. Hypertension 1999; 33:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/33\">",
"      Myers MG. Effects of caffeine on blood pressure. Arch Intern Med 1988; 148:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/34\">",
"      van Dusseldorp M, Smits P, Thien T, Katan MB. Effect of decaffeinated versus regular coffee on blood pressure. A 12-week, double-blind trial. Hypertension 1989; 14:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/35\">",
"      Salvaggio A, Periti M, Miano L, Zambelli C. Association between habitual coffee consumption and blood pressure levels. J Hypertens 1990; 8:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/36\">",
"      Winkelmayer WC, Stampfer MJ, Willett WC, Curhan GC. Habitual caffeine intake and the risk of hypertension in women. JAMA 2005; 294:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/37\">",
"      Lovallo WR, Wilson MF, Vincent AS, et al. Blood pressure response to caffeine shows incomplete tolerance after short-term regular consumption. Hypertension 2004; 43:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/38\">",
"      Noordzij M, Uiterwaal CS, Arends LR, et al. Blood pressure response to chronic intake of coffee and caffeine: a meta-analysis of randomized controlled trials. J Hypertens 2005; 23:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/39\">",
"      Bak AA, Grobbee DE. A randomized study on coffee and blood pressure. J Hum Hypertens 1990; 4:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/40\">",
"      Superko HR, Myll J, DiRicco C, et al. Effects of cessation of caffeinated-coffee consumption on ambulatory and resting blood pressure in men. Am J Cardiol 1994; 73:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/41\">",
"      Taubert D, Roesen R, Sch&ouml;mig E. Effect of cocoa and tea intake on blood pressure: a meta-analysis. Arch Intern Med 2007; 167:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/42\">",
"      Ammon HP. Biochemical mechanism of caffeine tolerance. Arch Pharm (Weinheim) 1991; 324:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/43\">",
"      James JE. Chronic effects of habitual caffeine consumption on laboratory and ambulatory blood pressure levels. J Cardiovasc Risk 1994; 1:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/44\">",
"      Grobbee DE, Rimm EB, Giovannucci E, et al. Coffee, caffeine, and cardiovascular disease in men. N Engl J Med 1990; 323:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/45\">",
"      Kleemola P, Jousilahti P, Pietinen P, et al. Coffee consumption and the risk of coronary heart disease and death. Arch Intern Med 2000; 160:3393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/46\">",
"      Lopez-Garcia E, van Dam RM, Willett WC, et al. Coffee consumption and coronary heart disease in men and women: a prospective cohort study. Circulation 2006; 113:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/47\">",
"      Lopez-Garcia E, van Dam RM, Li TY, et al. The relationship of coffee consumption with mortality. Ann Intern Med 2008; 148:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/48\">",
"      de Vreede-Swagemakers JJ, Gorgels AP, Weijenberg MP, et al. Risk indicators for out-of-hospital cardiac arrest in patients with coronary artery disease. J Clin Epidemiol 1999; 52:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/49\">",
"      Cornelis MC, El-Sohemy A, Kabagambe EK, Campos H. Coffee, CYP1A2 genotype, and risk of myocardial infarction. JAMA 2006; 295:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/50\">",
"      Vlachopoulos C, Kosmopoulou F, Panagiotakos D, et al. Smoking and caffeine have a synergistic detrimental effect on aortic stiffness and wave reflections. J Am Coll Cardiol 2004; 44:1911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/51\">",
"      Bak AA, Grobbee DE. The effect on serum cholesterol levels of coffee brewed by filtering or boiling. N Engl J Med 1989; 321:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/52\">",
"      Wei M, Macera CA, Hornung CA, Blair SN. The impact of changes in coffee consumption on serum cholesterol. J Clin Epidemiol 1995; 48:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/53\">",
"      Lewis CE, Caan B, Funkhouser E, et al. Inconsistent associations of caffeine-containing beverages with blood pressure and with lipoproteins. The CARDIA Study. Coronary Artery Risk Development in Young Adults. Am J Epidemiol 1993; 138:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/54\">",
"      Yukawa GS, Mune M, Otani H, et al. Effects of coffee consumption on oxidative susceptibility of low-density lipoproteins and serum lipid levels in humans. Biochemistry (Mosc) 2004; 69:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/55\">",
"      Jee SH, He J, Appel LJ, et al. Coffee consumption and serum lipids: a meta-analysis of randomized controlled clinical trials. Am J Epidemiol 2001; 153:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/56\">",
"      de Roos B, Katan MB. Possible mechanisms underlying the cholesterol-raising effect of the coffee diterpene cafestol. Curr Opin Lipidol 1999; 10:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/57\">",
"      Larsson SC, Virtamo J, Wolk A. Coffee consumption and risk of stroke in women. Stroke 2011; 42:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/58\">",
"      Lopez-Garcia E, Rodriguez-Artalejo F, Rexrode KM, et al. Coffee consumption and risk of stroke in women. Circulation 2009; 119:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/59\">",
"      Larsson SC, M&auml;nnist&ouml; S, Virtanen MJ, et al. Coffee and tea consumption and risk of stroke subtypes in male smokers. Stroke 2008; 39:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38375/abstract/60\">",
"      Mostofsky E, Schlaug G, Mukamal KJ, et al. Coffee and acute ischemic stroke onset: the Stroke Onset Study. Neurology 2010; 75:1583.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1553 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-00FF42CD0A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38375=[""].join("\n");
var outline_f37_30_38375=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFECTS ON THE HEART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Molecular mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Blood pressure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Aortic stiffness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lipids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4862113\">",
"      STROKE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ALL-CAUSE AND CARDIOVASCULAR MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1553\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1553|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/27/28092\" title=\"table 1\">",
"      Caffeine source amount",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/5/17498?source=related_link\">",
"      Benefits and risks of caffeine and caffeinated beverages",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/12/26823?source=related_link\">",
"      Increased pulse pressure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/1/32794?source=related_link\">",
"      Principles of medication use during lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/27/441?source=related_link\">",
"      Supraventricular premature beats",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_30_38376="Proximal subungual onychomycosis - toenails";
var content_f37_30_38376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F61687%7EDERM%2F74473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F61687%7EDERM%2F74473&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Proximal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whitish discoloration originating under the surface of the proximal nail plate is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Proximal subungual onychomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 351px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Whitish discoloration originating under the surface of the proximal nail plate is present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38376=[""].join("\n");
var outline_f37_30_38376=null;
var title_f37_30_38377="The detailed neurologic examination in adults";
var content_f37_30_38377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The detailed neurologic examination in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38377/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38377/contributors\">",
"     Douglas Gelb, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38377/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38377/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38377/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38377/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/30/38377/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the information necessary to localize a lesion in patients with neurologic complaints can be obtained by taking a careful history. Even features that are usually considered to be examination findings can be deduced if the right questions are asked. As an example, to investigate temperature sensation, patients can be asked whether they have any problems detecting water temperature. With regard to fine touch discrimination, patients can be asked whether they have problems pulling the correct coin or other objects out of their pockets. Position sense can be explored by asking whether patients have problems knowing where their feet are on the car accelerator and brake pedals.",
"   </p>",
"   <p>",
"    Nevertheless, some important information can be learned only by examining the patient. Furthermore, the information obtained from a history depends upon the reliability of the informant. It is essential to have an independent source of information when the informant is a poor observer, has trouble communicating, or for some reason provides misleading information; the neurological examination serves this purpose.",
"   </p>",
"   <p>",
"    There is no clear consensus among experts regarding the optimal order of performing or presenting the neurologic examination or its components (eg, the motor examination). The order used in this topic is my preferred order for presenting the results of the patient's neurologic examination. It is important that clinicians have a sequence of their choosing that they use consistently.",
"   </p>",
"   <p>",
"    Components of the standard neurologic examination are found in Table 1 and discussed in detail in this review (",
"    <a class=\"graphic graphic_table graphicRef82393 \" href=\"mobipreview.htm?32/49/33565\">",
"     table 1",
"    </a>",
"    ). The text is adapted, with permission, from Reference 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38377/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The examination of comatose patients is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=see_link&amp;anchor=H4#H4\">",
"     \"Stupor and coma in adults\", section on 'General examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     A SCREENING NEUROLOGIC EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practicing physicians usually do not have the time to perform complete neurologic examinations on all patients. They must be able to perform a rapid examination that screens for most common abnormalities. The results of this screening examination can be used together with the history to decide whether certain components of the examination must be conducted in more detail.",
"   </p>",
"   <p>",
"    For screening purposes in patients without neurologic complaints, the following neurologic examination is generally adequate and can be completed in five minutes or less.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mental status &mdash; Test patients for orientation to person, place, and time. Make sure they can follow at least one complicated command, taking care not to give them any nonverbal cues. If their responses are appropriate and they are able to relate a detailed and coherent medical history, no further mental status testing is necessary (unless they have cognitive complaints). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mental status examination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Cranial nerves &mdash; Test visual fields in one eye, both pupillary responses to light, eye movements in all directions, facial strength, and hearing to finger rub. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cranial nerve examination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Motor system &mdash; Test strength in the following muscles bilaterally: deltoids, triceps, wrist extensors, hand interossei, iliopsoas, hamstrings, ankle dorsiflexors. Test for a pronator drift. Test finger tapping, finger-to-nose, and heel-knee-shin performance. Test tandem gait and walking on the heels. (See",
"      <a class=\"local\" href=\"#H45\">",
"       'Motor examination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Reflexes &mdash; Test plantar responses and biceps, triceps, patellar, and ankle reflexes bilaterally. (See",
"      <a class=\"local\" href=\"#H64\">",
"       'Reflex examination'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Sensation &mdash; Test light touch sensation in all four distal limbs, including double simultaneous stimulation. Test vibration sense at the great toes. (See",
"      <a class=\"local\" href=\"#H72\">",
"       'Sensory examination'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This examination must be expanded when an asymmetry or other abnormality is found. As an example, if the triceps muscle is weak in one arm, other muscles innervated by the radial nerve must be tested, as well as other muscles in the distribution of the C7 nerve root. The examination must also be expanded to focus upon patients' specific complaints. Patients complaining of memory loss, for example, need thorough mental status testing even if their performance on the screening examination is perfectly normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MENTAL STATUS EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of mental status should specifically note deficits in the following spheres:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Level of consciousness (arousal)",
"     </li>",
"     <li>",
"      Attention and concentration",
"     </li>",
"     <li>",
"      Memory (immediate, recent, and remote)",
"     </li>",
"     <li>",
"      Language",
"     </li>",
"     <li>",
"      Visual spatial perception",
"     </li>",
"     <li>",
"      Executive functioning",
"     </li>",
"     <li>",
"      Mood and thought content",
"     </li>",
"     <li>",
"      Praxis",
"     </li>",
"     <li>",
"      Calculations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details of this evaluation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23303?source=see_link\">",
"     \"The mental status examination in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20041?source=see_link\">",
"     \"Approach to the patient with aphasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The portion of the neurologic examination for which presentation in a consistent sequence is most important is the mental status examination. Certain findings on the mental status examination can only be interpreted by knowing a patient's ability to perform other more fundamental tasks. As an example, difficulty with simple calculations may have some localizing significance in a patient who is otherwise cognitively intact, but not in a patient who is unable to answer any questions because of impaired language function or a depressed level of consciousness. This ambiguity is avoided by reporting the level of alertness first, then language function, and then memory. The remainder of the mental status examination can be presented in any order.",
"   </p>",
"   <p>",
"    When reporting the results of mental status testing, it is most informative to convey patients' actual responses, rather than interpretations such as \"mildly abnormal\" or \"slightly concrete.\" A confusing array of terminology is often used to report the findings on mental status testing; some are defined in Table 2 (",
"    <a class=\"graphic graphic_table graphicRef65883 \" href=\"mobipreview.htm?32/39/33405\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CRANIAL NERVE EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Olfaction (CN I)",
"    </span>",
"    &nbsp;&mdash;&nbsp;I almost never test the sense of smell. It is difficult to know whether patients who cannot identify a particular scent have a disturbance of olfaction or whether they are just not familiar with that scent. I take patients at their word when they give a history of olfactory problems. When formal testing is desired, olfaction is examined by having the patient occlude one nostril and identify a common scent (eg, coffee, peppermint, cinnamon) placed under the other nostril.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Vision (CN II)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Visual fields",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient cover his or her left eye. Stand facing the patient from two arm's lengths away, close your right eye, and stretch your arms forward and to the sides so that your hands are at about \"1:30\" and \"10:30\" and just barely visible in your peripheral vision. They should be the same distance from you and the patient. Hold the index finger on each hand extended. Quickly flick the finger on either the left, right, or both hands, and ask the patient to identify where the movement occurs while looking directly at your nose. Move your hands down to roughly \"4:30\" and \"7:30\" and test again. Then test analogous portions of the visual field of the patient's left eye (using your right eye as a control).",
"   </p>",
"   <p>",
"    There are many alternatives to the technique described here for testing visual fields [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38377/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ask patients to tell you when they first see a test stimulus as you slowly move it in from the periphery at various orientations.",
"     </li>",
"     <li>",
"      Ask patients to count the number of fingers you hold up at various spots in the field.",
"     </li>",
"     <li>",
"      Ask patients to tell you when they can detect that a small stimulus is red as you move it in from the periphery of the field (the \"kinetic red target\" method). A pin with a 5 mm red top is typically used.",
"     </li>",
"     <li>",
"      Ask patients to describe examiner's face (ask if any part of face is missing or appears distorted).",
"     </li>",
"     <li>",
"      Ask patients to compare visual clarity of fingers presented simultaneously in the two upper (then the two lower) visual quadrants.",
"     </li>",
"     <li>",
"      Ask patients to count one or two fingers presented in each of the four quadrants as described above.",
"     </li>",
"     <li>",
"      Ask patients to compare the color of two identical red objects presented simultaneously in the two upper (then the two lower) visual quadrants (object \"less red\" or duller is abnormal).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regardless of the technique used, each eye must be tested separately. Otherwise, if there is a defect in a portion of the visual field of only one eye, the other eye will be able to compensate and the defect will not be detected. One example of this situation is the bitemporal hemianopia that can occur with a lesion in the optic chiasm; the defective hemifield of each eye corresponds to the intact hemifield of the other eye, so the patient may be completely unaware of the deficit.",
"   </p>",
"   <p>",
"    Each technique has advantages and disadvantages, and some neurologists have very strong opinions about which is best. In one study, the kinetic red target technique was more sensitive than other methods, and combinations of two techniques (especially the combination of the kinetic red target technique with the quick finger flick method described first) improved sensitivity further [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38377/abstract/2\">",
"     2",
"    </a>",
"    ]. The reason I prefer the first method described is that the visual stimulus can be presented very briefly, minimizing the opportunity for the patient to shift fixation and maximizing the likelihood that the stimulus is actually in the intended region of the visual field. Also, patients with cognitive or mental status abnormalities can often participate more effectively in this test but have difficulty with the other approaches. A baseline level of attention and cognitive ability is also required for automated visual perimetry. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37848?source=see_link&amp;anchor=H22#H22\">",
"     \"Homonymous hemianopia\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Homonymous hemianopia is a visual field defect involving either the two right or the two left halves of the visual fields of both eyes. Specific examples of these visual field defects and their neuroanatomic correlation are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37848?source=see_link\">",
"     \"Homonymous hemianopia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Acuity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Place a hand-held visual acuity card 14 inches in front of the patient's right eye while the left eye is covered. The patient should wear his or her usual corrective lenses. Ask the patient to read the lowest line on the chart",
"    <span class=\"nowrap\">",
"     (20/20).",
"    </span>",
"    If the patient cannot do so, move up a line, and continue doing so until you reach a line where the majority of items are read correctly. Note which line this is and how many errors the patient makes on this line. Repeat the process for the left eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Funduscopic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduce the room illumination as much as possible. Turn on the ophthalmoscope light, adjust the output to the small round beam of white light, and adjust the lens to zero diopters. Examine the patient's right eye by holding the ophthalmoscope to your right eye in your right hand, and examine the patient's left eye by holding the instrument to your left eye in your left hand. Hold the thumb of the opposite hand on the patient's eyebrow above the eye you are examining.",
"   </p>",
"   <p>",
"    Ask the patient to look straight ahead, and shine the beam of light on the pupil and look for the red reflex - an orange glow reflected from the retina. Move in closer towards the patient's pupil, staying focused on the red reflex. Look for the optic disc, and bring it into focus by adjusting the ophthalmoscope lens. Red lens numbers indicate minus diopters, used with myopic (nearsighted) eyes, while black numbers indicate plus diopters, used for focusing on hyperopic (farsighted) eyes or eyes that have undergone surgical lens removal.",
"   </p>",
"   <p>",
"    Once the optic disc is clearly identified and sharply focused, the funduscopic examination should proceed to inspect the clarity of the disc outline, and observe for the presence or absence of venous pulsations. The retinal vessels should be followed peripherally in all directions, and the retina should be searched at the same time. Abnormalities of retinal vessels or retinal lesions should be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pupillary light reflex (CN II and III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduce the room illumination as much as possible. Shine a penlight on the bridge of the patient's nose so that you can see both pupils without directing light at either of them. Check that they are the same size.",
"   </p>",
"   <p>",
"    Now move the penlight so that it is directly shining on the right pupil, and check to see that both pupils have constricted to the same size. Next, move the penlight back to the bridge of the nose so that both pupils dilate, and then shine the light directly on the left pupil, again checking for equal constriction of the two eyes. Finally, move the penlight rapidly from the left pupil to the right; the pupil size should not change. Swing the light back to the left pupil; again, the pupil size should remain constant. Repeat this \"swinging flashlight\" maneuver several times to be sure there is no consistent tendency for the pupils to be larger when the light is directed at one eye than when it is directed at the other one. If this relative afferent pupillary defect is found, it suggests an abnormality in the anterior visual pathways. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Afferent pupillary defect'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Eye movements (CN III, IV, and VI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;First observe the patient's eyelids for ptosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31255?source=see_link\">",
"     \"Overview of ptosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Have the patient fixate on your finger held about two feet away, in the vertical and horizontal midline. Observe for nystagmus. Jerk nystagmus is a repetitive, quick movement of the eyes in one direction, alternating with a slower movement of the eyes in the opposite direction, several times in a row. Pendular nystagmus is a slow sinusoidal oscillation of the eyes that may occur in any direction, without fast phases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34165?source=see_link\">",
"     \"Overview of nystagmus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ask the patient to avoid any movement of the head but to continue watching your finger as you slowly move it to the patient's right. Observe the smoothness and range of the patient's eye movements. Keep your finger at the far right of the patient's gaze for several seconds while observing for nystagmus. Move your finger slowly to the patient's left and repeat the observations. Return your finger to the vertical and horizontal midline, then move it slowly up, repeating the observations. Then move your finger slowly down and repeat the observations. As the patient looks down, the examiner should hold the patient's upper eyelid to prevent the eye from being covered and nystagmus obscured. Finally, return to the midline position, and move your finger diagonally down and to the left; then return to the midline and move your finger down and to the right.",
"   </p>",
"   <p>",
"    Eye movement abnormalities may be masked by convergence if the target is too close to the patient. On the other hand, if you stand too far away, it may be difficult for you to see subtle abnormalities. I often position my head close to the patient and move the target (my finger) back and forth behind me.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Facial sensation (CN V)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lightly touch the patient's right forehead once, and then repeat on the opposite side. Ask the patient if the two stimuli felt the same. Repeat this procedure on the cheek and on the chin. This is usually adequate testing. In some circumstances, the testing should be repeated applying light pressure with a pin. Recall that the angle of the jaw and neighboring cheek is not supplied by the trigeminal nerve, but rather by the great auricular nerve and the C2 - C3 nerve roots (",
"    <a class=\"graphic graphic_figure graphicRef70877 \" href=\"mobipreview.htm?12/32/12802\">",
"     figure 1",
"    </a>",
"    ). Above the ear, the posterior boundary of the trigeminal nerve territory abuts the territory of the lesser occipital nerve and, superiorly, the greater occipital nerve.",
"   </p>",
"   <p>",
"    Testing of the corneal reflex is not routinely necessary, but it is useful in uncooperative patients or when the rest of the examination suggests that there may be a problem with facial sensation or strength. It is tested by having the patient look to the far left, then touching the patient's right cornea with a fine wisp of cotton (introduced from the patient's right, outside the field of vision) and observing the reflexive blink that occurs in each eye. The process is then repeated with the left eye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Facial strength",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Muscles of mastication (CN V)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient open the jaw against resistance, then close the jaw against resistance. Have the patient move the chin from side to side.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Muscles of facial expression (CN VII)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient close his or her eyes tightly. Observe whether the lashes are buried equally on the two sides and whether you can open either eye manually. Then have the patient look up and wrinkle the forehead; note whether the two sides are equally wrinkled. Have the patient smile, and observe whether one side of the face is activated more quickly or more completely than the other.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Hearing (CN VIII)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For a bedside examination, it usually suffices to perform a quick hearing assessment by holding your fingers a few inches away from the patient's ear and rubbing them together softly. Alternatively, you can hold your hand up as a sound screen and ask the patient to repeat a few numbers that you whisper behind your hand, while rhythmically tapping the opposite ear to keep it from contributing. Each ear should be tested separately. Other similar methods can be used to occlude hearing in one ear while testing the other ear; a systematic review of one technique reported good sensitivity and specificity for hearing impairment (90 to 100 percent and 70 to 87 percent, respectively, in adults) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38377/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most textbooks advocate the Weber and Rinne tests for distinguishing conductive hearing loss from sensorineural deafness. I do not; I find that patients have difficulty understanding what is being asked and they give inconsistent responses (especially on the Weber test). Even if these tests gave consistently reliable results, they would still not be as sensitive or as informative as an audiogram. These tests are described and evaluation of hearing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=see_link\">",
"     \"Evaluation of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6684574\">",
"    <span class=\"h2\">",
"     Vestibular function (CN VIII)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral vestibular function can be assessed through the observation of gait and balance as well as the appearance of spontaneous",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elicited nystagmus (if present). These and other bedside tests of vestibular function are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=see_link\">",
"     \"Approach to the patient with vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Palatal movement (CN IX and X)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the patient to say \"aaah\" or yawn, and observe whether the two sides of the palate move fully and symmetrically. The palate is most readily visualized if the patient is sitting or standing, rather than supine.",
"   </p>",
"   <p>",
"    There is generally no need to test the gag reflex in a screening neurologic examination. When there is reason to suspect reduced palatal sensation or strength, the reflex can be checked by observing the response when you touch the posterior pharynx on one side with a cotton swab and then comparing it to the response elicited by touching the other side. About 20 percent of normal individuals do not have a gag reflex; the test is most informative when the responses are asymmetric.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Dysarthria (CN IX, X and XII)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysarthria is an impairment of the motor functions necessary for speech production; it is not a language disorder. When the patient speaks, listen for articulation errors, abnormalities of voice quality, and irregularities of rate or rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Head rotation/shoulder elevation (CN XI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient turn the head all the way to the left. Place your hand on the left side of the chin and ask the patient to resist you as you try turning the head back to the right. Palpate the right sternocleidomastoid muscle with your other hand at the same time. Repeat this maneuver in the other direction to test the left sternocleidomastoid. To test shoulder elevation, ask the patient to shrug the shoulders while you resist the movement with your hands.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Tongue movement (CN XII)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient protrude the tongue and move it rapidly from side to side. Ask the patient to push the tongue against the left cheek from inside the mouth while you push against it from outside, then do the same on the right side of the mouth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Specific ocular signs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Asymmetric pupils (anisocoria)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localizing the lesion in a patient with anisocoria requires first determining whether the larger or smaller pupil is abnormal. The smaller pupil is abnormal when the degree of anisocoria is greatest in darkened settings, while the larger pupil is abnormal when the degree of anisocoria is greatest in bright light. Other ocular and neurologic signs further aid in the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31206?source=see_link\">",
"     \"Approach to the patient with anisocoria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Afferent pupillary defect",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anisocoria indicates a lesion in the efferent fibers supplying the pupillary sphincter muscles. A lesion in the afferent limb of the pupillary reflex (ie, in the retina or optic nerve) does not produce anisocoria. Such a lesion is best appreciated on the \"swinging flashlight test.\" To understand this test, one must recognize two facts. First, pupillary size is determined by an average of the illumination detected by each eye. For a simple demonstration of this, observe a normal subject's right pupil while covering the left eye: the pupil enlarges because the average illumination has been effectively halved. Second, the efferent limb of the pupillary reflex is bilateral, so that both pupils receive the same command and they are always the same size. They are only unequal when the efferent pathways are not working properly.",
"   </p>",
"   <p>",
"    Now consider what happens when a patient has an optic nerve lesion that, for purposes of illustration, is in the left optic nerve and reduces perceived illumination in that eye by 50 percent (",
"    <a class=\"graphic graphic_figure graphicRef71937 \" href=\"mobipreview.htm?41/15/42239\">",
"     figure 2",
"    </a>",
"    ). A bright light directed at the left eye will still increase perceived illumination in that eye compared to ambient room light. The average of the perceived illumination in the two eyes will thus also increase, and both pupils will constrict. Assume that this produces a change in pupil size from 5 to 3 mm. A bright light directed at the right eye will produce a similar response; in this case, the change in perceived illumination from ambient room light will be even greater, producing a change in pupil size from 5 to 2.5 mm, for example. It is difficult for an examiner to appreciate this subtle distinction in the magnitude of the pupillary response. But now consider what happens when the bright light is swung back and forth between the two eyes. When it is directed at the left eye, both pupils are 3 mm. When swung to the right eye, both pupils constrict to 2.5 mm. When swung back to the left eye, both pupils dilate back to 3 mm. Because the examiner usually can observe the pupil under bright light more readily than the other pupil, the examiner notes the left pupil dilating each time the light is directed at it. In effect, by swinging the bright light back and forth, the examiner is simply varying the intensity of the light perceived by the brain, and the pupils are constricting and dilating appropriately in response. This finding is termed a left afferent pupillary defect, or a left Marcus-Gunn pupil.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Gaze palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An eye movement abnormality in which the two eyes move conjugately but have limited movement in one direction is called a gaze palsy. It is due to malfunction of one of the \"gaze centers\" (cortical and brainstem regions responsible for conjugate gaze) or to interruption of the pathways leading from them. When the lesion is in a brainstem gaze center, the neurons there cannot be activated either voluntarily or by reflex (such as the oculocephalic reflex or \"doll's eyes response\"). This is called a",
"    <strong>",
"     nuclear gaze palsy.",
"    </strong>",
"    When the lesion is in a cortical gaze center, only voluntary gaze is impaired; reflexes can still activate the brainstem neurons responsible for gaze. This is called a",
"    <strong>",
"     supranuclear gaze palsy.",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Internuclear ophthalmoplegia",
"    </span>",
"    &nbsp;&mdash;&nbsp;An internuclear ophthalmoplegia or INO is produced by a lesion in the medial longitudinal fasciculus (MLF). This pathway connects the sixth nerve nucleus on one side up to the third nerve nucleus on the other, allowing for conjugate horizontal gaze. A lesion in the MLF is manifest by impaired adduction on the affected side accompanied by nystagmus in the other, abducting eye. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=see_link\">",
"     \"Internuclear ophthalmoplegia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Localization issues",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Facial weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of facial weakness can help differentiate between central and peripheral lesions. When one entire side of the face is weak, the lesion is usually peripheral. With a central lesion (such as a stroke in one cerebral hemisphere), the forehead muscles are often spared because the portion of the facial nerve nucleus supplying innervation to the forehead typically gets input from the motor strips of both cerebral hemispheres. The portion of the facial nerve nucleus innervating the lower face does not have the same bilateral input; its input is predominantly from the contralateral cortex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central lesion affects hearing in both ears almost equally. The only way to produce hearing loss restricted to one ear is with a peripheral lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Palate, pharynx, or larynx weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unilateral weakness of muscles of the palate, pharynx, or larynx indicates a peripheral lesion (ie, at the level of lower motor neuron, neuromuscular junction, or muscle). These muscles are innervated by fibers that originate in the nucleus ambiguus in the medulla and that travel in the glossopharyngeal and vagus nerves (cranial nerves IX and X, respectively). The nucleus ambiguus receives descending input from both cerebral hemispheres. A unilateral central lesion does not produce focal palatal, pharyngeal, or laryngeal weakness because input to the nucleus ambiguus from the other hemisphere remains intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     Dysarthria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dysarthria can result from any condition that damages motor control of the structures necessary for speech production, including cerebellar or basal ganglia disorders, and the specific characteristics of the dysarthria may be useful in localization and differential diagnosis. Dysarthria and dysphagia are prominent symptoms of lower motor neuron lesions of cranial nerves IX and X. These symptoms tend to be less prominent after unilateral central lesions because of bilateral cortical input to the nucleus ambiguus.",
"   </p>",
"   <p>",
"    Bilateral central lesions often produce dramatic speech and swallowing problems, however. This is known as pseudobulbar palsy because the interruption of descending input to the brainstem simulates a lesion in the brainstem itself (a \"bulbar\" lesion). The character of the dysarthria is different in patients with upper and lower motor neuron lesions. There is classically a strained, strangled character to the speech of the former, while the latter sound breathy, hoarse, and hypernasal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Neck weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The motor nerves of cranial nerve XI that innervate the sternocleidomastoid and trapezius muscles originate in the cervical spinal cord (at the C1-2 level for the sternocleidomastoid and the C3-4 level for the trapezius). They ascend alongside the spinal cord and enter the skull through the foramen magnum, and exit the skull through the jugular foramen. The descending cortical input to the nuclei controlling the trapezius originates almost exclusively in the contralateral cerebral hemisphere. The cortical input to the nucleus for the sternocleidomastoid muscle comes from both hemispheres, but predominantly the ipsilateral one. An additional confounding feature is that the left sternocleidomastoid rotates the head to the right (and vice versa).",
"   </p>",
"   <p>",
"    As a result, peripheral lesions produce weakness of the ipsilateral sternocleidomastoid and trapezius muscles, resulting in weakness of shoulder elevation on that side but impaired head rotation to the opposite side. Central lesions produce weakness of the ipsilateral sternocleidomastoid but the contralateral trapezius. When a central lesion is large enough to cause more extensive weakness (ie, hemiparesis) there is weakness of shoulder elevation on the side of the hemiparesis and weakness of head rotation toward the side of the hemiparesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h3\">",
"     Tongue weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypoglossal nerve (CN XII) receives descending cortical input from both hemispheres equally, except for fibers destined for the genioglossus muscle that receive their cortical input only from the contralateral hemisphere. There appears to be variability in this pattern; unilateral central lesions sometimes produce ipsilateral tongue weakness, more often produce contralateral tongue weakness, and most often produce no significant tongue weakness. Unilateral peripheral lesions produce weakness of the ipsilateral tongue muscles resulting in difficulty protruding the tongue to the opposite side. Atrophy and fasciculations are often prominent with peripheral lesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     MOTOR EXAMINATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Gait",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observe the patient's casual gait, preferably with the patient unaware of being observed. Have the patient walk toward you while walking on the heels, then walk away from you on tiptoes. Finally, have the patient walk in tandem, placing one foot directly in front of the other as if walking on a tightrope. Note if the patient is unsteady with any of these maneuvers or if there is any asymmetry of movement. Also look for festination, an involuntary tendency for steps to accelerate and become smaller.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Coordination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coordination testing is often referred to as cerebellar testing, but this is a misnomer. Although the cerebellum is very important in the production of coordinated movements and particular abnormal findings on coordination testing may suggest cerebellar disease, other systems also play critical roles. As an example, severe arm weakness will prevent a patient from performing finger-to-nose testing even though the cerebellum and its pathways may be intact.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h3\">",
"     Finger tapping",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the patient to make a fist with the right hand, and then to extend the thumb and index finger and tap the tip of the index finger on the tip of the thumb as quickly as possible. Repeat with the left hand. Observe for speed, accuracy, and regularity of rhythm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h3\">",
"     Rapid alternating movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient alternately pronate and supinate the right hand against a stable surface (eg, a table, the patient's own thigh or left hand) as rapidly as possible; repeat for the left hand. Observe speed, accuracy, and rhythm. Impaired ability to perform this task is referred to as dysdiadochokinesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h3\">",
"     Finger-to-nose testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ask the patient to use the tip of his or her right index finger to touch the tip of your index finger, then the tip of his or her nose, then your finger again, and so forth. Hold your finger so that it is near the extreme of the patient's reach, and move it to several different positions during the testing. Repeat the test using the patient's left arm. Observe for accuracy and tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h3\">",
"     Heel-to-shin testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient lie supine, place the right heel on the left knee, and then move the heel smoothly down the shin to the ankle. Repeat using the left heel on the right shin. Again, observe for accuracy and tremor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Involuntary movements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observe the patient throughout the history and physical examination for the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tremor",
"     </li>",
"     <li>",
"      Myoclonus &mdash; rapid, shock-like muscle jerks",
"     </li>",
"     <li>",
"      Chorea &mdash; rapid, jerky twitches, similar to myoclonus but more random in location and more likely to blend into one another",
"     </li>",
"     <li>",
"      Athetosis &mdash; slow, writhing movements of the limbs",
"     </li>",
"     <li>",
"      Ballismus &mdash; large amplitude flinging limb movements",
"     </li>",
"     <li>",
"      Tics &mdash; abrupt, stereotyped, coordinated movements or vocalizations",
"     </li>",
"     <li>",
"      Dystonia &mdash; maintenance of an abnormal posture or repetitive twisting movements",
"     </li>",
"     <li>",
"      Other involuntary motor activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h2\">",
"     Pronator drift",
"    </span>",
"    &nbsp;&mdash;&nbsp;Have the patient stretch out the arms so that they are level and fully extended with the palms facing straight up, and then close the eyes. Watch for 5 to 10 seconds to see if either arm tends to pronate (so that the palm turns inward) and drift downward. A unilateral pronator drift in one arm suggests an upper motor neuron lesion affecting that arm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h2\">",
"     Strength testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the upper extremities, test shoulder abduction, elbow extension, elbow flexion, wrist extension, wrist flexion, finger extension, finger flexion, and finger abduction. In the lower extremities, test hip flexion, hip extension, knee flexion, knee extension, ankle dorsiflexion, and ankle plantar flexion. Additional testing may be necessary if some of these muscles are weak or if the patient complains of focal weakness to determine if the weakness is in the distribution of a specific nerve or nerve root.",
"   </p>",
"   <p>",
"    For each movement, place the limb near the middle of its range, and then ask the patient to resist you as you try to move the limb from that position. As an example, in testing shoulder abduction, the patient's arms should be horizontal, forming a letter T with the body, and the patient should try to maintain that position while you press down on both arms at a point between the shoulders and the elbows. When possible, place one hand above the joint being examined to stabilize the joint, and exert pressure with your other hand just below the joint, to isolate the specific movement you are trying to test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h3\">",
"     Grading strength",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common convention for grading muscle strength is the 0 to 5 Medical Research Council scale:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 = no contraction",
"     </li>",
"     <li>",
"      1 = visible muscle twitch but no movement of the joint",
"     </li>",
"     <li>",
"      2 = weak contraction insufficient to overcome gravity",
"     </li>",
"     <li>",
"      3 = weak contraction able to overcome gravity but no additional resistance",
"     </li>",
"     <li>",
"      4 = weak contraction able to overcome some resistance but not full resistance",
"     </li>",
"     <li>",
"      5 = normal; able to overcome full resistance",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most compelling feature of this scale is its reproducibility; an examiner is unlikely to assign a score of 1 to a muscle that another examiner graded 3 or stronger. A major limitation of the scale is that it is insensitive to subtle differences in strength. In particular, grade 4 covers a wide range, so that in most clinical situations the scale does not allow precise differentiation of the severity of weakness from one muscle to the next. Similarly, it is not a sensitive tool for documenting moderate changes in strength over time. Many clinicians try to compensate for this by using intermediate grades, such as 3+ or 5-, but this results in less reproducibility because there is no consensus on how these intermediate grades should be defined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h3\">",
"     Terminology of weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoparesis refers to weakness of a single limb. Hemiparesis is weakness of one side of the body. Paraparesis is weakness of both lower extremities. Quadriparesis is weakness of all four limbs. Monoplegia, hemiplegia, paraplegia, and quadriplegia are analogous terms that refer to complete or nearly complete paralysis of the involved limbs. Diplegia is a term that is best avoided because it is used differently by different authors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h2\">",
"     Muscle bulk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The muscles active in each movement should be inspected and palpated for evidence of atrophy while testing strength. Fasciculations (random, involuntary muscle twitches) should also be noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h2\">",
"     Muscle tone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Muscle tone is the slight residual tension present in voluntarily relaxed muscle. Tone is qualitatively assessed by asking the patient to relax and let you manipulate the limbs passively. This is harder for most patients than you might imagine, and you may need to try to distract them by engaging them in unrelated conversation, or ask them to let their limbs go limp, \"like a wet noodle.\"",
"   </p>",
"   <p>",
"    Several forms of increased tone (hypertonia) are distinguished, including spasticity, rigidity, and paratonia. Decreased tone (hypotonia) also occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h3\">",
"     Spasticity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spasticity depends upon the limb position and on how quickly the limb is moved, classically resulting in a \"clasp-knife phenomenon\" when the limb is moved rapidly. The limb moves freely for a short distance, but then there is a \"catch\" and you must use progressively more force to move the limb until at a certain point there is a sudden release and you can move the limb freely again. Spasticity is generally greatest in the flexors of the upper extremity and the extensors of the lower extremity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h3\">",
"     Rigidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rigidity, in contrast to spasticity, is characterized by increased resistance throughout the movement. Lead-pipe rigidity applies to resistance that is uniform throughout the movement. Cogwheel rigidity is characterized by rhythmic interruption of the resistance, producing a ratchet-like effect. Rigidity is usually accentuated by distracting the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H61\">",
"    <span class=\"h3\">",
"     Paratonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paratonia (also called gegenhalten) is increased resistance that becomes less prominent when the patient is distracted; without such distraction, the patient seems unable to relax the muscle. This is particularly common in patients who are anxious or demented. When it is prominent, other abnormalities of tone are difficult to assess.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H62\">",
"    <span class=\"h2\">",
"     Upper versus lower motor neuron lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several examination findings help to distinguish central from peripheral lesions in the motor system. Deep tendon reflexes (see",
"    <a class=\"local\" href=\"#H65\">",
"     'Tendon reflexes'",
"    </a>",
"    below) provide one clue; reflexes are typically hyperactive with a central lesion and hypoactive with a peripheral one. The Babinski sign (see",
"    <a class=\"local\" href=\"#H11228107\">",
"     'Plantar response'",
"    </a>",
"    below) is a reliable indicator of a central lesion. Atrophy and fasciculations are common with lower motor neuron disease and unusual with upper motor neuron disease.",
"   </p>",
"   <p>",
"    The pattern of muscle involvement is also helpful. A central lesion usually results in weakness that is more pronounced in the flexors of the lower extremities than in the extensors, but in the upper extremities the extensors are weaker than the flexors. This is often called pyramidal weakness, but it does not occur with pure lesions of the pyramidal tracts. Instead, it is the net result of disrupting all the descending motor tracts and is probably most appropriately called an upper motor neuron (UMN) pattern of weakness. The UMN pattern of weakness also causes supination of the upper extremity to be weaker than pronation; this accounts for the finding of a pronator drift, in which the arm pronates and drifts downward when the patient is asked to hold it extended with palms up (supinated). This is a fairly sensitive indicator of subtle UMN weakness. It is also useful as a test for internal consistency because patients with nonorganic weakness will often allow their arm to drift downward but fail to pronate it.",
"   </p>",
"   <p>",
"    Another feature distinguishing a central lesion from a peripheral one is muscle tone (see",
"    <a class=\"local\" href=\"#H58\">",
"     'Muscle tone'",
"    </a>",
"    above). A central lesion is characterized by spasticity, whereas tone is normal or reduced with a peripheral lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63\">",
"    <span class=\"h3\">",
"     Patterns of lower motor neuron weakness",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with weakness due to diffuse disease of the peripheral nervous system, the specific pattern of muscle involvement often provides useful localizing information. As an example, predominantly distal weakness usually suggests a disease of peripheral nerves, but predominantly proximal weakness typically occurs in muscle disorders and neuromuscular junction diseases.",
"   </p>",
"   <p>",
"    For patients with weakness due to focal lesions in the peripheral nervous system, adequate localization can be achieved in most cases by remembering a few simple patterns. In each extremity, consider three principal joints: the hip, knee, and ankle in the lower extremities, and the elbow, wrist, and metacarpophalangeal joint in the upper extremities. At each joint, consider flexion and extension separately. This gives six principal movements in each limb. Most localization problems can be solved by remembering the innervation patterns for these six principal movements (plus shoulder abduction and finger abduction in the upper extremities).",
"   </p>",
"   <p>",
"    In the upper extremities, the pattern can be remembered by ordering the movements in a kind of spiral that proceeds down the arm (",
"    <a class=\"graphic graphic_figure graphicRef58656 \" href=\"mobipreview.htm?10/47/10995\">",
"     figure 3",
"    </a>",
"    ): shoulder abduction (A), elbow flexion (B), elbow extension (C), wrist extension (D), wrist flexion (E), finger flexion (F), finger extension (G), and finger abduction (H). The corresponding roots then proceed in order: C5 (A), C5-6 (B), C6-7 (C), C6-7 (D), C7-8 (E), C8 (F), C8 (G), and T1 (H). All the extension movements (C, D, and G) are innervated by the radial nerve. The two distal flexion movements (E and F) are supplied by the median nerve, and the proximal one (B) by the musculocutaneous nerve. The axillary nerve supplies the deltoid muscle, which is the main shoulder abductor (A), and the interosseous muscles (H) are innervated by the ulnar nerve.",
"   </p>",
"   <p>",
"    In the lower extremities, the pattern is simpler (",
"    <a class=\"graphic graphic_figure graphicRef64884 \" href=\"mobipreview.htm?30/36/31297\">",
"     figure 4",
"    </a>",
"    ). The movements can be ordered in sequence down the front first and then the back: hip flexion (A), knee extension (B), ankle dorsiflexion (C), hip extension (D), knee flexion (E), and ankle plantar flexion (F). The corresponding roots are: L2-3 (A), L3-4 (B), L4-5 (C), L4-5 (D), L5-S1 (E), and S1-2 (F). The sciatic nerve innervates the muscles responsible for knee flexion (E); its peroneal branch supplies ankle dorsiflexion (C), while its tibial branch supplies ankle plantar flexion (F). Knee extensor muscles are innervated by the femoral nerve. The innervation of the iliopsoas muscle, which flexes the hip, arises very proximally from the L2 and L3 nerve roots; some consider this to be part of the femoral nerve, and others simply call it the \"nerve to iliopsoas.\" The gluteus muscles, responsible for hip extension (D), are innervated by the gluteal nerves.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H64\">",
"    <span class=\"h1\">",
"     REFLEX EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relaxation is critical during the reflex examination. Tendon reflexes are difficult to elicit when patients tense the muscles being tested. It is helpful to distract patients by engaging them in conversation while testing their reflexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H65\">",
"    <span class=\"h2\">",
"     Tendon reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biceps, triceps, brachioradialis, knee (patellar), and ankle (Achilles) reflexes are the ones commonly tested. The joint under consideration should be at about 90 degrees and fully relaxed. It is often helpful to cradle the joint in your own arm to support it. With your other arm, hold the end of the hammer and let the head of the hammer drop like a pendulum so that it strikes the tendon:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biceps &mdash; just anterior to the elbow",
"     </li>",
"     <li>",
"      Triceps &mdash; just posterior to the elbow",
"     </li>",
"     <li>",
"      Brachioradialis &mdash; about 10 cm above the wrist on the radial aspect of the forearm",
"     </li>",
"     <li>",
"      Knee &mdash; just below the patella",
"     </li>",
"     <li>",
"      Ankle &mdash; just behind the ankle",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When a patient has reflexes that are difficult to elicit, you can amplify them by using reinforcement procedures: Ask the patient to clench his or her teeth or (when testing lower extremity reflexes) to hook together the flexed fingers of both hands and pull. This is also known as the Jendrassik maneuver.",
"   </p>",
"   <p>",
"    Clonus is a rhythmic series of muscle contractions induced by stretching the tendon. It most commonly occurs at the ankle, where it is typically elicited by suddenly dorsiflexing the patient's foot and maintaining light upward pressure on the sole.",
"   </p>",
"   <p>",
"    When reflexes are brisk, it is difficult to detect slight asymmetry. For the most sensitive comparison, it is best to reduce the stimulus until it is just barely above threshold for eliciting the reflex. I typically set aside my reflex hammer and use my fingertips for this purpose. I look for two manifestations of asymmetry:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the threshold stimulus the same on each side, or do I consistently need to hit harder on one side than the other?",
"     </li>",
"     <li>",
"      If the threshold stimulus is the same on each side, does it elicit the same magnitude of response on each side?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such subtle distinctions are most readily made by testing the reflex on one side immediately after testing the corresponding reflex on the other side, rather than testing all reflexes in one limb before testing the contralateral limb.",
"   </p>",
"   <p>",
"    Another technique I use to heighten sensitivity to subtle reflex asymmetry is to place my finger on the patient's tendon and strike my finger rather than striking the tendon directly. This helps me aim more accurately and allows me to feel the tendon contraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H67\">",
"    <span class=\"h3\">",
"     Grading reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common convention for grading deep tendon reflexes is simple but imprecise:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      0 = absent",
"     </li>",
"     <li>",
"      1 = reduced (hypoactive)",
"     </li>",
"     <li>",
"      2 = normal",
"     </li>",
"     <li>",
"      3 = increased (hyperactive)",
"     </li>",
"     <li>",
"      4 = clonus",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some examiners use a grade of 5 to designate sustained clonus, reserving 4 for unsustained clonus that eventually fades after 2 to 10 beats. Some examiners also include a reflex grade of",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    to indicate a reflex that can only be obtained using reinforcement.",
"   </p>",
"   <p>",
"    The obvious limitation of this scheme is that it provides no guidelines for determining when reflexes are reduced, normal, or increased. This is left up to individual judgment, based upon the examiner's sense of the range of reflexes present in the normal population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H68\">",
"    <span class=\"h3\">",
"     Interpreting reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Comparison between reflexes in one part of the body and another is much more important than the absolute reflex grade. The most important comparison is between corresponding reflexes on the right and left, where even subtle asymmetry may be significant. As an example, patients with an S1 radiculopathy may have an ankle jerk that would be considered normal, yet it is clearly less brisk than the ankle jerk on the other side. This is another limitation of the reflex grading scale; it does not express subtle distinctions that may be clinically important. For this reason, many examiners augment the scale by using + or - to designate intermediate grades. These grades have very little reproducibility from one examiner to another (or even for a single examiner from one examination to the next). They are only useful for indicating that asymmetry exists, not for quantifying it in any meaningful way.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H69\">",
"    <span class=\"h3\">",
"     Affected nerves",
"    </span>",
"    &nbsp;&mdash;&nbsp;The nerve root corresponding to each commonly tested deep tendon reflex is as follows: the biceps and brachioradialis reflexes are mediated by the C5-6 roots, the triceps reflex by the C6-7 roots (mainly C7), the knee jerk by the L3-4 roots (mainly L4), and the ankle jerk by the S1 root. The internal hamstring reflex is less often tested, but it is mediated by the L5 nerve root.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11228107\">",
"    <span class=\"h2\">",
"     Plantar response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using a blunt, narrow surface (eg, a wooden Q tip, key, or handle of a reflex hammer), stroke the sole of the patient's foot on the lateral edge, starting near the heel and proceeding along the lateral edge almost to the base of the little toe, then curve the path medially just proximal to the base of the other toes. This should take the form of a smooth J stroke. Always start by applying minimal pressure. This is usually adequate but, if no response occurs, repeat the maneuver with greater pressure.",
"   </p>",
"   <p>",
"    The normal response is for all the toes to flex (a \"flexor plantar response\"). When there is damage to the central nervous system motor pathways, an abnormal reflex occurs: the great toe extends (dorsiflexes) and the other toes fan out. This is called an extensor plantar response; it is also known as a Babinski sign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H70\">",
"    <span class=\"h2\">",
"     Superficial reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The abdominal reflexes, cremasteric reflexes, and other superficial reflexes are not usually relevant to standard neurologic examinations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H71\">",
"    <span class=\"h2\">",
"     Primitive reflexes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The grasp, root, snout, and palmomental reflexes are known as primitive reflexes or",
"    <strong>",
"     frontal release signs.",
"    </strong>",
"    These tests do not fit easily into any examination category. They are reflex responses, but their pathways are far more complicated than the monosynaptic arcs of the deep tendon reflexes. I do not test these reflexes. They have very little localizing value, and there is no convincing evidence that they reflect frontal lobe pathology. They are not reliable indicators of abnormal function and, except for the grasp, all are seen in a substantial proportion of normal individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H72\">",
"    <span class=\"h1\">",
"     SENSORY EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sensory examination involves testing first the primary sensory modalities (ie, light touch, pain and temperature, vibration, joint position sense) and then the discriminative sensory functions (ie, stereognosis, graphesthesia, point localization, two point discrimination, and extinction). The former test the integrity of the afferent sensory pathways, whereas the latter test the ability of sensory and association cortices to analyze and interpret sensory input.",
"   </p>",
"   <p>",
"    The sensory examination is frequently the most frustrating part of the neurologic examination. The instructions often must be repeated several times or more before patients understand what they are being asked to do. This part of the examination is also tiresome and somewhat uncomfortable for patients. For these reasons, the sensory examination is usually one of the last things I test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H73\">",
"    <span class=\"h2\">",
"     Light touch",
"    </span>",
"    &nbsp;&mdash;&nbsp;To test for light touch sensation, have the patient close his or her eyes and tell you whether you are touching the left hand, right hand, or both simultaneously. Repeat this several times, using a single light touch applied sometimes to the medial aspect of the hand and sometimes to the lateral aspect. Note whether the patient consistently fails to detect stimulation in one location. Also note whether the patient consistently \"extinguishes\" the stimulus on one side of the body when both sides are stimulated simultaneously. Next, touch the patient once lightly on the medial aspect of each hand simultaneously, and ask if they feel the same. Ask the same question for the lateral aspect of each hand. If any abnormalities are detected, extend your region of testing proximally in the limb to map out the precise area of abnormality. Perform analogous testing on the feet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74\">",
"    <span class=\"h2\">",
"     Pain/temperature",
"    </span>",
"    &nbsp;&mdash;&nbsp;When preparing to test pain and temperature sensation, explain to the patient that you will be touching each finger with either the sharp or the dull end of a safety pin, and demonstrate each. Then with the patient's eyes closed, lightly touch the palmar aspect of the thumb with the sharp point of the pin and ask the patient to say \"sharp\" or \"dull.\" Repeat this for each finger of each hand, usually using the sharp point but including one dull stimulus on each hand to be sure the patient is paying attention. Next, touch the patient with the pin once lightly on the medial aspect of each hand, and ask if they feel equally sharp. Ask the same question for the lateral aspect of each hand. If any abnormalities are detected, extend your region of testing proximally in the limb to map out the precise area of abnormality. Perform analogous testing on the feet. Discard the pin in a container for contaminated \"sharps.\"",
"   </p>",
"   <p>",
"    It is not usually necessary to test both pain and temperature; either will suffice. You can test temperature in a fashion analogous to pain; a reasonable stimulus is the flat portion of a tuning fork after it has been immersed in cold water and dried.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75\">",
"    <span class=\"h2\">",
"     Joint position sense",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the finger and thumb of one hand, stabilize the distal interphalangeal joint of the patient's left thumb by holding it on the medial and lateral aspects. With the finger and thumb of your other hand, hold the medial and lateral aspects of the tip of the thumb and move it slightly up or down. Have the patient close his or her eyes and identify the direction of movement. Repeat several times. Most normal patients can identify movements of a few degrees or less. Perform analogous testing of the patient's right thumb and both great toes. If abnormalities are detected, proceed to more proximal joints in the same limb until a joint is found where position sense is intact.",
"   </p>",
"   <p>",
"    The Romberg test also helps to assess position sense. Have the patient stand with both feet together, and then note whether the patient can maintain balance after closing his or her eyes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H76\">",
"    <span class=\"h2\">",
"     Vibration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vibration sense can be tested by tapping a 128-Hz tuning fork lightly against a solid surface to produce a slight (silent) vibration. With the patient's eyes closed, hold the nonvibrating end of the tuning fork firmly on the distal interphalangeal joint of the patient's left thumb and ask the patient if the vibration is detectable. Let the vibration fade until the patient no longer detects it, then apply the tuning fork to your own thumb to see if you can still feel any vibration. Repeat this testing on the patient's right thumb and both great toes.",
"   </p>",
"   <p>",
"    For one of the limbs, stop the vibration before applying the tuning fork to the limb to be sure that the patient is paying attention. If not, clarify to the patient that you are only interested in actual vibration, not just pressure. If any abnormalities are detected, apply the tuning fork to progressively more proximal joints until one is found where the vibration is detected normally.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H77\">",
"    <span class=\"h2\">",
"     Graphesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;To test for graphesthesia, ask the patient to close the eyes and identify a number from 0 to 9 that you draw on his or her index finger using a ballpoint pen. Repeat with several other numbers and compare to the other hand. There is rarely any need to test graphesthesia in the feet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H78\">",
"    <span class=\"h2\">",
"     Stereognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;To test for stereognosis, ask the patient to close the eyes and identify a small object (eg, nickel, dime, quarter, penny, key, paper clip) you place in his or her right hand. Test the left hand in the same way.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79\">",
"    <span class=\"h2\">",
"     Two-point discrimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two point discrimination is the ability to recognize two points applied simultaneously to the skin as distinct from a single point.",
"   </p>",
"   <p>",
"    To test this, patients (with eyes closed) are asked to discriminate between the touch of one versus two simultaneously applied stimuli (eg, points of a caliper) to the skin, usually on a digit. The initial distance between the two applied points is gradually decreased from an initial test at about 2 cm until the patient can no longer distinguish between two points, determining the shortest distance at which two points can be distinguished.",
"   </p>",
"   <p>",
"    Normative values vary by age and location of the region tested. Children and young adults (up to 39 years) can distinguish two points at 4 mm separation, while adults over the age of 80 years may not be able to distinguish two points closer than 8.5 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38377/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The normal threshold for two-point discrimination is several centimeters on the back.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H80\">",
"    <span class=\"h2\">",
"     Localization of sensory deficits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathways for different sensory modalities cross at different levels in the nervous system, making them very useful for localizing lesions. Unlike the distinction between UMN and lower motor neuron lesions in the motor pathways, there are not really any examination findings that help to confine a lesion to a specific portion of a sensory pathway.",
"   </p>",
"   <p>",
"    For most localization problems, precise knowledge of the sensory fields of specific peripheral nerves and nerve roots is unnecessary. It is usually sufficient to remember the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensation travels from the thumb and index finger via the C6 nerve root, from the middle finger via the C7 root, and from the fourth and fifth fingers via the C8 root.",
"     </li>",
"     <li>",
"      For the remainder of the upper extremity, the root innervation \"fans out\" from the hand (",
"      <a class=\"graphic graphic_figure graphicRef58656 \" href=\"mobipreview.htm?10/47/10995\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      These innervation patterns cover both the anterior and posterior aspects of the upper extremity. The upper extremity dermatomes are detailed (",
"      <a class=\"graphic graphic_figure graphicRef53006 \" href=\"mobipreview.htm?21/8/21634\">",
"       figure 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The",
"      <strong>",
"       L",
"      </strong>",
"      5 dermatome includes the",
"      <strong>",
"       l",
"      </strong>",
"      arge toe and the",
"      <strong>",
"       l",
"      </strong>",
"      ateral",
"      <strong>",
"       l",
"      </strong>",
"      ower",
"      <strong>",
"       l",
"      </strong>",
"      eg; the",
"      <strong>",
"       S",
"      </strong>",
"      1 dermatome includes the",
"      <strong>",
"       s",
"      </strong>",
"      mall toe and",
"      <strong>",
"       s",
"      </strong>",
"      ole. Roots L4, L3, and L2 cover the region fanning out medially and proximally from the L5 dermatome. The S2 dermatome extends from the S1 dermatome up the back of the leg. The lower extremity dermatomes are detailed (",
"      <a class=\"graphic graphic_figure graphicRef50419 \" href=\"mobipreview.htm?10/36/10822\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The median nerve carries sensation from all fingers except the fifth finger and half of the fourth, which are served by the ulnar nerve. These nerve territories extend proximally up to the wrist on the palmar aspect of the hand. On the dorsal aspect, the ulnar nerve territory still extends to the wrist, but the median nerve territory fades into radial nerve territory at the metacarpal phalangeal joints. (",
"      <a class=\"graphic graphic_figure graphicRef54042 \" href=\"mobipreview.htm?41/32/42505\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The common peroneal nerve innervates the lateral leg and the dorsum of the foot; the tibial nerve innervates the sole. (",
"      <a class=\"graphic graphic_figure graphicRef54042 \" href=\"mobipreview.htm?41/32/42505\">",
"       figure 7",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9728271\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most of the information necessary to localize a lesion in patients with neurologic complaints can be obtained by taking a careful history, some important information can be learned only by examining the patient.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major elements of the neurologic examination include mental status, cranial nerves, motor, reflex, and sensory examinations. A screening neurologic examination assesses general aspects of these five spheres and can be performed in five minutes or less. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'A screening neurologic examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Essential features of a complete neurologic examination are outlined in the Table (",
"      <a class=\"graphic graphic_table graphicRef82393 \" href=\"mobipreview.htm?32/49/33565\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Depending on abnormalities elicited in the history or during the initial portion of the examination, the clinician chooses to examine certain spheres in greater or lesser detail as described above in order to \"localize\" the lesion and develop a differential diagnosis. (See individual topic headings above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Gelb, DJ. The Neurologic Examination. In: Introduction to clinical neurology. Butterworth Heinemann, Woburn, MA 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38377/abstract/2\">",
"      Kerr NM, Chew SS, Eady EK, et al. Diagnostic accuracy of confrontation visual field tests. Neurology 2010; 74:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38377/abstract/3\">",
"      Pirozzo S, Papinczak T, Glasziou P. Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ 2003; 327:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38377/abstract/4\">",
"      van Nes SI, Faber CG, Hamers RM, et al. Revising two-point discrimination assessment in normal aging and in patients with polyneuropathies. J Neurol Neurosurg Psychiatry 2008; 79:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38377/abstract/5\">",
"      Cope EB, Antony JH. Normal values for the two-point discrimination test. Pediatr Neurol 1992; 8:251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5095 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38377=[""].join("\n");
var outline_f37_30_38377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9728271\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      A SCREENING NEUROLOGIC EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MENTAL STATUS EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CRANIAL NERVE EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Olfaction (CN I)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Vision (CN II)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Visual fields",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Acuity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Funduscopic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pupillary light reflex (CN II and III)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Eye movements (CN III, IV, and VI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Facial sensation (CN V)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Facial strength",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Muscles of mastication (CN V)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Muscles of facial expression (CN VII)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Hearing (CN VIII)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6684574\">",
"      Vestibular function (CN VIII)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Palatal movement (CN IX and X)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Dysarthria (CN IX, X and XII)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Head rotation/shoulder elevation (CN XI)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Tongue movement (CN XII)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Specific ocular signs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Asymmetric pupils (anisocoria)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Afferent pupillary defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Gaze palsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Localization issues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Facial weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Palate, pharynx, or larynx weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - Dysarthria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Neck weakness",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      - Tongue weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      MOTOR EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Gait",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Coordination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      - Finger tapping",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      - Rapid alternating movements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      - Finger-to-nose testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      - Heel-to-shin testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Involuntary movements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      Pronator drift",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      Strength testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      - Grading strength",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      - Terminology of weakness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      Muscle bulk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      Muscle tone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      - Spasticity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      - Rigidity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H61\">",
"      - Paratonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H62\">",
"      Upper versus lower motor neuron lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H63\">",
"      - Patterns of lower motor neuron weakness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H64\">",
"      REFLEX EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H65\">",
"      Tendon reflexes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H67\">",
"      - Grading reflexes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H68\">",
"      - Interpreting reflexes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H69\">",
"      - Affected nerves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11228107\">",
"      Plantar response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H70\">",
"      Superficial reflexes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H71\">",
"      Primitive reflexes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H72\">",
"      SENSORY EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H73\">",
"      Light touch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74\">",
"      Pain/temperature",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H75\">",
"      Joint position sense",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H76\">",
"      Vibration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H77\">",
"      Graphesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H78\">",
"      Stereognosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H79\">",
"      Two-point discrimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H80\">",
"      Localization of sensory deficits",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9728271\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/5095\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5095|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/32/12802\" title=\"figure 1\">",
"      Cutaneous fields head neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/15/42239\" title=\"figure 2\">",
"      Afferent pupillary defect",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/47/10995\" title=\"figure 3\">",
"      Upper extremity nerve roots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/36/31297\" title=\"figure 4\">",
"      Lower extremity nerve roots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/8/21634\" title=\"figure 5\">",
"      Cervical dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/36/10822\" title=\"figure 6\">",
"      Lumbosacral dermatomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/32/42505\" title=\"figure 7\">",
"      Peripheral nerve innervation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/5095|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/49/33565\" title=\"table 1\">",
"      Neurologic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/39/33405\" title=\"table 2\">",
"      Mental status exam terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/30/31206?source=related_link\">",
"      Approach to the patient with anisocoria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/36/20041?source=related_link\">",
"      Approach to the patient with aphasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/19/32057?source=related_link\">",
"      Approach to the patient with vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/32/39429?source=related_link\">",
"      Evaluation of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/61/37848?source=related_link\">",
"      Homonymous hemianopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/49/20246?source=related_link\">",
"      Internuclear ophthalmoplegia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/23/34165?source=related_link\">",
"      Overview of nystagmus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/33/31255?source=related_link\">",
"      Overview of ptosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/48/23303?source=related_link\">",
"      The mental status examination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_30_38378="Investigational therapies for hepatitis C virus infection";
var content_f37_30_38378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational therapies for hepatitis C virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38378/contributors\">",
"     Andrew W Tai, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38378/contributors\">",
"     Raymond T Chung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38378/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38378/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/30/38378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/30/38378/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/30/38378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The search for new therapies for chronic hepatitis C virus (HCV) is ongoing. Current treatment leads to a sustained virologic response (SVR) in 60 to 80 percent of treatment-na&iuml;ve patients with genotype 1 treated with peginterferon,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and a protease inhibitor, and in patients with genotypes 2 or 3 treated with peginterferon and ribavirin. However, the SVR rate is significantly lower with genotype 4 infection, as well as in African-Americans, Latinos, transplant recipients, and those with HIV coinfection. Furthermore, current therapy is associated with significant side effects, which often preclude treatment or force its premature discontinuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a result, major research efforts are underway to identify new therapies that can increase the SVR rate, lower the incidence of side effects, have fewer drug-drug interactions,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    shorten the duration of treatment. The main targets of most new therapies are the HCV-encoded proteins that are vital to the replication and life cycle of the virus. These targets include the HCV-encoded",
"    <span class=\"nowrap\">",
"     NS2/3",
"    </span>",
"    autoprotease, the",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    serine protease, the NS3 RNA helicase, the NS5A protein, and the NS5B RNA dependent RNA polymerase (RdRp). Another line of investigation has focused on host-encoded proteins that are essential for viral replication, such as cyclophilins.",
"   </p>",
"   <p>",
"    This topic review will summarize the current state of knowledge of some of the investigational therapies for chronic HCV infection, including those whose efficacy appears to have been disproven. These can be divided conceptually into:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Derivatives of interferon and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"     </li>",
"     <li>",
"      Treatments targeting HCV-encoded proteins",
"     </li>",
"     <li>",
"      Treatments targeting host-encoded proteins",
"     </li>",
"     <li>",
"      Therapeutic and preventive vaccines",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only those agents for which information is available in the public domain are highlighted in this review. Not all agents will be discussed. Our intent in this topic is not to comprehensively review all of the available clinical trial data, but rather to discuss key clinical trials and also to provide a conceptual framework of current investigational HCV treatment strategies.",
"   </p>",
"   <p>",
"    A general approach to the treatment of patients with chronic HCV as well as the use of standard interferon, peginterferon,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    for the treatment of chronic HCV are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=see_link\">",
"     \"Overview of the management of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=see_link\">",
"     \"Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=see_link\">",
"     \"Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     HCV REPLICATION MODELS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A major limitation to progress in drug development for HCV had been the absence of a suitable in vitro replication system to test new drug candidates. However, an HCV replication model (the \"replicon\") using a hepatoma cell line was first described in 1999 and has proven to be invaluable for the development of new antiviral agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/1\">",
"     1",
"    </a>",
"    ]. More recently, a fully infectious HCV isolate has been identified that recapitulates the full viral life cycle in cell culture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, in vitro assays have been developed for important HCV-encoded proteins that can be used to screen prospective antiviral agents. These include assays for the HCV-encoded",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    serine protease, the NS3 RNA helicase, and the NS5B RNA dependent RNA polymerase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DERIVATIVES OF CURRENT TREATMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modifications of current forms of interferons are currently in clinical trials. In addition, novel delivery systems (such as infusion pumps) are in early stages of testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1054566799\">",
"    <span class=\"h2\">",
"     Interferon-lambda",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/27/27064?source=see_link\">",
"     Pegylated interferon alfa-2a",
"    </a>",
"    and alfa-2b are currently used for the treatment of HCV. Interferon lambda-1 (IL-29) is a type III interferon that activates similar intracellular signaling pathways to induce antiviral interferon-stimulated genes. However, the receptors for lambda interferons are expressed in a more limited distribution than alfa interferons, suggesting that interferon-lambda may be associated with a lower rate of adverse events than interferon alfa.",
"   </p>",
"   <p>",
"    The results of a phase II trial (EMERGE 2b) comparing three different doses (120, 180, or 240 mcg weekly) of peginterferon lambda-1a with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    to peginterferon alfa-2a with ribavirin in treatment-na&iuml;ve, patients without cirrhosis and with HCV genotypes 1-4 have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients with genotype 1 or 4 were treated for 48 weeks, while patients with genotype 2 or 3 were treated for 24 weeks. Approximately 39 percent of patients in the 180 mcg lambda and alfa arms had genotype 1a infection, and only about 6 percent had genotype 4 infection. Importantly, many (25 to 40 percent) patients had unknown IL28B genotypes, a factor known to be associated with sustained virologic response (SVR) rates. In the 180 mcg lambda arm, 38 percent of patients had unfavorable IL28B genotypes, and about 40 percent were not genotyped (37 percent did not consent), while in the alfa arm, 57 percent of patients had unfavorable IL28B genotypes, and 25 percent were not genotyped. Patients in the lambda 240 mcg arm were reduced to 180 mcg after an interim analysis of safety and virologic response at study week 12.",
"   </p>",
"   <p>",
"    Although rates of treatment discontinuation due to adverse events were not markedly different between patients receiving interferon lambda 180 mcg weekly and alfa 180 mcg weekly (8 of 102 versus 12 of 103), interferon dose modification or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dose modification was required in only 7.8 and 10.8 percent of patients in the interferon lambda 180 mcg weekly arm, respectively, compared with 28 and 33 percent of patients in the interferon alfa arm. This was due in large part to lower rates of anemia (hemoglobin &lt;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or a fall of &ge;4.5",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    in patients taking peginterferon lambda (5.9 percent versus 31 percent in patients taking peginterferon alfa) as well as lower rates of neutropenia",
"    <span class=\"nowrap\">",
"     (&le;750/mm",
"     <sup>",
"      3",
"     </sup>",
"     ;",
"    </span>",
"    1.0 percent versus 20 percent). Furthermore, myalgia, pyrexia, chills, and arthralgias were reported in only 6, 8, 4, and 6 percent, respectively, in patients taking 180 mcg of peginterferon lambda weekly, compared with 33, 33, 21, and 20 percent of patients taking peginterferon alfa.",
"   </p>",
"   <p>",
"    However, these lower rates of adverse events and",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    dose reduction among patients taking peginterferon lambda did not translate to higher SVR rates. An SVR 24 weeks after completing therapy (SVR24) was achieved by 37 percent in both the peginterferon lambda 180",
"    <span class=\"nowrap\">",
"     mcg/week",
"    </span>",
"    and the peginterferon alfa arms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ribavirin derivatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     Ribavirin",
"    </a>",
"    has several antiviral and immunomodulatory effects that may contribute to its efficacy as adjunctive therapy in HCV when combined with interferon. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most significant dose-limiting side effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    is hemolytic anemia. Ribavirin derivatives with a lower tendency to cause hemolytic anemia have been studied, although none has yet been shown to be as effective as ribavirin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Development of levovirin, the L-enantiomer of ribavirin, has been terminated since it was found to be inferior to ribavirin in combination with peginterferon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Taribavirin (Viramidine), a prodrug of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , failed to show non-inferiority to ribavirin in two phase III trials (VISER 1 and 2) using fixed-dose taribavirin (600 mg twice daily), though lower rates of anemia were observed with taribavirin compared with ribavirin in both trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/7\">",
"     7",
"    </a>",
"    ]. Post-hoc analysis suggested that the taribavirin dosing may have been inadequate in the VISER trials. As a result, a subsequent phase IIb trial was conducted in 278 treatment-na&iuml;ve genotype 1 patients evaluating weight-based taribavirin dosing (20, 25, and 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) compared with weight-based ribavirin in combination with peginterferon. There were no significant differences in SVR rates among the four treatment arms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/8\">",
"     8",
"    </a>",
"    ]. However, the 20 and 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    taribavirin arms experienced significantly lower rates of anemia (Hgb &lt;10",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    than the ribavirin arm (13, 16, and 33 percent, respectively), but up to 40 percent of patients receiving taribavirin experienced diarrhea compared with 21 percent of those receiving ribavirin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIRECT ACTING ANTIVIRAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characterization of hepatitis C virus (HCV)-encoded proteins and their functions has permitted development of strategies aimed at interrupting HCV replication. The FDA-approved DAAs",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    are two agents that target the",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    serine protease. Other key potential drug targets include the p7 ion channel, the",
"    <span class=\"nowrap\">",
"     NS2/3",
"    </span>",
"    autoprotease, the NS3 RNA helicase, the NS5A nonstructural protein, and the NS5B RNA-dependent RNA polymerase (RdRp). The strategy of targeting HCV-encoded proteins with small molecule inhibitors has been referred to as \"Direct acting antiviral (DAA) therapy\" or \"Specifically Targeted Antiviral Therapy for HCV (STAT-C).\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299756\">",
"    <span class=\"h2\">",
"     Role of HCV 1a versus 1b genotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genotype 1 HCV can be further divided into subgenotypes, of which 1a and 1b are the most common worldwide. Genotype 1a is more prevalent in the United States, while 1b is more prevalent in Europe and Japan. This is relevant because genotype 1a HCV is associated with lower rates of SVR to many DAA combinations compared with 1b.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299779\">",
"    <span class=\"h2\">",
"     Role of IL28b gene polymorphisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human genetic polymorphisms near the IL28B gene, which codes for interferon lambda 3, have been shown to be significant pretreatment predictors of response to interferon-based HCV treatment. One such polymorphism is the C or T allele at rs12979860. The favorable CC genotype is associated with SVR not only with",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/9\">",
"     9",
"    </a>",
"    ], but also with triple therapy incorporating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/10\">",
"     10",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <strong>",
"    </strong>",
"    Of note, the IL28B genotype appears to be associated with treatment response to at least some interferon-free regimens. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=see_link&amp;anchor=H16092947#H16092947\">",
"     \"Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection\", section on 'IL28B polymorphisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     NS3/4A protease inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HCV RNA genome encodes a single polyprotein of approximately 3000 amino acids. This polyprotein is cleaved during and after translation by both host and viral-encoded proteases into the 10 mature viral proteins. The",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    viral protein contains a serine protease activity that is required for cleavage of the viral polyprotein at four sites.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     Telaprevir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/40/27273?source=see_link\">",
"     boceprevir",
"    </a>",
"    are both",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    serine protease inhibitors. The data supporting their use and treatment regimens using these drugs for patients with genotype 1 are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=see_link\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=see_link&amp;anchor=H148834010#H148834010\">",
"     \"Treatment regimens for chronic hepatitis C virus genotype 1\", section on 'Treatment regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Limitations to the first-generation protease inhibitors include the need for thrice-daily dosing and significant drug-drug interactions, particularly with many HIV antiretrovirals and with calcineurin inhibitors, which are widely used in liver transplant recipients (",
"    <a class=\"graphic graphic_table graphicRef78070 \" href=\"mobipreview.htm?11/30/11744\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66181 \" href=\"mobipreview.htm?7/31/7664\">",
"     table 2",
"    </a>",
"    ). Toxicities seen with protease inhibitors include anemia (often requiring blood transfusion or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    dose reduction) and rashes (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"     telaprevir",
"    </a>",
"    ). Finally, as a class,",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitors have a low barrier to viral resistance, which can be alleviated somewhat by the higher potency of some of the second-generation inhibitors currently in clinical development.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299832\">",
"    <span class=\"h2\">",
"     NS5A inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HCV NS5A protein is essential for viral replication and for the assembly of infectious virions, although the precise molecular mechanisms by which NS5A accomplishes these functions are uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/12\">",
"     12",
"    </a>",
"    ]. The mechanism of action of HCV NS5A inhibitors is therefore unclear. As a class, NS5A inhibitors exhibit extraordinary potency in the low picomolar range, but like",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitors, they have a low barrier to viral resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299861\">",
"    <span class=\"h2\">",
"     NS5B polymerase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhibitors of the NS5B RNA-dependent RNA polymerase (RdRp) fall into two broad classes: nucleos(t)ide analog inhibitors (NIs) and non-nucleoside inhibitors (NNIs). NIs bind to the NS5B active site, while NNIs bind to one of at least three allosteric binding pockets outside the active site. Binding of the NNIs to one of these allosteric binding pockets results in a conformational change in the active site, thereby inhibiting RNA polymerase activity.",
"   </p>",
"   <p>",
"    Because NIs and NNIs bind to distinct sites on the NS5B protein, the genotypic sensitivities and resistance profiles of these drugs are expected to differ. As a general rule, NNIs are more genotype-selective, and all NNIs in clinical development have been optimized against genotype 1 NS5B, while NIs show broader in vitro potency against multiple HCV genotypes. Another potential advantage of NIs is that the NS5B active site is relatively intolerant to amino acid substitutions. As a result, active site NS5B mutations that confer resistance to NIs are more likely to also impair RNA polymerase activity compared with mutations in NNI allosteric binding pockets, thus rendering the mutant virus less \"fit\" compared with wild-type virus. This hypothesis is supported by cell culture experiments demonstrating that NIs are much less likely to select for resistance mutations than NNIs and protease inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unfortunately, development of a number of promising HCV NIs has been halted due to toxicity (eg, R1626 and",
"    <span class=\"nowrap\">",
"     BMS-986094/INX-189).",
"    </span>",
"    Another NI, IDX184, has been placed on partial clinical hold due to its structural similarity to BMS-986094.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299890\">",
"    <span class=\"h1\">",
"     DAA COMBINATION STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The \"ideal\" anti-HCV therapy would employ one or two oral medications taken once daily for a short duration (eg, 4 to 12 weeks) with minimal side effects or drug-drug interactions. Such a regimen would have very high (&gt;90 percent) rates of SVR against all HCV genotypes (or at least against both genotype 1a and 1b HCV) regardless of liver fibrosis stage, prior interferon nonresponse, race, or IL28B genotype. There is no regimen currently in clinical development that meets all of these goals. However, rapid progress is being made towards all-oral, interferon-free regimens with excellent SVR rates against genotype 1 HCV, even in prior null responders to peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Because DAA monotherapy is typically associated with the rapid emergence of viral resistance, the great majority of phase II and III HCV clinical trials have employed combinations of antiviral therapies. Initial trials of next-generation DAAs have been in combination with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , with more recent trials studying interferon-free and even",
"    <span class=\"nowrap\">",
"     interferon/ribavirin-free",
"    </span>",
"    regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299897\">",
"    <span class=\"h2\">",
"     Triple therapy: DAA + peginterferon + ribavirin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299912\">",
"    <span class=\"h3\">",
"     Faldaprevir (BI 2010335)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Faldaprevir is a once-daily",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitor in phase III clinical development. Preliminary data from an open-label phase II trial with 159 treatment-na&iuml;ve patients with HCV genotype 1 have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/14\">",
"     14",
"    </a>",
"    ]. The patients were randomly assigned to receive faldaprevir 120 mg daily for 12 or 24 weeks after a three-day lead-in of peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Peginterferon and ribavirin were continued for a total of 24 to 48 weeks, depending upon the patient's viral load. If the patient had a viral load &lt;25 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    at week 4 as well as undetectable virus at weeks 8 to 18 (extended rapid virologic response), the peginterferon and ribavirin were stopped at 24 weeks. For all other patients, peginterferon and ribavirin were continued for 48 weeks. Sustained virologic response rates at 24 weeks after completion of therapy (SVR24) were similar between the 12- and 24-week faldaprevir groups (63 and 72 percent, respectively), and side effects were similar to those seen with peginterferon and ribavirin therapy.",
"   </p>",
"   <p>",
"    Preliminary data have also been reported from a phase II trial of faldaprevir. In that trial, 429 treatment-na&iuml;ve patients with HCV genotype 1 were assigned to receive one of three faldaprevir regimens or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/15\">",
"     15",
"    </a>",
"    ]. In addition, patients were treated with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 24 or 48 weeks (patients were treated for 24 weeks if they achieved a rapid virologic response [negative HCV RNA after four weeks of treatment] or for 48 weeks if they did not). The preliminary report focused on patients assigned to receive 24 weeks of faldaprevir without a lead-in period and found that these patients had SVR24 rates that were significantly higher than the SVR24 rates in patients who received placebo (83 versus 56 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H299953\">",
"    <span class=\"h3\">",
"     Danoprevir (ITMN-191/RG7227)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Danoprevir is another",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitor. More recent trials of danoprevir have employed boosting with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    , which improves danoprevir's pharmacokinetics and allows the use of lower danoprevir doses.",
"   </p>",
"   <p>",
"    In the DAUPHINE phase IIb trial, 421 treatment-na&iuml;ve, patients without cirrhosis and with genotype 1 or 4 HCV were assigned to receive boosted danoprevir at one of three doses in combination with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 24 weeks, to receive danoprevir with peginterferon and ribavirin using response-guided therapy for 12 or 24 weeks, or to receive peginterferon and ribavirin alone with rollover to danoprevir plus peginterferon and ribavirin offered to those without a complete early virologic response at week 12 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/16\">",
"     16",
"    </a>",
"    ]. Fifty-eight, 32, and 8 percent had genotype 1a, 1b, or 4 infection, respectively, and 72 percent had the unfavorable IL28B non-CC genotype. In a preliminary report, by intention-to-treat analysis, SVR24 rates among patients receiving 24 weeks of triple therapy ranged from 66 to 89 percent and were 69 percent overall in the response-guided therapy arm. Patients in the arm receiving the highest dose of danoprevir (200 mg) for a fixed 24 week course had an SVR24 rate of 89 percent. SVR rates from the control arm were not available at the time of this report. Genotype 1a and 1b patients receiving danoprevir 200 mg for a fixed 24 week course had SVR rates of 84 and 97 percent, respectively, while IL28B CC and non-CC genotype patients in this arm had SVR24 rates of 96 and 86 percent, respectively. Three to 8 percent of patients withdrew due to adverse events attributed to boosted danoprevir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58395763\">",
"    <span class=\"h3\">",
"     Simeprevir (TMC435)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simeprevir is a once-daily",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitor that is in phase III development. In a phase IIb trial (PILLAR), 386 treatment-na&iuml;ve patients with genotype 1 HCV were assigned to receive 12 or 24 weeks of simeprevir at 75 or 150 mg daily, or placebo, in addition to",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    for 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/17\">",
"     17",
"    </a>",
"    ]. Those in simeprevir-containing arms stopped therapy at 24 weeks if they had HCV RNA below the lower limit of quantification at week 4 and undetectable HCV RNA at weeks 12, 16, and 20. All others continued",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    for a total of 48 weeks. Seventy-five to 86 percent of patients in the simeprevir-containing arms achieved an SVR24, compared with 65 percent of those receiving",
"    <span class=\"nowrap\">",
"     placebo/peginterferon/ribavirin.",
"    </span>",
"    The highest SVR rate (86 percent) was observed in patients receiving 150 mg of simeprevir for 24 weeks. Of note, SVR24 rates were similar for genotype 1a and 1b patients (82 and 84 percent, respectively) in the simeprevir 150 mg arms, while they were 66 and 89 percent in those receiving 75 mg of simeprevir. Seventy-nine to 86 percent of patients receiving simeprevir were eligible to stop treatment at 24 weeks, of whom 85 to 96 percent achieved an SVR24. In the simeprevir arms, 3.6 percent discontinued treatment early due to adverse events, compared with 5.2 percent of those in the placebo arm.",
"   </p>",
"   <p>",
"    In a second phase IIb trial (ASPIRE), simeprevir was combined with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for the treatment of patients with HCV genotype 1 who had failed prior treatment with peginterferon and ribavirin. All patients received peginterferon and ribavirin for 48 weeks. In addition, patients received simeprevir at 100 or 150 mg daily for 12, 24, or 48 weeks or placebo. Among patients treated with simeprevir 150 mg daily, SVR24 rates were 85 percent for prior relapsers, 75 for prior partial responders, 51 percent for prior null responders, and 31 to 82 percent for patients with cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/18\">",
"     18",
"    </a>",
"    ]. Corresponding rates for patients treated with peginterferon, ribavirin, and placebo were 37, 9, 19, and 0 percent, respectively. Among patients with genotype 1a infection, SVR24 rates in prior relapsers, prior partial responders, and prior null responders were 85, 56, and 42 percent, respectively, compared with SVR24 rates of 84, 88, and 58 percent in those with genotype 1b infection. Nine percent of patients in the simeprevir 150 mg arms discontinued therapy due to adverse events.",
"   </p>",
"   <p>",
"    Simeprevir has also been studied in patients with HCV genotypes other than genotype 1. In a phase IIa open-label trial, 37 patients with HCV genotypes 2 through 6 received seven days of simeprevir (200 mg once daily). The changes in mean HCV RNA level from baseline were highest in patients with genotypes 6 and 4 (-4.4 and -3.5 log",
"    <sub>",
"     10",
"    </sub>",
"    , respectively), followed by genotypes 2 and 5 (-2.7 and -2.2 log",
"    <sub>",
"     10",
"    </sub>",
"    , respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/19\">",
"     19",
"    </a>",
"    ]. No change in mean HCV RNA level was seen in patients with genotype 3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58395770\">",
"    <span class=\"h3\">",
"     Asunaprevir (BMS-650032)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asunaprevir is a",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protease inhibitor given once or twice daily. Preliminary results from a phase II trial combining asunaprevir with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    suggest high SVR rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/20\">",
"     20",
"    </a>",
"    ]. In stage 1 of this trial (phase IIa), 47 treatment-na&iuml;ve patients with HCV genotype 1 were assigned to receive one of three dosing regimens of asunaprevir or placebo in addition to",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    for a total of 48 weeks. SVR24 rates among patients in the asunaprevir arms were 83 to 92 percent, compared with 46 percent for patients who received placebo. In stage 2 (phase IIb) of this trial, 238 treatment-na&iuml;ve patients with genotype 1 or 4 infection have been assigned to receive",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    for 48 weeks or three different response-guided regimens of asunaprevir and",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    for 24 to 48 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300001\">",
"    <span class=\"h3\">",
"     Daclatasvir (BMS-790052)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daclatasvir is a once-daily NS5A inhibitor currently in phase III trials. Preliminary results have been reported for a phase IIb trial of daclatasvir (COMMAND-1) in treatment-na&iuml;ve patients with genotype 1 or 4 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/21\">",
"     21",
"    </a>",
"    ]. In this study, 395 patients (365 with genotype 1) were assigned to receive 20 or 60 mg daily of daclatasvir or placebo in combination with",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     .",
"    </span>",
"    At week 12, patients treated with daclatasvir who had HCV RNA levels below the lower limit of quantification (25 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    at week 4 and undetectable HCV RNA at week 10 were reassigned to daclatasvir or placebo with",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    through 24 weeks of therapy. Those without a response continued",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    to week 48. SVR rates at 12 weeks after completing therapy (SVR12) were 65, 64, and 36 percent among patients with genotype 1 receiving daclatasvir 20 mg daily, 60 mg daily, or placebo, respectively. Seventy-one and 72 percent of patients receiving daclatasvir achieved a protocol-defined response, of whom 75 to 87 percent went on to achieve an SVR12. SVR12 rates were only 59, 58, and 38 percent among genotype 1a patients, while they were 78, 87, and 31 percent among genotype 1b patients. Treatment discontinuations due to adverse events were 4 percent in the daclatasvir arms and 9 percent in the placebo arm.",
"   </p>",
"   <p>",
"    Preliminary results have also been reported for a phase IIb trial of daclatasvir (COMMAND-2) in 420 patients with HCV genotype 1 who were prior null or partial responders to treatment with peginterferon-based therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/22\">",
"     22",
"    </a>",
"    ]. Prior partial responders were assigned to receive either",
"    <span class=\"nowrap\">",
"     placebo/peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    for 48 weeks or response-guided therapy regimens incorporating daclatasvir 20 or 60 mg daily with",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    for 24 weeks, while prior null responders were assigned to the two daclatasvir arms. Those receiving daclatasvir who achieved an HCV RNA below the lower limit of quantitation at week 4 and undetectable HCV RNA at week 12 were re-assigned to either stop therapy at week 24 or to continue with an additional 24 weeks of",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin.",
"    </span>",
"    Those without a response continued with another 24 weeks of",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin.",
"    </span>",
"    At 12 weeks, a complete early virologic response (cEVR; undetectable HCV RNA at week 12) was more common in patients treated with daclatasvir 20 or 60 mg daily compared with those treated with placebo. Among prior partial responders, the cEVR rates were 44, 57, and 0 percent, respectively, with cEVR rates among genotype 1a partial responders receiving daclatasvir being 34 and 41 percent, respectively, compared with 70 and 77 percent, respectively, among genotype 1b partial responders. Among prior null responders, the corresponding cEVR rates were 30 and 34 percent for the daclatasvir 20 and 60 mg groups (prior null responders were not assigned to receive placebo), with cEVR rates among genotype 1a null responders being 19 and 28 percent compared with 51 and 46 percent among genotype 1b null responders.",
"   </p>",
"   <p>",
"    In light of the significantly lower rates of SVR with",
"    <span class=\"nowrap\">",
"     daclatasvir/peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    among patients with genotype 1a infection observed in the COMMAND-1 and COMMAND-2 trials, the COMMAND-3 phase III trial comparing 60 mg daily of",
"    <span class=\"nowrap\">",
"     daclatasvir/peginterferon/ribavirin",
"    </span>",
"    with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?20/6/20585?source=see_link\">",
"      telaprevir",
"     </a>",
"     /peginterferon/ribavirin",
"    </span>",
"    in patients with chronic genotype 1 infection has been amended to limit enrollment to patients with genotype 1b infection only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300042\">",
"    <span class=\"h3\">",
"     Sofosbuvir (GS-7977)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sofosbuvir is a once-daily uridine NS5B nucleotide analog inhibitor (NI) in phase III clinical trials. A phase II trial (PROTON) of sofosbuvir included 121 treatment-na&iuml;ve patients without cirrhosis and with HCV genotype 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients were assigned to receive sofosbuvir (200 or 400 mg daily) or placebo plus peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 12 weeks. Patients were then treated with peginterferon and ribavirin for an additional 12 weeks if an extended rapid virologic response was achieved, or else for an additional 36 weeks. Preliminary results showed SVR12 rates of 88 percent for the 200 mg sofosbuvir group, 91 percent for the 400 mg group, and approximately 40 percent for the placebo group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/24\">",
"     24",
"    </a>",
"    ]. No virologic breakthrough was observed during therapy with either sofosbuvir dose, and no sofosbuvir-related adverse events forcing treatment discontinuation were observed. Of note, all 13 patients with the unfavorable IL28B TT genotype who received sofosbuvir attained an SVR12.",
"   </p>",
"   <p>",
"    In another phase II trial (ATOMIC), 332 treatment-na&iuml;ve patients without cirrhosis and with HCV genotype 1, 4, or 6 (95 percent genotype 1) were treated with sofosbuvir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 12 weeks (n = 52) or 24 weeks (n = 125), or were treated with all three drugs for 12 weeks followed by sofosbuvir, with or without ribavirin, for an additional 12 weeks (n = 156) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/25\">",
"     25",
"    </a>",
"    ]. Seventy-three percent of patients were genotype 1a. On intention-to-treat analysis, 87 to 89 percent of patients with genotype 1 achieved an SVR24. Nine of eleven patients (82 percent) with genotype 4 achieved an SVR24 (the other two patients were lost to follow-up at the end of treatment), and all five patients with genotype 6 achieved an SVR24. Of the seven patients who completed treatment and subsequently relapsed, six carried a non-CC IL28B allele. However, the overall SVR24 rate was similar for those with CC and non-CC alleles. Adverse events lead to discontinuation of treatment in 30 patients (9 percent). The most common reasons for treatment discontinuation, anemia and neutropenia, were thought to be related to peginterferon and ribavirin.",
"   </p>",
"   <p>",
"    The phase II ELECTRON trail studied sofosbuvir in 60 patients with HCV genotype 2 (18 patients) or 3 (42 patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/26\">",
"     26",
"    </a>",
"    ]. The patients with HCV genotype 2 or 3 were assigned to one of six treatment arms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Group 1 (10 patients): 12 weeks of sofosbuvir and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"     </li>",
"     <li>",
"      Group 2 (9 patients): 12 weeks of sofosbuvir and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and 4 weeks of peginterferon",
"     </li>",
"     <li>",
"      Group 3 (10 patients): 12 weeks of sofosbuvir and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and 8 weeks of peginterferon",
"     </li>",
"     <li>",
"      Group 4 (11 patients): 12 weeks of sofosbuvir and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      and 12 weeks of peginterferon",
"     </li>",
"     <li>",
"      Group 5 (10 patients): 12 weeks of sofosbuvir monotherapy",
"     </li>",
"     <li>",
"      Group 6 (10 patients): 8 weeks of sofosbuvir,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      , and peginterferon",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of the patients who received 12 weeks of sofosbuvir and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    (groups 1 to 4) achieved an SVR at 24 weeks, regardless of treatment with peginterferon. All of the patients who received 8 weeks of triple therapy (group 6) achieved an SVR after 12 weeks, as did all 9 patients for whom data were available at 24 weeks. Six of 10 patients who received sofosbuvir monotherapy (group 5) achieved an SVR at 24 weeks.",
"   </p>",
"   <p>",
"    No patients discontinued treatment due to adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300107\">",
"    <span class=\"h3\">",
"     Mericitabine (RG7128)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mericitabine is another NS5B NI currently in phase II clinical trials. In the PROPEL phase IIb study, 408 genotype 1 or 4 treatment-na&iuml;ve patients were assigned to 4 fixed mericitabine plus",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    arms for 24 to 48 weeks compared with a control arm of",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    for 48 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/27\">",
"     27",
"    </a>",
"    ]. Mericitabine was given for 8 to 12 weeks. Although patients in the mericitabine arms had relatively high rates of HCV RNA undetectability at week 12 (68 to 87 percent) compared with 49 percent in the control arm, the SVR24 rates were substantially lower in the mericitabine group (33 to 51 percent in the mericitabine arms, compared with 50 percent for the control arm). Much of the difference was accounted for by high rates of relapse (29 to 52 percent in mericitabine arms), in particular, among IL28B non-CC patients (36 to 68 percent relapsed). Not surprisingly, non-CC IL28B patients had substantially lower SVR24 rates (19 to 41 percent in mericitabine arms, compared with 38 percent in the control arm) than IL28B CC patients (60 to 91 percent compared with 58 percent). Similarly, patients with cirrhosis also had lower SVR24 rates (22 to 41 percent compared with 47 percent in the control arm).",
"   </p>",
"   <p>",
"    In the JUMP-C phase IIb trial, 166 patients with genotype 1 or 4 infection were assigned to receive either 48 weeks of",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    or mericitabine 1000 mg twice daily with peginterferon",
"    <span class=\"nowrap\">",
"     alfa-2a/ribavirin",
"    </span>",
"    for 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/28\">",
"     28",
"    </a>",
"    ]. Those in the mericitabine arm attaining undetectable HCV RNA from week 4 to 22 (eRVR) were eligible to stop therapy at week 24; otherwise they continued",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    through week 48. About 26 percent of the patients had cirrhosis. Although 91 percent of patients receiving mericitabine had undetectable HCV RNA at week 24, only 57 percent of patients in the mericitabine arm achieved SVR24 compared with 37 percent receiving",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    alone. As in the PROPEL trial, patients with cirrhosis had significantly lower rates of SVR (38 and 22 percent in the mericitabine and control arms, respectively) compared with patients without cirrhosis (63 and 42 percent, respectively). Unfavorable non-CC IL28B genotypes were associated with lower rates of SVR (44 and 16 percent in the mericitabine and control arms, respectively) compared with CC genotype patients (78 and 56 percent, respectively). Seven and 15 percent of patients in the mericitabine and control arms, respectively, discontinued therapy due to adverse events. Logistic regression analysis did not identify genotype 1a versus 1b status as being independently associated with treatment response.",
"   </p>",
"   <p>",
"    These high rates of relapse among patients treated with mericitabine and",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    suggest that mericitabine may further benefit from combination with additional DAAs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300124\">",
"    <span class=\"h2\">",
"     Quadruple therapy: Two DAAS + peginterferon + ribavirin",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300139\">",
"    <span class=\"h3\">",
"     Daclatasvir and asunaprevir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Daclatasvir and asunaprevir have been combined in regimens that include peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and in interferon-free regimens. An open label, phase IIa study examined the combination of daclatasvir and asunaprevir in genotype 1 prior null responder patients without cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/29\">",
"     29",
"    </a>",
"    ]. In one of the study arms, 10 patients received quadruple therapy with daclatasvir, asunaprevir, peginterferon alfa-2a, and ribavirin, all for 24 weeks. Nine of the 10 patients had unfavorable non-CC IL28B genotypes, and nine were genotype 1a. All 10 patients receiving quadruple therapy achieved an SVR12, and nine achieved an SVR24. The single patient who did not achieve an SVR had an HCV RNA level below the limit of quantification, which then became undetectable on retesting 35 days later. Similarly, one patient had detectable virus at week 48 but had undetectable virus on retesting 13 days later. Two patients from this group had transient elevations of the ALT to greater than three times the upper limit of normal. There were no discontinuations or interruptions of study treatment.",
"   </p>",
"   <p>",
"    This study was expanded to examine additional genotype 1 prior null responders without cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/30\">",
"     30",
"    </a>",
"    ]. Two of the arms in this trial tested fixed regimens of daclatasvir, asunaprevir (at 200 mg once or twice daily), peginterferon, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 24 weeks in 41 patients. Ninety-one and 85 percent of these patients were genotype 1a; 94 and 100 percent had unfavorable CT or TT IL28B genotypes. Ninety-five and 90 percent of patients taking asunaprevir once or twice daily, respectively, attained an SVR4 in an interim analysis. There were no on-treatment virologic breakthroughs, and there was one relapse in the asunaprevir twice daily group. There were no discontinuations due to adverse events in either group.",
"   </p>",
"   <p>",
"    Although these are small studies, it is apparent that the potential inconvenience and side effects of interferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    -containing quadruple therapy may be offset by high SVR rates in patients without cirrhosis with several negative prognostic predictors of treatment response (prior null responders with genotype 1a infection and unfavorable IL28B genotypes). It remains to be seen whether similarly high rates of SVR with low rates of adverse events can be achieved with this regimen in prior null responder genotype 1a patients with cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300147\">",
"    <span class=\"h3\">",
"     Danoprevir and mericitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary results of the MATTERHORN study examining a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted danoprevir, mericitabine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    with or without peginterferon in genotype 1 prior nonresponders without cirrhosis have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/31\">",
"     31",
"    </a>",
"    ]. In this study, 50 prior partial responders received 24 weeks of boosted danoprevir, mericitabine, peginterferon, and ribavirin, while 151 prior null responders received either 24 weeks of quadruple therapy or 24 weeks of quadruple therapy followed by an additional 24 weeks of",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin.",
"    </span>",
"    An additional 49 partial responders received 24 weeks of triple therapy with boosted danoprevir, peginterferon, and ribavirin. The results in treatment arms without peginterferon are discussed below. (See",
"    <a class=\"local\" href=\"#H300239\">",
"     'Danoprevir and mericitabine with and without ribavirin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Forty-eight and 61 percent of the quad partial responders and the quad null responders, respectively, had genotype 1a infection, while 100 and 97 percent had non-CC IL28B genotypes. Eighty-six percent of prior partial responders achieved an SVR12 with quadruple therapy, while 84 percent of prior null responders achieved an SVR12. In comparison, only 67 percent of prior partial responders receiving boosted danoprevir with",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    achieved an SVR12, largely due to a high rate of relapse in this arm. Subgroup analysis revealed that 96 and 100 percent of genotype 1b partial and null responders, respectively, achieved an SVR12 with quadruple therapy, compared with 75 and 73 percent of genotype 1a partial and null responders.",
"   </p>",
"   <p>",
"    A phase II trial of boosted danoprevir, mericitabine, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 24 weeks in prior null responder or treatment-na&iuml;ve patients with compensated cirrhosis and genotype 1 or 4 HCV is currently under way.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300164\">",
"    <span class=\"h2\">",
"     Interferon-free combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The identification of potent DAAs targeting different HCV proteins has led to the development of clinical trials testing interferon-free, all-oral HCV treatment regimens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300198\">",
"    <span class=\"h3\">",
"     Sofosbuvir with and without ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase II trial of sofosbuvir with and without interferon has been conducted in patients with genotype 1-3 infection. In the ELECTRON trial, 25 treatment-na&iuml;ve and 10 prior null responder genotype 1 patients were treated with sofosbuvir and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/26\">",
"     26",
"    </a>",
"    ]. Eighty-eight and 90 percent, respectively, had genotype 1a infection; 56 and 80 percent, respectively, had non-CC IL28B genotypes. Of the 25 treatment-na&iuml;ve patients, 21 (84 percent) achieved an SVR at 24 weeks and 4 relapsed during follow-up. Only 1 of 10 patients who had failed prior treatment achieved an SVR.",
"   </p>",
"   <p>",
"    This observation suggests that prior null response is a predictor of treatment response even with interferon-free DAA regimens. Because of suboptimal SVR rates to sofosbuvir and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in genotype 1 patients, the combination of sofosbuvir and the NS5A inhibitor GS-5885, with and without ribavirin, is currently being studied in a phase III trial in treatment-na&iuml;ve patients with genotype 1 infection.",
"   </p>",
"   <p>",
"    Because sofosbuvir also has activity against genotypes 2 and 3 HCV, the ELECTRON trial studied sofosbuvir without peginterferon in patients without cirrhosis who had genotype 2 or 3 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/26\">",
"     26",
"    </a>",
"    ]. Ten patients received 12 weeks of sofosbuvir plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and 10 received 12 weeks of sofosbuvir monotherapy. All of the patients who received 12 weeks of sofosbuvir and ribavirin achieved an SVR at 24 weeks. Six of 10 patients who received sofosbuvir monotherapy achieved an SVR at 24 weeks. A phase III trial of sofosbuvir and ribavirin for 12 weeks in treatment-na&iuml;ve and treatment-experienced patients with genotype 2 or 3 infection is currently under way.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300206\">",
"    <span class=\"h3\">",
"     Sofosbuvir and daclatasvir with and without ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sofosbuvir has also been combined with the NS5A inhibitor daclatasvir, with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    in treatment na&iuml;ve patients without cirrhosis with genotype 1-3 infection. There were three different dosing regimens, two of which contained sofosbuvir and daclatasvir without ribavirin, all for 24 weeks. Preliminary results found an SVR4 of 100 percent in all genotype 1 patients, approximately 72 percent of whom had genotype 1a infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/32\">",
"     32",
"    </a>",
"    ]. Forty of 44 patients (91 percent) in the genotype",
"    <span class=\"nowrap\">",
"     2/3",
"    </span>",
"    arms achieved an SVR4. Two patients discontinued due to adverse events considered unrelated to study therapy and were lost to follow-up; their HCV RNA levels were undetectable at their last visits (weeks 12 and 24). Despite these impressive results, further clinical development of this combination is uncertain as the company that developed sofosbuvir is now pursuing the combination of sofosbuvir with its own NS5A inhibitor GS-5885 rather than with daclatasvir.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300214\">",
"    <span class=\"h3\">",
"     ABT-450, ABT-267, ABT-333, and ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another promising interferon-free regimen is the combination of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted protease inhibitor",
"    <span class=\"nowrap\">",
"     ABT-450/r,",
"    </span>",
"    the NS5A inhibitor ABT-267, the NS5B NNI ABT-333, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . Preliminary results of a phase II open-label trial in treatment-na&iuml;ve and prior null responder patients without cirrhosis and with genotype 1 infection have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/33\">",
"     33",
"    </a>",
"    ]. Patients were treated with",
"    <span class=\"nowrap\">",
"     ABT-450/r",
"    </span>",
"    with combinations of ABT-267, ABT-333, and ribavirin for 8, 12, and 24 weeks; preliminary results were presented only for the 8- and 12-week treatment arms. Among treatment na&iuml;ve patients, about 70 percent had non-CC IL28B genotypes, and about two-thirds had genotype 1a infection; the corresponding proportions among the null responder arms were 97 and 60 percent. SVR12 rates in the treatment-na&iuml;ve arms ranged from 85 to 98 percent, with the highest SVR rate of 98 percent observed in patients receiving 12 weeks of quadruple therapy. Eighty-eight percent of treatment-na&iuml;ve patients receiving only 8 weeks of quadruple therapy were also able to attain SVR12. Ninety-three percent of prior null responders who took quadruple therapy for 12 weeks attained an SVR12. Genotype 1a infection had a relatively small effect on SVR; among treatment-na&iuml;ve patients taking quadruple therapy for 12 weeks, SVR12 rates were 98 and 100 percent for genotype 1a and 1b patients, respectively. The corresponding SVR12 rates for prior null responders who took the same 12-week regimen were 89 and 100 percent. There were no study drug-related serious adverse events; 2 of the 448 patients in the trial did stop treatment due to adverse events attributed to a study drug. Both of these patients went on to achieve an SVR. Among treatment na&iuml;ve patients and null responders, 6.7 and 12 percent, respectively, developed primarily unconjugated hyperbilirubinemia (greater than twice the upper limit of normal). The combination of these three DAAs, with and without ribavirin, is being studied in phase III trials. It will be important to determine whether these high SVR rates will also be observed in patients with cirrhosis.",
"   </p>",
"   <p>",
"    Another trial looked at the combination of",
"    <span class=\"nowrap\">",
"     ABD-450/r,",
"    </span>",
"    ABT-333, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    . The phase II open-label trial included 50 patients with HCV genotype 1 who were either treatment-na&iuml;ve (33 patients) or had failed prior therapy (17 patients; 10 were partial responders, and 7 were null responders) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/34\">",
"     34",
"    </a>",
"    ]. All patients were treated for 12 weeks. Patients who were treatment-na&iuml;ve received",
"    <span class=\"nowrap\">",
"     ABT-450/r",
"    </span>",
"    at one of two doses (250 mg ABT-450 and 100 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    daily [group 1] or 150 mg ABT-450 and 100 mg ritonavir daily [group 2]) plus ABT-333 (400 mg twice daily) and weight-based ribavirin. Patients who had failed prior treatment received the lower dose of",
"    <span class=\"nowrap\">",
"     ABT-450/r",
"    </span>",
"    along with ABT-333 (400 mg twice daily) and weight-based ribavirin (group 3). An SVR 12 weeks after the end of treatment was achieved in 18 of 19 patients (95 percent) in group 1, 13 of 14 patients (93 percent) in group 2, and in 8 of 17 patients (47 percent) in group 3.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300231\">",
"    <span class=\"h3\">",
"     Daclatasvir and asunaprevir",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phase IIa studies of daclatasvir, asunaprevir, peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    quadruple therapy discussed above also tested daclatasvir and asunaprevir without peginterferon or ribavirin. In the first phase IIa trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/29\">",
"     29",
"    </a>",
"    ], 11 patients received daclatasvir and asunaprevir without either peginterferon or ribavirin. Four of the 11 patients in this arm achieved an SVR12 and an SVR24. At 48 weeks, one patient had detectable virus but had undetectable virus on retesting 43 days later. Six of the patients experienced on-treatment viral breakthrough with resistance to both drugs demonstrated. Four had complete HCV RNA suppression with the addition of peginterferon and ribavirin, but two relapsed once treatment was stopped. The other two had undetectable HCV at their most recent follow-up (14 and 42 weeks, respectively). Only two of the 11 patients in this arm had genotype 1b infection; both achieved an SVR. There were no serious adverse events or treatment discontinuations due to adverse events.",
"   </p>",
"   <p>",
"    In a second trial, the interferon-free combination of daclatasvir and asunaprevir was tested in 10 prior null responder Japanese patients without cirrhosis and with genotype 1b chronic HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/35\">",
"     35",
"    </a>",
"    ]. The open-label study included 10 patients who were to receive both drugs for 24 weeks. Eight of the 10 patients had an IL28B CT genotype, while two had the favorable CC genotype. Nine patients completed 24 weeks of therapy, whereas one patient stopped therapy after two weeks due to grade 4 hyperbilirubinemia. All nine patients achieved an SVR12 and an SVR24. In addition, while the patient who only received two weeks of therapy had low-levels of HCV RNA at discontinuation of therapy, HCV RNA was undetectable at follow-up visits between one and 24 weeks after discontinuation. The most common adverse events were diarrhea, headache, and mildly elevated transaminases. The higher SVR rates in this trial could potentially be explained by all of the patients having genotype 1b infection.",
"   </p>",
"   <p>",
"    A third trial tested daclatasvir and asunaprevir in patients with HCV genotype 1b who were prior null responders or who were unable to take peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/36\">",
"     36",
"    </a>",
"    ]. An SVR24 was achieved by 33 of 43 patients (77 percent). Among those with a prior null response, 19 of 21 (91 percent) achieved an SVR, whereas among those who were unable to take peginterferon and ribavirin, 14 of 22 (64 percent) achieved an SVR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300239\">",
"    <span class=\"h3\">",
"     Danoprevir and mericitabine with and without ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the INFORM-SVR phase IIb study, 169 treatment-na&iuml;ve patients without cirrhosis and with chronic genotype 1 HCV were assigned to receive a combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted danoprevir, mericitabine, and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/37\">",
"     37",
"    </a>",
"    ]. In both arms, patients achieving unquantifiable HCV RNA (&lt;43 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    between weeks 2 and 8 and an undetectable HCV RNA (&lt;15 int.",
"    <span class=\"nowrap\">",
"     unit/mL)",
"    </span>",
"    at week 10 were reassigned to either discontinue treatment at week 12 or continue the assigned regimen until week 24. Those who did not achieve the protocol-defined virologic response completed 24 weeks of the assigned regimen. About two-thirds of the patients were genotype 1a, and about 70 percent had non-CC IL28B genotypes. The",
"    <span class=\"nowrap\">",
"     danoprevir/mericitabine",
"    </span>",
"    without ribavirin arm was stopped prematurely due to high rates of virologic breakthrough (18 of 86 patients in this arm) and relapse, as was the 12 week option with ribavirin. Results have been presented only for the 64 patients who received boosted danoprevir, mericitabine, and ribavirin for 24 weeks. The SVR12 rate in this group was 41 percent, and was 26 and 71 percent for the genotype 1a and 1b patients, respectively. Only 31 percent of the genotype 1a patients who achieved the protocol-defined virologic response went on to attain an SVR12, as opposed to 80 percent of the genotype 1b patients. One patient in this 24-week triple therapy group discontinued therapy due to an adverse event (oropharyngeal discomfort).",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted danoprevir, mericitabine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    for 24 weeks was also tested in the MATTERHORN phase IIa study in genotype 1 prior partial responders and null responders without cirrhosis. Although both arms enrolled both genotype 1a and 1b patients, interim results were presented only for genotype 1b patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/31\">",
"     31",
"    </a>",
"    ]. Genotype 1a patients in these arms were offered intensified therapy with",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    due to \"unacceptable relapse rates\", and interim results were not presented for these patients. Of the 23 genotype 1b prior partial responders and the 32 genotype 1b prior null responders, 96 and 94 percent, respectively, had unfavorable IL-28B genotypes. End-of-treatment HCV undetectability and SV4 and SVR12 rates in the prior partial responders with genotype 1b infection were 87, 44, and 39 percent, respectively; the corresponding figures for prior null responders were 88, 68, and 55 percent, respectively. These figures indicate a substantial rate of relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H300247\">",
"    <span class=\"h3\">",
"     Faldaprevir and BI 207127 with and without ribavirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of faldaprevir and the NS5B NNI BI 207127 has been tested in treatment-na&iuml;ve patients with genotype 1 chronic HCV. In the SOUND-C2, open-label phase IIb trial, 362 patients were assigned to five different fixed dosing regimens of faldaprevir 120 mg daily and BI 207127 given twice or three times daily, ranging from 16 to 40 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/38\">",
"     38",
"    </a>",
"    ]. Four arms included",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , while one tested faldaprevir and BI 207127 without ribavirin. Approximately 40 percent of the patients had genotype 1a infection, and approximately 75 percent of patients had non-CC IL28B genotypes; 7 to 12 percent had cirrhosis. The SVR12 rate with ribavirin ranged from 52 to 69 percent and was 39 percent without ribavirin. Patients with genotype 1a infection had SVR rates ranging from 38 to 47 percent in the arms with ribavirin and a rate of only 11 percent in the ribavirin-free arm, with high rates of virologic breakthrough among genotype 1a patients (21 to 47 percent in ribavirin-containing arms, 56 percent in the ribavirin-free arm). By contrast, genotype 1b patients had SVR12 rates ranging from 56 to 85 percent in the arms with ribavirin, with the highest rate in patients receiving twice daily BI 207127 for 28 weeks, and 57 percent without ribavirin. Patients with the CC IL28B genotype had higher rates of SVR12 (63 to 84 percent) than non-CC patients (48 to 64 percent) in the ribavirin-containing arms. Five to 11 percent of patients receiving 28 weeks or less of therapy discontinued treatment due to adverse events, while 25 percent of the patients receiving 40 weeks of therapy stopped due to adverse events. There were high rates of unconjugated hyperbilirubinemia (13 to 46 percent) attributed to UGT 1A1 inhibition by faldaprevir.",
"   </p>",
"   <p>",
"    Subgroup analysis of the 33 patients with compensated cirrhosis in the SOUND-C2 trial were also reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/39\">",
"     39",
"    </a>",
"    ]. Univariate regression analysis did not identify an association between the presence of cirrhosis and attaining an SVR12. However, there were higher rates of treatment discontinuation due to adverse events among patients with cirrhosis compared with those without cirrhosis (29 versus 12 percent in those receiving thrice-daily BI 207127) and higher plasma trough concentrations of both drugs among patients with cirrhosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TREATMENTS TARGETING HOST-ENCODED FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like all viruses, hepatitis C virus (HCV) depends upon host factors for all phases of its life cycle: entry, replication, and virion",
"    <span class=\"nowrap\">",
"     assembly/secretion.",
"    </span>",
"    Another approach to HCV therapy is to target the host factors that the virus uses for its own life cycle. A theoretical advantage of this strategy is that the genetic barrier for viral resistance may be higher than for DAA therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cyclophilin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cyclosporin A, an immunosuppressant, inhibits HCV replication in cell culture replicon models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/40\">",
"     40",
"    </a>",
"    ]. The antiviral effect of cyclosporin A is due to its inhibition of the cellular protein cyclophilin A, which in turn appears to modulate NS5A function by mechanisms that are not yet fully defined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A synthetic nonimmunosuppressive form of cyclosporin, alisporivir or Debio-025, exhibits potent activity against both HCV and HIV in cell culture systems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/42\">",
"     42",
"    </a>",
"    ]. However, cases of pancreatitis (one fatal) in patients receiving alisporivir, peginterferon, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    as part of a phase III trial have led to a partial clinical hold by the FDA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from prior trials suggest improved SVR rates when alisporivir is combined with standard treatment. A multicenter randomized phase IIb trial compared alisporivir in combination with",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    with",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    alone in 288 treatment-naive patients with HCV genotype 1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one arm, patients received standard-of-care",
"      <span class=\"nowrap\">",
"       peginterferon/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      for 48 weeks. In the alisporivir24 and alisporivir48 arms, patients received alisporivir plus",
"      <span class=\"nowrap\">",
"       peginterferon/ribavirin",
"      </span>",
"      for 24 and 48 weeks, respectively. Finally, in the alisporivir-RGT arm, patients received triple therapy for either 24 weeks if they achieved a four-week rapid virologic response or for 48 weeks if they did not. Alisporivir was given at 600 mg twice daily for the first week followed by 600 mg daily.",
"     </li>",
"     <li>",
"      Over 95 percent of the patients were Caucasian, and 33 percent of the",
"      <span class=\"nowrap\">",
"       peginterferon/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      arm patients had the favorable IL28B rs12979860 CC allele compared with only 19 to 24 percent of the patients in the alisporivir arms.",
"     </li>",
"     <li>",
"      SVR rates were 55 percent in the peginterferon-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      arm, 76 percent in the alisporivir48 arm, 69 percent in the alisporivir-RGT arm, and 53 percent in the alisporivir24 arm. Of note, while only 17 percent of patients with the unfavorable IL28B rs12979860 TT allele achieved an SVR on",
"      <span class=\"nowrap\">",
"       peginterferon/ribavirin,",
"      </span>",
"      62 and 73 percent of such patients in the alisporivir48 and alisporivir-RGT arms achieved an SVR, respectively.",
"     </li>",
"     <li>",
"      In the alisporivir treatment arms, 2.8 to 6.9 percent of patients discontinued therapy due to adverse events compared with 4.1 percent of patients receiving standard-of-care. In the alisporivir48 arm, 6.8 percent of patients had a total bilirubin greater than five times the upper limit of normal; this was associated with the alisporivir loading dose and in all cases resolved to less than five times the upper limit of normal by week four. Hyperbilirubinemia was not associated with increases in alanine aminotransferase or gamma glutamyl transferase.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preliminary results are available from a dose-ranging phase IIa trial of alisporivir in patients with genotype 1 HCV who were prior null responders to",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/45\">",
"     45",
"    </a>",
"    ]. The study included 50 patients who had experienced a &lt;2 log",
"    <sub>",
"     10",
"    </sub>",
"    reduction in viral load at 12 weeks of",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    therapy who were randomly assigned to one of five four-week dosing regimens followed by an additional 44 weeks of peginterferon and ribavirin.",
"   </p>",
"   <p>",
"    Four weeks of alisporivir at 400 mg daily as monotherapy or in combination with peginterferon (with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) did not result in a significant change in viral load. The two arms that did experience a significant fall in viral load were alisporivir at 800 mg daily combined with",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    (-2.38 log",
"    <sub>",
"     10",
"    </sub>",
"    decrease in HCV RNA) and alisporivir at 400 mg twice daily for seven days as a loading dose followed by alisporivir at 400 mg once daily combined with",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    (-1.96 log",
"    <sub>",
"     10",
"    </sub>",
"    decrease). All patients have continued on combination",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    after the initial four-week dosing period for a total of 48 weeks of therapy; the final results of this trial are pending.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1241569081\">",
"    <span class=\"h2\">",
"     MicroRNA-122 inhibition",
"    </span>",
"    &nbsp;&mdash;&nbsp;MicroRNAs are a large class of small RNA molecules that regulate messenger RNA levels",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    translation through sequence-specific direct interactions with their targets. One of the microRNAs expressed in humans, miR-122, is abundantly and specifically expressed in the liver. MiR-122 directly interacts with the 5' noncoding region of the HCV RNA genome and upregulates viral RNA levels in infected cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/46\">",
"     46",
"    </a>",
"    ]. Notably, all HCV genotypes have conserved miR-122 binding sites. A modified oligonucleotide designed to antagonize miR-122 (miravirsen; Santaris Pharma) was shown to inhibit HCV RNA in chimpanzees with no viral resistance detected by deep sequencing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results of a Phase IIa multiple ascending-dose trial in humans have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/48\">",
"     48",
"    </a>",
"    ]. Thirty-six treatment-naive patients with chronic genotype 1 infection were assigned to four arms, which received once-weekly subcutaneous injections of placebo saline or miravirsen at 3",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    or 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    for four weeks. The 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group was eligible to begin",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    three weeks after the last dose of miravirsen at the discretion of the investigators, while the two other miravirsen arms could do so at six weeks after the last miravirsen dose. Only two, five, three, and two patients in the placebo, 3",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    miravirsen arms, respectively, actually began",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    therapy. The mean maximum decline in HCV RNA was -0.4 log",
"    <sub>",
"     10",
"    </sub>",
"    , -1.2 log",
"    <sub>",
"     10",
"    </sub>",
"    , -2.9 log",
"    <sub>",
"     10",
"    </sub>",
"    , and -3.0 log",
"    <sub>",
"     10",
"    </sub>",
"    in the placebo, 3",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and 7",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    arms, respectively. SVR rates were not a study endpoint and were not reported. No mutations were detected in the miR-122 binding regions of HCV RNA in any of the treatment cohorts. There were no discontinuations in therapy from adverse events.",
"   </p>",
"   <p>",
"    Attractive features of this approach include the absence of observed viral resistance thus far and the potential for pan-genotypic activity. However, the requirement for parenteral administration is a disadvantage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HCV VACCINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are substantial challenges to the development of an effective HCV vaccine. There is extensive sequence diversity among the six different known genotypes of HCV. In addition, a large number of viral quasispecies in infected individuals result in the rapid selection of viral escape mutants. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=see_link&amp;anchor=H148838165#H148838165\">",
"     \"Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1\", section on 'Viral resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Furthermore, patients with HCV infection generate HCV antibodies that are generally ineffective at clearing viral infection. Spontaneous HCV clearance in acutely infected individuals is associated with broad and early T-cell responses to HCV, and therefore a successful vaccine will likely have to elicit both CD4+ and CD8+ T-cell responses. Finally, the lack of a small animal model of chronic HCV infection adds greatly to the challenge of vaccine development.",
"   </p>",
"   <p>",
"    Conceptually, the goals of HCV vaccination can be either to prevent chronic infection in the exposed individual (preventive vaccination) or to help clear a chronic infection in the already-infected individual by boosting the host immune response (therapeutic vaccination).",
"   </p>",
"   <p>",
"    A hepatitis C immune globulin (Civacir) is being studied in a phase II trial to evaluate its effect on recurrent hepatitis C following liver transplantation; results from this trial are not yet available.",
"   </p>",
"   <p>",
"    A high dose monoclonal antibody against the HCV E2 protein has been studied in a phase II trial in patients with HCV genotype 1a undergoing liver transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/49\">",
"     49",
"    </a>",
"    ]. While recurrence of HCV infection was not prevented by the regimen, significant delays in the reappearance of viremia compared with the placebo control population were observed, and selection of E2 variants was observed. Further study of combining this strategy with a direct acting antiviral is planned.",
"   </p>",
"   <p>",
"    A therapeutic HCV vaccine in clinical development is a DNA-based vaccine (ChronVac-C). In this approach, a gene encoding the HCV",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protein is introduced into the patient's skeletal muscle by a technique called DNA electroporation. The muscle tissue then expresses the HCV",
"    <span class=\"nowrap\">",
"     NS3/4A",
"    </span>",
"    protein with the goal of stimulating HCV-specific immune responses. A phase",
"    <span class=\"nowrap\">",
"     I/II",
"    </span>",
"    study of ChronVac-C in 12 genotype 1, treatment-na&iuml;ve patients tested four different doses of the vaccine given monthly for four months. The highest dose tested resulted in detectable T-cell responses in one patient and moderate HCV viral load reductions of up to -1.2 log",
"    <sub>",
"     10",
"    </sub>",
"    and -2.4 log",
"    <sub>",
"     10",
"    </sub>",
"    in two out of three patients treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another therapeutic vaccine, GI-5005, is also in development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/51\">",
"     51",
"    </a>",
"    ]. This vaccine contains a fusion of the HCV core and NS3 proteins and has been designed as a T-cell vaccine. In a phase IIb trial of 133 patients with HCV genotype 1 (96 of whom were treatment-na&iuml;ve), patients were assigned to receive either a monthly vaccination along with peginterferon and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    or peginterferon and ribavirin alone for 48 weeks. There was a trend toward higher SVR rates in patients in the vaccination arm compared with those who received standard of care (47 versus 35 percent), but the results did not reach statistical significance. Similar nonsignificant trends were noted when patients were stratified by their prior treatment status. For prior nonresponders, the SVR rates were 17 versus 5 percent, respectively, and for treatment-na&iuml;ve patients they were 58 and 48 percent, respectively. In subgroup analysis, among treatment-na&iuml;ve patients, three of the five patients with the unfavorable IL28B TT genotype achieved SVR24 in the GI-5005 arm, compared with none of the five treated with peginterferon and ribavirin alone. This led to an expansion of the trial to study an additional 17 treatment-na&iuml;ve, IL28B TT genotype patients, the results of which have been pooled with the original 10 IL28B TT patients from the first cohort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/3\">",
"     3",
"    </a>",
"    ]. Ten of the 16 patients (63 percent) who received GI-5005 achieved an undetectable HCV RNA level at the end of treatment, compared with 3 of the 11 patients (27 percent) who received only peginterferon and ribavirin. SVR data have not yet been reported.",
"   </p>",
"   <p>",
"    A third therapeutic vaccine (TG4040) has been studied in a phase I trial. TG4040 is a recombinant poxvirus vaccine that expresses HCV proteins NS3, NS4, and NS5B.",
"   </p>",
"   <p>",
"    Several other approaches to HCV vaccines include recombinant HCV subunit vaccines, peptide vaccines designed to elicit T-cell specific immune responses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/52\">",
"     52",
"    </a>",
"    ], and virus-like particles expressing HCV envelope proteins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/53\">",
"     53",
"    </a>",
"    ]. Although some of these vaccines have shown promise in preclinical models, more study is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLEMENTARY/ALTERNATIVE MEDICINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Silybum marianum (milk thistle)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Milk thistle is a popular herbal product used by patients with chronic hepatitis C. The extract of milk thistle seeds is called silymarin and contains a number of flavonoid compounds, of which the dominant compound is called silibinin (also known as silybin). A survey of 1145 participants in the multicenter HALT-C trial of maintenance peginterferon in prior nonresponders to conventional HCV therapy revealed that 16 percent acknowledged having used silymarin in the past and another 17 percent were using it at the time of study enrollment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of small studies have yielded conflicting results concerning the effectiveness of milk thistle",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    silymarin in hepatitis C and chronic liver disease. A systematic review concluded that although silymarin may decrease serum aminotransferases in patients with hepatitis C, there was no clear benefit to this or other herbal medications for chronic HCV infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/55\">",
"     55",
"    </a>",
"    ]. Similar conclusions were reached in an evidence report on the efficacy of milk thistle in liver disease performed through the Agency for Healthcare Research and Quality (",
"    <a class=\"external\" href=\"file://www.ahrq.gov/\">",
"     www.ahrq.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    On the other hand, it has been argued that many of the discrepant results on the effectiveness of silymarin can be explained by the lack of standardization among silymarin preparations, particularly in the United States where herbal preparations are essentially unregulated.",
"   </p>",
"   <p>",
"    More recent data using standardized silymarin and silibinin preparations have demonstrated antiviral activity against HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. One study using a standardized silymarin preparation found significant suppression of HCV replication in cell culture models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/56\">",
"     56",
"    </a>",
"    ]. Another study used an intravenous infusion of varying doses of silibinin into prior nonresponders to",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    each day for 7 to 14 consecutive days as lead-in therapy to",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    therapy plus oral silymarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/57\">",
"     57",
"    </a>",
"    ]. Silibinin infusion was generally well tolerated, and a significant decline in HCV RNA was observed in patients receiving IV silibinin monotherapy (up to a &ndash;3 log",
"    <sub>",
"     10",
"    </sub>",
"    decline in patients receiving 20",
"    <span class=\"nowrap\">",
"     mg/kg/day).",
"    </span>",
"    Of the 14 patients receiving the 15",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    and 20",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    doses, six achieved an HCV RNA level of &lt;15 int.",
"    <span class=\"nowrap\">",
"     unit/mL",
"    </span>",
"    after a 14-day silibinin infusion combined with the addition of",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    on day eight. Data on SVR rates have not yet been reported.",
"   </p>",
"   <p>",
"    A phase II assigned, placebo-controlled clinical trial sponsored by the National Institutes of Health evaluated two different doses of oral silymarin monotherapy given for 24 weeks in 154 prior nonresponders to",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"    </span>",
"    who had elevated ALT levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/59\">",
"     59",
"    </a>",
"    ]. There was no difference between the treatment arms with regard to changes in alanine aminotransferase activity and HCV RNA levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of other herbal therapies have been associated with serious side effects, including fatalities. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=see_link\">",
"     \"Hepatotoxicity due to herbal medications and dietary supplements\"",
"    </a>",
"    .) Furthermore, a systematic review of 13 controlled trials of 14 different herbal treatments of HCV found no firm evidence of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/55\">",
"     55",
"    </a>",
"    ]. A randomized, placebo-controlled 12-week trial of a combination of Chinese herbal medications for chronic HCV and fatigue failed to demonstrate any improvement in ALT, serum HCV RNA level, or quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     INEFFECTIVE AND PROBABLY INEFFECTIVE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple therapies have been studied in chronic HCV that are most likely ineffective.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542140\">",
"    <span class=\"h2\">",
"     Albinterferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;A form of interferon alfa genetically fused to albumin (Albuferon, Human Genome Sciences) underwent clinical testing but is no longer being developed by the manufacturer because of toxicity concerns. Possible advantages that were identified in early-stage clinical studies compared with other forms of interferon are its long half-life and improved side effect profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/62\">",
"     62",
"    </a>",
"    ]. Additional trials suggested that the main advantage of albinterferon compared with peginterferon is its lower dosing frequency (every two weeks rather than every week). There is no evidence that albinterferon is more effective than peginterferon with respect to SVR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/63-65\">",
"     63-65",
"    </a>",
"    ], except possibly in nonresponders to prior interferon-based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542201\">",
"    <span class=\"h2\">",
"     Amantadine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    , an influenza antiviral drug, has been studied as monotherapy and in combination with other anti-HCV treatments. Several studies have found that amantadine in combination with interferon is ineffective in treatment-na&iuml;ve patients with chronic HCV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. Two trials of triple therapy with interferon,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , and amantadine compared with",
"    <span class=\"nowrap\">",
"     interferon/ribavirin",
"    </span>",
"    alone in prior nonresponders to interferon monotherapy yielded discordant results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Three more recent studies have failed to demonstrate increased SVR rates with the addition of amantadine to",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    in treatment-na&iuml;ve patients with genotype 1 infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/72,73\">",
"     72,73",
"    </a>",
"    ] or other genotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/74\">",
"     74",
"    </a>",
"    ]. In aggregate, these data suggest that adding amantadine to peginterferon and ribavirin does not increase rates of SVR in treatment-na&iuml;ve individuals, and there is insufficient evidence to conclude whether amantadine offers any clinical benefit in prior nonresponders to HCV therapy.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     Nitazoxanide",
"    </a>",
"    &mdash; Nitazoxanide is an antiprotozoal drug approved for the treatment of Cryptosporidium parvum and Giardia lamblia diarrhea. However, it also has been reported to display broad anti-infective activity against organisms as diverse as helminths, Clostridium difficile, and several viruses. Nitazoxanide inhibits both HBV and HCV replication in cell culture models [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/75\">",
"     75",
"    </a>",
"    ]. The mechanism of nitazoxanide activity against HCV may be mediated by phosphorylation of the host proteins kinase R and eIF2alpha, which in turn inhibits HCV replication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two phase II trials called STEALTH C-2 and STEALTH C-3 have been completed in the United States in patients with genotype 1 infection. Both studies compared a four-week",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    lead-in followed by 48 weeks of",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     /nitazoxanide",
"    </span>",
"    with a four-week placebo lead-in followed by 48 weeks of",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin/placebo.",
"    </span>",
"    STEALTH C-2 was conducted in 64 genotype 1 prior nonresponders to",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin,",
"    </span>",
"    including prior null responders and prior partial responders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/77\">",
"     77",
"    </a>",
"    ]. There was no significant change in mean serum RNA during the four-week nitazoxanide lead-in phase. Seven percent of the patients receiving nitazoxanide plus",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    achieved an SVR, while none of the patients receiving",
"    <span class=\"nowrap\">",
"     peginterferon/ribavirin",
"    </span>",
"    alone did.",
"   </p>",
"   <p>",
"    STEALTH C-3 was conducted in 112 genotype 1 treatment-na&iuml;ve patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/78\">",
"     78",
"    </a>",
"    ]. Forty-four percent of patients in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/24/5508?source=see_link\">",
"     nitazoxanide",
"    </a>",
"    arm achieved an SVR compared with 32 percent of patients in the standard-of-care arm. It should be noted, however, that the SVR rate in the standard-of-care arm was significantly lower than the approximately 45 percent rate observed in other clinical trials of",
"    <span class=\"nowrap\">",
"     peginterferon/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"      ribavirin",
"     </a>",
"     .",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H542208\">",
"    <span class=\"h2\">",
"     Other ineffective treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other modalities have been tried in the treatment of chronic hepatitis C with generally discouraging results. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytokines and immunomodulators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/79\">",
"       79",
"      </a>",
"      ], interleukin-12 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/80\">",
"       80",
"      </a>",
"      ], levamisole [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/81\">",
"       81",
"      </a>",
"      ], interleukin-2 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/82\">",
"       82",
"      </a>",
"      ], and monotherapy with thymic extracts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/83\">",
"       83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antioxidants such as N-acetylcysteine and vitamin E [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypericin, a natural derivative of the common St. John's wort plant [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/85\">",
"       85",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12373?source=see_link\">",
"       Ursodeoxycholic acid",
"      </a>",
"      (UDCA) appears to lower serum aminotransferase levels in patients with chronic HCV but there is no evidence that UDCA improves liver histology or increases rates of SVR when combined with other HCV therapies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/86\">",
"       86",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Nonsteroidal anti-inflammatory drugs (NSAIDs) have the potential for enhancing the effects of interferon and have thus been evaluated as combination therapy. One study found that the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/36/43592?source=see_link\">",
"       ketoprofen",
"      </a>",
"      with interferon resulted in significantly higher SVR compared with interferon monotherapy (33 versus 10 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/87\">",
"       87",
"      </a>",
"      ], while another study found no benefit to adding ketoprofen to interferon monotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/30/38378/abstract/88\">",
"       88",
"      </a>",
"      ]. No studies have been performed to assess whether the addition of NSAIDs improves SVR rates when added to",
"      <span class=\"nowrap\">",
"       peginterferon/",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"        ribavirin",
"       </a>",
"      </span>",
"      combination therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=see_link\">",
"       \"Patient information: Hepatitis C (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/22/4451?source=see_link\">",
"       \"Patient information: Latest medicines for hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=see_link\">",
"       \"Patient information: Hepatitis C (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The search for new therapies for chronic hepatitis C virus (HCV) is ongoing. These can be divided conceptually into: derivatives of current treatment; treatments targeting HCV-encoded proteins; treatments targeting host-encoded proteins; and therapeutic and preventive vaccines.",
"     </li>",
"     <li>",
"      Modifications of current forms of interferons and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/25/27033?source=see_link\">",
"       ribavirin",
"      </a>",
"      derivatives are currently in clinical trials. The available data suggest that these approaches are unlikely to result in significantly improved sustained virologic response (SVR) rates compared with current therapy, but may have a more favorable side effect profile. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Derivatives of current treatments'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Characterization of HCV-encoded proteins and their functions has permitted development of strategies aimed at interrupting HCV replication. Key potential drug targets include the",
"      <span class=\"nowrap\">",
"       NS2/3",
"      </span>",
"      autoprotease, the NS3 RNA helicase, the",
"      <span class=\"nowrap\">",
"       NS3/4A",
"      </span>",
"      serine protease, the NS5A protein, and the NS5B RNA-dependent RNA polymerase. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Direct acting antiviral therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early-phase clinical trials have demonstrated that interferon-free DAA combination therapy can result in high rates of SVR, even in difficult-to-treat genotype 1 null responder patients. (See",
"      <a class=\"local\" href=\"#H300164\">",
"       'Interferon-free combinations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Another approach to HCV therapy is to target the host proteins that the virus uses for its own life cycle. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Treatments targeting host-encoded factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HCV vaccination can be aimed either at preventing chronic infection in the exposed individual (preventive vaccination) or at helping to clear a chronic infection in the already-infected individual by boosting the host immune response (therapeutic vaccination). Both approaches are in development but must overcome significant technical challenges before a clinically useful product is to be expected. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'HCV vaccines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/1\">",
"      Lohmann V, K&ouml;rner F, Koch J, et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/2\">",
"      Wakita T, Pietschmann T, Kato T, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11:791.",
"     </a>",
"    </li>",
"    <li>",
"     Shiffman ML, Muir AJ, Vierling JM, et al. GI-5005 therapeutic vaccine enhances virologic clearance by Peg-IFN/ribavirin in na&iuml;ve HCV genotype 1 patients with IL28B genotype T/T. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/4\">",
"      Watson J. Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives of ribavirin. Curr Opin Investig Drugs 2002; 3:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/5\">",
"      Lin CC, Yeh LT, Vitarella D, Hong Z. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals. Antivir Chem Chemother 2003; 14:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/6\">",
"      Pockros PJ, Pessoa MG, Diago M, et al. Combination of levovirin (LVV) and peginterferon alfa-2a (40 kD) (Pegasys&reg;) fails to generate a virological response comparable to ribavirin (RBV, Copegus&reg;) and peginterferon alfa-2a (40 kD) in patients with chronic hepatitis C. Hepatology 2004; 40(Suppl 1):391A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/7\">",
"      Benhamou Y, Afdhal NH, Nelson DR, et al. A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-na&iuml;ve patients with chronic hepatitis C: ViSER1 results. Hepatology 2009; 50:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/8\">",
"      Poordad F, Lawitz E, Shiffman ML, et al. Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010; 52:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/9\">",
"      Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139:120.",
"     </a>",
"    </li>",
"    <li>",
"     Jacobson IM, Catlett I, Marcellin, P et al. Telaprevir substantially improves SVR rates across all IL28B genotypes in the ADVANCE trial. Presented at the 46th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany; March 30-April 3, 2011.",
"    </li>",
"    <li>",
"     Poordad F, Bronowicki JP, Gordon SC, et al. IL28B polymorphism predicts virological response in patients with chronic hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. Presented at the 46th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany; March 30-April 3, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/12\">",
"      Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. PLoS Pathog 2008; 4:e1000032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/13\">",
"      McCown MF, Rajyaguru S, Le Pogam S, et al. The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors. Antimicrob Agents Chemother 2008; 52:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/14\">",
"      Dieterich D, Asselah T, Guyader D, et al. SILEN-C3: Treatment for 12 or 24 weeks with BI201335 combined with peginterferon alfa-2a and ribavirin (P/R) in treatment-naive patients with chronic genotype-1 HCV infection. Hepatology 2011; 54:378A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/15\">",
"      Sukowski MS, Asselah T, Ferenci P, et al. Treatment with the second generation HCV protease inhibitor BI 20133 results in high and consistent SVR rates - Results from SILEN-C1 in treatment-naive patients across different baseline factors. Hepatology 2011; 54:473A.",
"     </a>",
"    </li>",
"    <li>",
"     Everson G, Cooper C, H&eacute;zode C, et al. High SVR24 rates with ritonavir-boosted danoprevir plus Peg-IFNalfa-2a (40 kD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012.",
"    </li>",
"    <li>",
"     Fried M, Buti M, Dore GJ, et al. TMC435 in combination with peginterferon and ribavirin in treatment-na&iuml;ve HCV genotype 1 patients: final analysis of the PILLAR phase IIb study. Presented at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases, San Francisco, CA; November 4-8, 2011. Abstract LB-5.",
"    </li>",
"    <li>",
"     Zeuzem S, Bert T, Gane E, et al. TMC435 with peginterferon and ribavirin in treatment-experienced HCV genotype 1 patients: the ASPIRE study, a randomised Phase IIb trial. EASL 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/19\">",
"      Moreno C, Berg T, Tanwandee T, et al. Antiviral activity of TMC435 monotherapy in patients infected with HCV genotypes 2-6: TMC435-C202, a phase IIa, open-label study. J Hepatol 2012; 56:1247.",
"     </a>",
"    </li>",
"    <li>",
"     Bronowicki J-P, Pol S, Thuluvath P. Asunaprevir (ASV; BMS-650032), an NS3 protease inhibitor, in combination with peginterferon and ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C infection). EASL 2012.",
"    </li>",
"    <li>",
"     H&eacute;zode C, Hirschfield GM, Ghesquiere W, et al. Daclatasvir, an NS5A replication complex inhibitor, combined with peginterferon alfa-2a and ribavirin in treatment-na&iuml;ve HCV-genotype 1 or 4 subjects: phase 2b COMMAND-1 SVR12 results. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012. Abstract 755.",
"    </li>",
"    <li>",
"     Ratziu V, Gadano A, Pol S, et al. Triple therapy with daclatasvir (DCV; BMS-790052), peginterferon alfa-2a and ribavirin in HCV-infected prior null and partial responders: 12-week results of phase 2b COMMAND-2 trial). EASL abstract 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/23\">",
"      Lawitz E, Lalezari JP, Hassanein T, et al. Once-daily PSI-7977 plus PEG/RBV in treatment-naive patients with HCV GT1: Robust end of treatment response rates are sustained post-treatment. Hepatology 2011; 54:472A.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.medscape.com/viewarticle/753329 (Accessed on November 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/25\">",
"      Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/26\">",
"      Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368:34.",
"     </a>",
"    </li>",
"    <li>",
"     Wedemeyer H, Jensen D, Herring R Jr., et al. Efficacy and safety of mericitabine (MCB) in combination with PEG-IFNalfa-2a/RBV in G1/4 treatment na&iuml;ve HCV patients: final analysis from the PROPEL study. Presented at the 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain; April 18-22, 2012.",
"    </li>",
"    <li>",
"     Pockros PJ, Jensen D, Tsai N, et al. SVR24 among g1/4 treatment-na&iuml;ve patients receiving mericitabine in combination with PEG-IFNalfa-2a/RBV: final analysis from the JUMP-C study. Presented at the 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain; April 18-22, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/29\">",
"      Lok AS, Gardiner DF, Lawitz E, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012; 366:216.",
"     </a>",
"    </li>",
"    <li>",
"     Lok A, Gardiner D, H&eacute;zode C, et al. Confirmation that quadruple therapy with daclatasvir (NS5A inhibitor), asunaprevir (NS3 inhibitor) and peginterferon/ribavirin results in high rate of SVR4 in HCV genotype 1 null responders. Presented at the 47th Annual Meeting of the European Association for the Study of the Liver, Barcelona, Spain; April 18-22, 2012",
"    </li>",
"    <li>",
"     Feld JJ, Jacobson IM, Jensen DM, et al. Up to 100% SVR4 rates with ritonavir-boosted danoprevir (DNVr), mericitabine and ribavirin with or without peginterferon alfa-2a (40 kD) in HCV genotype 1-infected partial and null responders: results from the MATTERHORN study. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012.",
"    </li>",
"    <li>",
"     Sulkowski M, Gardiner D, Lawitz E, et al. Potent viral suppression with the all-oral combination of daclatasvir (NS5A inhibitor) and GS-7977 (nucleotide NS5B inhibitor), +/- ribavirin, in treatment-naive patients with chronic HCV GT1, 2, or 3 (100% SVR gt1, 91% gt2). EASL 2012.",
"    </li>",
"    <li>",
"     Kowdley KV, Lawitz E, Poordad F, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT 267, ABT-333, and ribavirin achieves SVR12 rates (observed data) of 99% in treatment-na&iuml;ve patients and 93% in prior null responders with HCV genotype 1 infection. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/34\">",
"      Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013; 368:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/35\">",
"      Chayama K, Takahashi S, Toyota J, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/36\">",
"      Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol 2013; 58:655.",
"     </a>",
"    </li>",
"    <li>",
"     Gane EJ, Pockros P, Zeuzem S, et al. Interferon-free treatment with a combination of mericitabine and danoprevir/r with or without ribavirin in treatment-na&iuml;ve HCV genotype 1-infected patients. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012.",
"    </li>",
"    <li>",
"     Zeuzem S, Soriano V, Asselah T, et al. Interferon (IFN)-free combination treatment with the HCV NS3/4A protease inhibitor faldaprevir (BI 201335) and the non-nucleoside NS5B inhibitor BI 207127 &plusmn; ribavirin: final results of SOUND-C2 and predictors of response. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012.",
"    </li>",
"    <li>",
"     Soriano V, Gane E, Angus P, et al. Efficacy and safety of the interferon-free combination of faldaprevir (BI 201335) + BI 207127 &plusmn; ribavirin in treatment-na&iuml;ve patients with HCV gt-1 and compensated liver cirrhosis:results from the SOUND-C2 study. Presented at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA; November 9-13, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/40\">",
"      Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003; 38:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/41\">",
"      Yang F, Robotham JM, Nelson HB, et al. Cyclophilin A is an essential cofactor for hepatitis C virus infection and the principal mediator of cyclosporine resistance in vitro. J Virol 2008; 82:5269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/42\">",
"      Paeshuyse J, Kaul A, De Clercq E, et al. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006; 43:761.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.medpagetoday.com/InfectiousDisease/Hepatitis/32252 (Accessed on April 20, 2012).",
"    </li>",
"    <li>",
"     Flisiak R, Pawlotsky JM, Crabbe R et al. Once daily alisporivir (DEB025) plus Peg-IFN-alfa-2A/ribavirin results in superior sustained virologic response (SVR24) in chronic hepatitis C genotype 1 treatment-na&iuml;ve patients &ndash; the ESSENTIAL study. Presented at the 46th Annual Meeting of the European Association for the Study of the Liver. Berlin, Germany; March 30-April 3, 2011; abstract #190.",
"    </li>",
"    <li>",
"     Nelson DR, Ghalib RH, Sulkowski M, et al. Efficacy and safety of the cyclophilin inhibitor Debio 025 in combination with pegylated interferon alpha-2a and ribavirin in previously null-responder genotype 1 HCV patients. Presented at the 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark; April 22-26, 2009; abstract #95.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/46\">",
"      Jopling CL, Yi M, Lancaster AM, et al. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/47\">",
"      Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010; 327:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/48\">",
"      Janssen HL, Reesink HW, Lawitz EJ, et al. Treatment of HCV Infection by Targeting MicroRNA. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/49\">",
"      Gordon FD, Chung RT, Curry MP, et al. Monoclonal antibody MBL-HCV1 suppresses return of HCV following liver transplantation. Hepatology 2011; 54:1434A.",
"     </a>",
"    </li>",
"    <li>",
"     Sallberg M, Frelin L, Diepolder H, et al. A first clinical trial of therapeutic vaccination using naked DNA delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis C. Presented at the 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark; April 22-26, 2009; abstract #43.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/51\">",
"      Pockros P, Jacobson I, Boyer TD, et al. GI-5005 therapeutic vaccine plus PEG-IFN/ribavirin improves sustained virologic response versus PEG-IFN/ribavirin in piror non-responders with genotype 1 chronic HCV infection. Hepatology 2010; 52:404A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/52\">",
"      Folgori A, Capone S, Ruggeri L, et al. A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 2006; 12:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/53\">",
"      Elmowalid GA, Qiao M, Jeong SH, et al. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proc Natl Acad Sci U S A 2007; 104:8427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/54\">",
"      Seeff LB, Curto TM, Szabo G, et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 2008; 47:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/55\">",
"      Liu J, Manheimer E, Tsutani K, Gluud C. Medicinal herbs for hepatitis C virus infection: a Cochrane hepatobiliary systematic review of randomized trials. Am J Gastroenterol 2003; 98:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/56\">",
"      Polyak SJ, Morishima C, Shuhart MC, et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin. Gastroenterology 2007; 132:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/57\">",
"      Ferenci P, Scherzer TM, Kerschner H, et al. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology 2008; 135:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/58\">",
"      Wagoner J, Negash A, Kane OJ, et al. Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology 2010; 51:1912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/59\">",
"      Fried MW, Navarro VJ, Afdhal N, et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial. JAMA 2012; 308:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/60\">",
"      Koh C, et al. Clinical, virological, biochemical outcomes after 20 years of sustained virological response (SVR) in chronic hepatitis C: The NIH experience. AASLD 2010; Abstract 228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/61\">",
"      Jakkula M, Boucher TA, Beyendorff U, et al. A randomized trial of Chinese herbal medicines for the treatment of symptomatic hepatitis C. Arch Intern Med 2004; 164:1341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/62\">",
"      Bain VG, Kaita KD, Yoshida EM, et al. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol 2006; 44:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/63\">",
"      Zeuzem S, Sulkowski MS, Lawitz EJ, et al. Albinterferon Alfa-2b was not inferior to pegylated interferon-&alpha; in a randomized trial of patients with chronic hepatitis C virus genotype 1. Gastroenterology 2010; 139:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/64\">",
"      Neumann AU, Pianko S, Zeuzem S, et al. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-na&iuml;ve patients with genotype 1, chronic hepatitis C. J Hepatol 2009; 51:21.",
"     </a>",
"    </li>",
"    <li>",
"     Nelson D, Benhamou Y, Chuang WL, et al. Efficacy and safety results of albinterferon alfa-2b in combination with ribavirin in interferon-alfa treatment na&iuml;ve patients with genotype 2 or 3 chronic hepatitis C. Presented at the 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen, Denmark; April 22-26, 2009; abstract #1042.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/66\">",
"      Nelson DR, Rustgi V, Balan V, et al. Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C. Clin Gastroenterol Hepatol 2009; 7:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/67\">",
"      Caronia S, Bassendine MF, Barry R, et al. Interferon plus amantadine versus interferon alone in the treatment of na&iuml;ve patients with chronic hepatitis C: a UK multicentre study. J Hepatol 2001; 35:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/68\">",
"      Tabone M, Laudi C, Delmastro B, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001; 35:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/69\">",
"      Helbling B, Stamenic I, Viani F, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 2002; 35:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/70\">",
"      Brillanti S, Levantesi F, Masi L, et al. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/71\">",
"      Teuber G, Pascu M, Berg T, et al. Randomized, controlled trial with IFN-alpha combined with ribavirin with and without amantadine sulphate in non-responders with chronic hepatitis C. J Hepatol 2003; 39:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/72\">",
"      Ferenci P, Formann E, Laferl H, et al. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-na&iuml;ve patients with chronic hepatitis C genotype 1 infection. J Hepatol 2006; 44:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/73\">",
"      von Wagner M, Hofmann WP, Teuber G, et al. Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection. Hepatology 2008; 48:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/74\">",
"      Langlet P, D'Heygere F, Henrion J, et al. Clinical trial: a randomized trial of pegylated-interferon-alpha-2a plus ribavirin with or without amantadine in treatment-na&iuml;ve or relapsing chronic hepatitis C patients. Aliment Pharmacol Ther 2009; 30:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/75\">",
"      Korba BE, Montero AB, Farrar K, et al. Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antiviral Res 2008; 77:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/76\">",
"      Jiang D, Guo H, Xu C, et al. Identification of three interferon-inducible cellular enzymes that inhibit the replication of hepatitis C virus. J Virol 2008; 82:1665.",
"     </a>",
"    </li>",
"    <li>",
"     Shiffman ML, Ahmed A, Jacobson IM, et al. Phase 2 randomized, double-blind placebo-controlled study of nitazoxanide with peginterferon alfa-2a and ribavirin in nonresponders with chronic hepatitis C genotype 1: final report. Presented at the 45th Annual Meeting of the European Association for the Study of the Liver, Vienna, Austria; April 14-18, 2010; abstract #1188.",
"    </li>",
"    <li>",
"     Bacon BR, Shiffman ML, Lim JK, et al. Phase 2 randomized, double-blind, placebo-controlled study of nitazoxanide plus peginterferon and ribavirin in HCV genotype 1 na&iuml;ve patients: week 12 sustained virologic response rate. Presented at Digestive Disease Week, New Orleans, USA; May 1-5, 2010; Abstract #711b.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/79\">",
"      Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998; 28:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/80\">",
"      Pockros PJ, Patel K, O'Brien C, et al. A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy. Hepatology 2003; 37:1368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/81\">",
"      Clifford BD, Smith L, Allan C, et al. Levamisole and interferon alfa-2b as combination therapy for chronic hepatitis C: Results of a pilot study (abstract). Gastroenterology 1995; 108:A1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/82\">",
"      Pardo M, Castillo I, Oliva H, et al. A pilot study of recombinant interleukin-2 for treatment of chronic hepatitis C. Hepatology 1997; 26:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/83\">",
"      Raymond RS, Fallon MB, Abrams GA. Oral thymic extract for chronic hepatitis C in patients previously treated with interferon. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 129:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/84\">",
"      Id&eacute;o G, Bellobuono A, Tempini S, et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur J Gastroenterol Hepatol 1999; 11:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/85\">",
"      Jacobson JM, Feinman L, Liebes L, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001; 45:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/86\">",
"      Chen W, Liu J, Gluud C. Bile acids for viral hepatitis. Cochrane Database Syst Rev 2003; :CD003181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/87\">",
"      Andreone P, Gramenzi A, Cursaro C, et al. Interferon-alpha combined with ketoprofen as treatment of na&iuml;ve patients with chronic hepatitis C: a randomized controlled trial. J Viral Hepat 2003; 10:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/30/38378/abstract/88\">",
"      Fabris P, Tositti G, Negro F, et al. Interferon alfa-2b alone or in combination with ketoprofen as treatment for interferon-naive chronic hepatitis C patients. Aliment Pharmacol Ther 1999; 13:1329.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3638 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E9920BD3B2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38378=[""].join("\n");
var outline_f37_30_38378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      HCV REPLICATION MODELS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DERIVATIVES OF CURRENT TREATMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1054566799\">",
"      Interferon-lambda",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ribavirin derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIRECT ACTING ANTIVIRAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299756\">",
"      Role of HCV 1a versus 1b genotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299779\">",
"      Role of IL28b gene polymorphisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NS3/4A protease inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299832\">",
"      NS5A inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299861\">",
"      NS5B polymerase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H299890\">",
"      DAA COMBINATION STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H299897\">",
"      Triple therapy: DAA + peginterferon + ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H299912\">",
"      - Faldaprevir (BI 2010335)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H299953\">",
"      - Danoprevir (ITMN-191/RG7227)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58395763\">",
"      - Simeprevir (TMC435)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58395770\">",
"      - Asunaprevir (BMS-650032)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300001\">",
"      - Daclatasvir (BMS-790052)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300042\">",
"      - Sofosbuvir (GS-7977)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300107\">",
"      - Mericitabine (RG7128)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H300124\">",
"      Quadruple therapy: Two DAAS + peginterferon + ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300139\">",
"      - Daclatasvir and asunaprevir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300147\">",
"      - Danoprevir and mericitabine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H300164\">",
"      Interferon-free combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300198\">",
"      - Sofosbuvir with and without ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300206\">",
"      - Sofosbuvir and daclatasvir with and without ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300214\">",
"      - ABT-450, ABT-267, ABT-333, and ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300231\">",
"      - Daclatasvir and asunaprevir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300239\">",
"      - Danoprevir and mericitabine with and without ribavirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H300247\">",
"      - Faldaprevir and BI 207127 with and without ribavirin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TREATMENTS TARGETING HOST-ENCODED FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cyclophilin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1241569081\">",
"      MicroRNA-122 inhibition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HCV VACCINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLEMENTARY/ALTERNATIVE MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Silybum marianum (milk thistle)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      INEFFECTIVE AND PROBABLY INEFFECTIVE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542140\">",
"      Albinterferon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542201\">",
"      Amantadine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H542208\">",
"      Other ineffective treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3638\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3638|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/30/11744\" title=\"table 1\">",
"      Telaprevir drug interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/31/7664\" title=\"table 2\">",
"      Boceprevir drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/2/25642?source=related_link\">",
"      Hepatotoxicity due to herbal medications and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/59/35768?source=related_link\">",
"      Mechanism of action and efficacy of standard interferon alfa for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/45/43735?source=related_link\">",
"      Overview of the management of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/4/17478?source=related_link\">",
"      Patient information: Hepatitis C (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/39/32370?source=related_link\">",
"      Patient information: Hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/22/4451?source=related_link\">",
"      Patient information: Latest medicines for hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14474?source=related_link\">",
"      Predictors of a sustained virologic response following treatment with peginterferon and ribavirin for chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15785?source=related_link\">",
"      Studies of telaprevir and boceprevir in the treatment of chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/47/24314?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotype 1",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/37/600?source=related_link\">",
"      Treatment regimens for chronic hepatitis C virus genotypes 2, 3, and 4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_30_38379="Fall risk assessment prevention";
var content_f37_30_38379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F82170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=16\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F82170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=16\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Approach to fall risk assessment and targeted interventions to reduce falls",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Risk factors",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interventions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Postural hypotension",
"       </td>",
"       <td>",
"        Behavioral recommendation such as ankle pumps or hand clenching; elevate head of bed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use of any benzodiazepines or other sedative-hypnotics",
"       </td>",
"       <td>",
"        Education about appropriate use of these medications;",
"nonpharmacologic treatment of sleep problems; medication taper and",
"discontinuation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At least four prescription drugs",
"       </td>",
"       <td>",
"        Medication review with patient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unsafe tub and toilet transfers",
"       </td>",
"       <td>",
"        Transfer training; environmental manipulations such as grab bars, raised toilet seats",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Environmental fall or tripping hazards",
"       </td>",
"       <td>",
"        Appropriate manipulations such as hazard removal, safer furniture, structures such as grab bars or stair handrails",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any gait impairment",
"       </td>",
"       <td>",
"        Gait training, appropriate assistive device, balance or strengthening exercises if indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any transfer or balance impairment",
"       </td>",
"       <td>",
"        Balance exercises, transfer training if indicated, environmental manipulations (walking devices, reachers, adaptive furniture such as higher chairs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Impairment of lower and upper extremity muscle strength or joint range of motion",
"       </td>",
"       <td>",
"        Resistive exercises",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38379=[""].join("\n");
var outline_f37_30_38379=null;
var title_f37_30_38380="Drugs prevent ERCP pancreatitis";
var content_f37_30_38380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmaceutical agents evaluated for the prevention of post-ERCP amylase elevation and/or pancreatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Postulated mechanism of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Inhibition of pancreatic secretion",
"       </td>",
"       <td>",
"        Somatostatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Octreotide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucagon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcitonin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Stimulation of pancreatic secretion and reduction of sphincter tone",
"       </td>",
"       <td>",
"        Secretin",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Reduction of sphincter tone",
"       </td>",
"       <td>",
"        Nifedipine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitroglycerin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Botulinum toxin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"7\">",
"        Inhibition of protease activation",
"       </td>",
"       <td>",
"        Aprotinin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gabaexate mesilate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C1-esterase inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heparins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ulinastatin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nafamostat",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Magnesium sulphate",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Antimicrobial agents",
"       </td>",
"       <td>",
"        Antibiotics",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Steroidal anti-inflammatory agents",
"       </td>",
"       <td>",
"        Glucocorticoids",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Nonsteroidal anti-inflammatory agents",
"       </td>",
"       <td>",
"        Diclofenac",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indomethacin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Valdecoxib",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"8\">",
"        Other anti-inflammatory agents",
"       </td>",
"       <td>",
"        Allopurinol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epinephrine spray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interleukin-10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pentoxifylline",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet-activating factor-acetylhidrolase",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Semapimod",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aprepitant",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Risperidone",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Antioxidants",
"       </td>",
"       <td>",
"        Beta-carotene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N-acetyl cysteine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium selenite",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Antimetabolites",
"       </td>",
"       <td>",
"        5-fluorouracil",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Silvano Loperfido, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38380=[""].join("\n");
var outline_f37_30_38380=null;
var title_f37_30_38381="TmGlucose";
var content_f37_30_38381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58196&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Splay in renal glucose reabsorption",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 280px; height: 214px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Filtration, reabsorption, and excretion of glucose as a function of plasma concentration in normal humans. The curves for reabsorption and secretion are drawn in two ways: (1) as idealized, sharply breaking curves; and (2) as rounded curves more descriptive of the true relationships. With a Tm for glucose of 375 mg/min and a GFR of 125 mL/min, glucose excretion should not begin until the plasma glucose concentration is greater than 300 mg/dL (sharply breaking curve). However, due to tubular heterogeneity (see text), there is \"splay\" in the glucose titration curve (rounded curves) and glucosuria begins when the plasma glucose concentration exceeds 180 to 200 mg/dL, well before the saturation of tubular reabsorptive capacity. The relative lack of splay in the HCO3- titration curve shown earlier may be due to the ability of distal HCO3- reabsorption to compensate for variations in proximal transport. This is in contrast to glucose, which is reabsorbed entirely in the proximal tubule.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Pitts, RF, Physiology of the Kidney and Body Fluids, 3d ed, Copyright &copy;1974 by Year Book Medical Publishers, Inc, Chicago. Used by permission. Adapted from Wright, HR, Russo, HF, Sheggs, HR, et al, Am J Physiol 1947; 149:130.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38381=[""].join("\n");
var outline_f37_30_38381=null;
var title_f37_30_38382="Causes LGI bleeding children";
var content_f37_30_38382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Major causes of lower gastrointestinal bleeding in children by age group",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 527px; background-image: url(data:image/gif;base64,R0lGODlhAwIPAsQAAP///wAzmQAAALKysoiIiERERLu7uyIiIt3d3ZmZmTMzMxEREWZmZu7u7szMzFVVVXd3d6qqqllZWQAZTOzs7MDAwEBAQICAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAADAg8CAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6CFF3MDgKV6p36poSwCpKZ7q3yyrCmucrSosbC1ra9/uXTBeMO9I7dxxXbKcMzCxivIzbx5zr/QKNJv1ri7wNi2133cbOTT4Cfabubb3qro6eKz7uPwJupt7Ov08/Yk+OWoERPoD+Aaffn4KYRnUA3CgLq++Tsmb+EziRMBNEzz8KDFgRk1VoxYjaC9jWg6/zr8eEclEQEGDKBsUYCAE5n3RpYkWa+IAwUCBChI8AImThw1aSS9cfSfTpA73xVRAEEEAQZFY85ksVRG1xpNKXbDCLUnEQUFSERYQMKBgAYHgh5woFErAARABVSF8IAEAQUAHgRV0CBwUAE2RxCIKzRvBAAMDidIINkAY6I1CxxYHJcwgsOEw4rYWsZlSpbLjDiILKCAgwYCHCQ4gIBA3xEHqhp19aCvgwUG1kJO+4DA38IKjNMG8HUxgs82GaQdwQDw0gVEhRdQgACA8wbYR3yOIFrkWKlRzR6pDiD5UAbFG7AWgHU3gANEmSeAHaEAhAQLrHYYfQxgxVxiVk0Hk/93aRGwgFwH3jWgAAgsRcB0+DlQQGXqkEaGaWeAGIaIpRkxlAjSebcAVgsESBly9dnVGwBuGRAYdr+xdZxiBzQAF4IMjmbjheMBAMEBzFUFQHgjWIhhAuzBlkB5E1Zp5ZVYZqnlllweRuKHqNXxZQoQgNZdjUYiiZdcMeK0pl5WLQCjCIIFtR9QC2zml4JDprWhAAcgSZkAUzKGpJMi4GfAg3FN2WEAkEYq6aSUVmrppZhmqqmkAowphqdcgAqGqI8IsOmpqKaqaqWdmiSmq+iYuuqstNYaaatktQQrOLLa6uuvmeKKXln9ZNQrsMgmG4Cw6umaaxDNTedCeWocq+z/tbUyWyyxYeoQLQzUpmEttuSmqm23+zwLxLcvhIvGuOXGGyypXtCLhb2hGrFdUFhdCMCiAoQHsMCMeQgGvPImTOm5PDk7rBAF+BabvwvYBCB4FstZ8b8Gf9HlxyCHLPKA+G5RchUnZ1HyUoQSSeFon3WnUcwcw9HxiLue1yy0NkVAIcU2OYixikMTcHMXR3+R8r3o6gzxYUGnNTBRUwMwKFA2P+Uwtw2fpHVqXYcd69evis312E43DdHDXqdtttvpFUT2RXGrDUrS9eacjN7G4N3F0lcAHoXgKIdk3t7q0r0zQ3M3nlDivDqOeN1vQ+N3vpDDfXbkmm/tud2fXG4y/9/tZG655OdQrroPG9r0mY01LPWVCLNrIboWhFORuxO7S7FyXM8tGDuQZ9yuMunpsr2udAW8bphQhdXJFqEHMDD1oITWhD2FSQll578FT2E806anvvgPBViPGEw7JufcMbdtfLHsCKYfIWLeIblAVe4qMX7gyHuc8tCHlToZYD4EMpCQJCQz7iUmKQ1QgIG6Z6PZ0Kx/SRiZBjfIwaD0bnCgS94Q7PcZ9hGGRzKriwg2JjT/0I4AEayfTRY0myUF7X82QJjCdrisD0LBh0oAIu/0ZaDI2KhOhGJOUKYHu6oNKgE1MdphDEBBqwlKLjisgQ55mDCGra5zYMvDYsTHxf8y3kqITUDjEdS4BDYKQYrAIaMZy+jFzYGxbMaaIx3dmAQ+DsGPazTcFvV4rTp+Do/nqxbsbEdIHhoyjHaEpBP81QP7UJKSURhkI5H1SEQe8otIwOQOhBckK2hyk7/qpOI+GckdWOZ7+6JPCWWZl37VhHtBKUD0luidwdBlN7NkgL/KFBS6MKGDyEzmlgBpBGYCwZlEKFl4tCO1n03nAVhBQIAWM6QexfB9NIrNcOqCk0umRQCPeUIWdRfAtSWSB7MMSoVcZ81EDSgBlCyQVQqkwBqCj5yuMGf+6FOYY6KudKD0ZBCY9EIG/oVOCizlYny0GXC6hS4POKddHlrKFeb/ZwnrnAI0/xhCAQ7hlYCKUMx+Q8vD1EZaf9KlEgPWS6H80i4sFaYuHwS9JoTUd+30SPl68VMQDlWE25LbHVcpyZJyoqg/DOpKjsoKqD5hpELAKg+0+kxBHhSpTa1c375qUlaa9XRLJWuIpOoJqw6Rqu5Matsm9066ypVxac1rXJ26Cbemka2ngevd1CrUhDIVr3bla4kEe1K/io+wUzUsZF+wIZlV1gQYDNdRMEgFx7YRsGtlrFLgVMIUjiCzAOHsFTwbRNCagas/WFkB5ASBys4yNAG9ZYVyCRe53La3gHJTXqrCmZ5mcrKBlaxebZC+AgCIMikcTzkP0E0fJUc0/9K9BU5m9BsDfIeh6kRuaJWb2OVR5gEyQYCGOFRKfXpHfSJYr5026wr80A6fT5KCMvfLXy+5drEDZB2LtIKAKBGqnNOZ6I9kUhgDO6ow25WYd/ObSVR2EbY+wDAONLxVIp6WQgBrFIKbxNsIBpdRhDIxdV3xJuJSGAqntHC2OLwDGtfAxjnA8btkHC9Vihdnou1EjHm8Kh8vN7J17RuRyWXk8h6WvHdbMraabL6zKlSdiwTXTFSLhCFL+VRURmgrn2wEf7Esy+3aMmuj8WVlhRmsV4byuhJDSi23gMtH8HKb5/VfMAU5BrAx5gojcCHsUSYvH7UaW7xjHd7iRE/gif9Aiu7jqHFSugF/WnSe+8tpZOr4Bp+OQahvbCICICBDOvITnYOGpBGAhyjYUfB1A4qkMU5aUa649YNB+mMAj7nXKuALAyKwmb6Ymc4VbLViCkBsyBjoKjgBjwFOpGuc6NpIASPeS4A9hlG/wNszKNlvkPQAFvpJSTRUtgg+oycFb+YoDDiAnPL3L+xMt94fdYtpt31kOJPZyjvYmM+6468nptsEDJj3THV5FOisuzP2ZjHEHcWvDHL7U4rliFf7XdawyrmtFwfyxzuO2CpnvNt9xsSakQBuGbScBS+HQcw9FvJRnXy8E1l5IP/82pRfQufN9LnIk0zUmivt5j0PCdD/izBzFzQdBU+H+cad/GuSj/ypRs+bWP+NVqoD3N9VtwKeUTB2IHT67BuM+grUXgK2p+BkUhTAA/Y9g7Ifw0Z294Ge93ypN1s9638zwpHoUiE01/1oC8p7JfkOLL/vNc5ht8EC0nnaB4VnPlQLX7VZPFyOAWUu95GLgOzkPRfNm6MvYXwq3Q51pPtaCC8jgfwUDhnA7K9mmw+Mb4AjE4zeJlG6wfuC7Gdf+xZh76qflOMLG3kxCwG8NJuZg3z7Mms/6dH5ce5RJjqfGNXM2QxqthGQn/wzCt3mPIfBkWxUeBYGCJ1psmEv6b2oSnPXPu1hwIvyr5HHwBsr4JEceVZ+/zN2fkeXfjDQfQhQNX8SKFaDRXcxccIVFPxjJm9SPZBBeihiIBBAe6lHgLOyfEj2dRwXSurGAorXUAMIgkXGeifgggAAg22XBXBkeCqQgj5TUOPHgi1ogFoXYNiAdkIYMjJIAjBYhCOAhPoFeJhzdcynVF7ncUw4Oko3hbjjen5mLFZ4PFu3hYiwdNHkg4GHgCrnhQDUhSXYV2ZoBUcohpEAhiRFhhgnh5YAh1nlhlQIhF1ncmj4eE6YBLUTBA4yfkNYiIZ4iEOIhShXBPYjIXZBWdoWBMWxgzxYiRZmh32EhyXQiM4TA4EIBB4Ie5Y4io2EiSyniSTAiZZ0Sz8RFP/GdhgaUkuKFhQEIBOf90uzEW/0VBuB0lNxJy0AQotBQH6kWIzZoohzSAR/MkXTNSSAEV+kVADVVCFKwjG+pxG3oScx810J4BaPgUkuNATEaIzkaC7IOHQQYyCvM2J3IRhD4U8NFTPT1hoOsH1IIjzaWE+U5k+YNI+uMYzlGJA9do7op4zquIolsBhoEo+xFxjwxX/CYz9G81KJ0o3ilFEmgE0AKZAc6WYEeYAGuW4IWVNJFHcasosNWI9mokIc4z0USWkZCCgwJXob2ZE26SumuHN6+AUpSAIa2WU3GZTH2Id8OAY9+SfckUFCuZSqkpNBR4eVgIhSOZVUqUEf+YP/ObeGhUOUzjdXRdl8GgeVlOCUPaCEMXiVY6iFaTiCUkiCoUCWHSaWWHlXaBOFkLeWYamWdsl1X+mWg4WXyQWWfxeEWslOXAl2hAmYOOeXXZlnj2gEPfkDVTmZlFmZA4KWTUgEsKFs+AcDdWZnx6aCSsmUpKkpcBmHO7kDfxFHAIUEYfGJK1iasskqmJmHRLAZ7mUfb2JLE4lEM3REvCQeedEXMdUACGZoNYFpwfmBs9mct1KbV1gEDLYohWEfGqlNDsBNKtIdFAROPiktslaLuRUhB8JgQOmc6HmadyiXKIBARGEfBdMy0+FeFOReJWB84PdeI0Y/2LYxx4ee6Qmd/1w4BJFmFYBhnRF1Sd6kJ+yzHCWAkVaxoOIZJOHYFfr2nwDanOoZBGaJLwAiHrGhm3mhjyYGKL85U5p2F8O5cMY5nk9UEzJRcRiaobK5oV3FnkAAF4lWLTQ6mzYaW6ioA4chLWwwjj3Kgj+aYUHKCJbZpE56iAJKPnrZl225l4U5CElKajhqm3TJOVaqmOgYpYeQpTTQoWLKhlNHpXf5pWz6l23amHwZp7VApuG2pGi6paVypUB1mIO5h3AqmIt5poVApy5np1uZmkQgRVIgSi/xpI76qJAaqZIaqRJAiA3pap95AgIFBKEpPJmKA0Z6pKI6qnw3AZU6fjboFi3AqP+cSqSfOkqkGquyaoym6pj50xnAZT2XAT60eBg6VW8BQxT5iADBiD+nxRim1nnHNh+v04pylwOhOqvSOq08VKuomj8I8GpHMU1s4Z8SlRaz9yMMFI4l4K3cBRydCjsmxAPRSq3u+q7KYq3H1ycV6SYTEn3fGn0UMqz+KGj4anzOla5CggDuuKM00K7wmrAKuyry+hL0SmnbmmjeylFAQzQS2ZA/uUIIcn8Tdj/pREpjBKoLO7IkmzANC3vyREm4JgIohSQAgxg55S9VE6NAsVuAImjAihgtRqHRIU/sIxnQWrJCO7TIcrInQbRIm7SqYrQMobRO+7SWwrSxMqlUW7X/Vnu1WCsypzqlf8qYeUl0c6qnRvWHXwuFaiqnfbqmYwWmr1elalt0bJuFgPqEXtm1bmu3bxu2cbuIZBuYZou3aOuHc6sJhCpqhmqYiFpVYhtVfCq4aSAaMWqDx5S1lFu5lnu5Trq1mplSemeDoiGAkQmrUDu6UCu1P7CakptDnqsNrClHpPu6SGu6PoCbBuI9SbSzF9Kbg7FLAcOsoNGiJMAaKzaLiFGsBEAZG3ggmrGbN4CwsPu8zSm7PDCd84Y/Y3Su3kVdjIYcypFCdZZdJZB4rkCu5Iq84Lcd3XGdAZJD0Nu+Iyu9O+CeKlRDAItfKDIg/PQPNiJfB6YN4vsv/0DhGv1qvvq0FPFpsJ7pvgoMr/CbAwXKaPNLbhJ2SScUod77GA4mGv87AhmLTemFF1ixFBnbvAtcwtPawDjwoSKJJjWEu9KCRJjBS6wRjCLmv8I3U3ORkkq0ABJEnm9yqTLgvCY8xLSquQVBxEh8pChcVUncxAC6xG+JuVI8xVRcxchkxHWLmHerxXmruHubjINbtlmctoFLt42rhl8cpl38piCXxgUZxn47xo67xWS8uH9QuDJ3uCKlx2Nqx2/Vt4FacoDrx6eIp46Ax9/Gx2MLtlMAmzHAqh11fITMBG1oyNQRUcOjA5AMycM4yZ91xmwJBPbJXJE4A5tMpPzGxv91vMqqLAPu5TwMphm5FBcL0B22ixmyiLu9eEJSpAB08Yv3sYv+gnnKe4Kg6smtBcpiLMoKpE8FnBaUYSMMGjRsIY0cQ7C7l73ZiiPiJB1o4i/DKkrsgb56h8yZqMxxzMyVRzNJcRRVlF5JETP1q7KT0WqWwY9pEc4NwlOHUsrNOwdWrEyCirhDMMrbcRvtfAtVdCQqRSEcS88XFRiucZF+0i/WVCQM7chaBNCiisg2YKZFgEDBEZE24c4zJBc2Es8U4sIVWVO+HJNo0ZI1a2Zy0c+SydFH6tFamrg9wMnhm7rVgtM9qtNlqsjaRHkq8KprQNRsltMDvcdVKAdCbIn/TF2olsykQk2jVW24V02ekgnUW7DV2dDRT72nyujPoArWLFkFYp0OZI3OgYw+aN28ap0FbX0Pbw3ISaeMsghpk7cYD3JCdUIYuUso3gN6MPFbztoXif27xyXVAY1MZb3IEDONNVRD7mYcJ+Q+2tt7urfW44F6oA1/MGbOhazXbTtnDCRtJ0JJ6YNAv/p9YwQT/JsABCsU72kAtf3YrWzGZTzISLGLjLZo/qJN+FTBpXQUPQwTDsYjddHcpe3GIAnHcc06wg0biRF3twHDlBSjQmHLMYFi+AS0RiHevH22pr2ePN0D1Jkg0yLWdz2DXX2ojOwDVLFs712k6f2UqC23/3/Lxb+9zP09CfFthIrMuOsdOvvNdJON4Fkp3XNJx71NuAsehnC91w8+4QJe4aiZ4egN4VJa32764RrOtyKu4CCemV7LyiMO3CUOxl2qSGHN4epN3RiOskD8fa1wwy2g1EuY4lwq4SRO1yfAZT6eDnXtBAWehAd+VYa6IMVFGIbyPISx2JhHa7gaeje71liw5CIA0gMO47DXTdtcadvbHpqtvzXDjSSQG1y+WjTOoQ3u5NdKz/CGv7d9Iv9Lz/Lhq29uSnF+o2Guxmb3sLhWGDuSkPfof+O5j28BkUnuUwAd2R00538sjin7JCr2PC0DtDPc6Phxgd5nO1mdoV7+dv9NjqWlDqCn3nrznQinPtWV2OovmOqCEOt5beOpXZc2k+srPsc+YOSRbga47tQXvutBIOycRV9hUOxDbel/5ZpbceQfVgbOrtXQTsmQqXnXd9g3NYFy91uGAu7Etcs6eN5vIOs8SOsmAOZDsDHWV68XydgygsoSQh7axRvZzOaPBdmUvkHZ/slDcEG51u0R2pr4WdvMPs8vhu4AHug64O7Pd0P0F3EisNz1Th2AISXmGWHh1LEw2e8vfuNC7uI2cDUSJxQRNxjgDe7oJd4qRu6lhJ8Oz+ImH8qDLgOhSwanLvEl//BEsPNj0PO2ru2v/oUQr6TH7t9y7Nu6Pt0x7qf/QD/ybxz1a0v1TL/GQ47iWG/iv+70idn1Yq71N9/GYk/oSV+WaVr2Nr/hX0/hQB6dOQ/1TY/zTx/hS0/gaR+Xc4/3vJ7u/x74hWinLoVZYOjac11Jq+7Ec8TuKnAynyr0NuDT4rj4jE9HT95NuGooBMwAyklTxBQburbYJFmPuxpLDBBMSdHLdIH67Gr5l+9ImY+t2noLnW+eo0F5uoZ6C7kk2VHNEpOd01ETEZ0i1pxeowT7sa8wjo/qdW7wD5i8ZcJCceH5upbn9QyiAzJPo2G/B+JPltHQdLfRUr38hNT8rj6vM79rH9zD0JhCseayDKWQpAReSTFwHEX8FC3+/8kPAoA4kqV5oqm6sqQQwLE807V947m+873/A3+CFrFoPCJHg2RS4EQQCqJDoqEQHAAFwULBMDgFjMbCqWggDgLFIkEIJwBvp8OgxmrDBICjzCjszSk4aO0hCCAwnQwpNjoavQRJTlJWWl5i1jA+cnYmLXmGip4AjjJtmqYeRWa2ur7Cxt6gqtZygtrmJpXqstD2AgOwyhIXGx/j/AYvp+AyP0P7RveGVVtfY2drb3N3e3+Dh4uPk4dNnyuhq58rr3c6uy/Dx9fO0+va3+uHtu9/+gPLB/DWQHwFDzrqh5CFwIWPGjo8AjEik4kUKSq8aMKixiIcO6L4CHKFyJH+Mv+aLGnyhMqVLVeSeAlzHcqRMmfe7JjT5cyONUHuTNnT49B/RSP+1HlU4lKSTYk+PZhUY1CbUUNeZZh14NSLVYFuLfFV6T4wKqLwEUBIY1eKY6mGjRkXq64tifLcTWE2BVq0PqO+9TpXRGC3vbZAAHAI0Yq9KNA+iACybcTClQcDsOxQc4kCBRY0gGAXwAMzDUg7WWDWwYE9pdc08MvnioAHSAFjFouZM0LeIwr8SdAGEYEzABQQIHDgLhjWBuQYRy67OFvcudMN9l1QuxYGCWqDQcCgGoPyI8AsSAxgfBgGshGUVhDHIeXN17HP5Q6QO3AAqsMXd5oIyjEngAELBGL/3IBSlKDcbU+VE6GEE1JYoYUXOnEfYYcxcB5jrwkQxxZcrLZAhyC6waAccDzY1DDIwBijjJjU15N+GqpQI0Ivztijjz/OguONOKKgo1RAIpkkkkbyROQ0THKlpJRTIgOlVU5GY+VJVHLZpStakgWMY7bIBhCY+vDopZpr8nCmYMGYVWYLvPBylopmRpUmm3vyKYObhsFZX50tyLnPn/Ho2aeiax5qny52mBPFIYSAEZsTBxAS4h1OJFDKHGq1phhxUoR6CBR3KECbZNA0StOir/bZam+9IAhAnFL09wADfRACgW21iUAnAQ4YOEKpowJw7KkIHLLHH1nmiaG001Jb/6211wipi6m2DoHWgaZ+F0YWxRYSLAEJZGGsIcgq61exhQIjKzpD6kOvOvbSw12tb8jB4AEHSMGrC89poR4gxBLc3YpQ4NrhGwyL8O6dy8h7Dr7xXDxNxutwF+4V/YrwHcGfdkhuuJ0GEkYdZiALxhrICvMcvNRYd9/G0Nw8L5bQPpWzxbtlu/MzFWscdH5GCx0M0dH4XHR2SCdNc89Qb9U001FTXPN1VgdENda1LI2z11dx/UzZg4Vt9tha53b2XGkz43Ywctez9tejwC2P3U3R3UvfWeU9995L/Z1L4XmyDfTTGh4OYeKLH8343VLzPfhRjauC+QgzXxR415JDvv81hyIcknAS8PJCripjKuK535YXpbkp/HUoqulIoL5Hi4TDPpTso9BOerGvnQGGGgu8lhgCtCUmabFgfCoyalyQ8GyycWj6xR0i3lHA8QiYtbwTtiHhukGgR27zYdYYEOBxBIDxHMAAfEeabX20L4V55qXe/nImWI8KwiBfGwAQgQVoQQrSa41ZHjCxVTwufXH5nSiCZzv2OOELjCiFWQSohRTZagHb6p95AOgv7D1nMWFAAAc3CL8hePAUEZyg4tRXl9qVzn0i2EsL7ZeW/AVLAeQrgHoMRCATOOhAKBRBAX+zBx6+kDQPhMQMw3KtK1Kod47oj+2mFyIocksxzAP/mQFNxqlijQiBI0jDGgpILkjhoYeFCB9tyAfBqWkoUbASghb1wbkdVXEretxjD8x3L5AgYAGr+gse7zNIQu7AkDqbXC4kWbc8QrISlnQaJcEWSMBlkhKbvBpABnWUUc4OR48MZZDQtw9TFgWVwFMlKyUhy7gNBJZDuWUoKMiPWgaBl4LTBQRUFioyREA5ajAOiPaQvQNxgXtO8B4XEjEHTJ3kk1dZJTBnIMzPVXKR6KJfFghEBjf8rxTA8s8ehNMAz9CvWK0RmK+y2cjrYDGf5eijIpQjhgaQwQDyISMVSqjOFDJGGCx8ogvDdSl7Vs6VYfGlJ4ZUwOKo0S9UUA5A/0NFrn2BRo4HW8Ba8HTPttVQdLkgg2kA0AAB6E6jVbjCAjxKMGgWUKQpyyBEeSfRqvGzEwcSUB61aVTfBZUTClCPKo8aUQmitJOePGlKJ5pUqRLhmwT5aVYo+g6sqkKrD7kqWLgKVk6I1RFe3SpUq3rWTqS1EWsda+ii+lZ+ONWnba3rXR8RV0XMVa1u5WtfG/HXipA1TCotLFrzernB7pWxTXBs7CBLQ8n6lbJIJWxkD6JLInyWCKxrnWZtZFmr3lB4t9uF7k4gnGmW1ImNGC0Zi3BYo9iws6jNBRdL94jPvlQyDXjAfEgQ2hbQdrJU5WxpcTK6LhKvAWCgKSEEUf9dlRWANrUbwUtbOyDsaleMTlBeeJUJGzryFC3Z5WmOmguTwDLFrKMYURjaF50XPgc4xCLEHxD2GymEJ1xZ6FQGG+DfYAEYEQ+4n2p0pRiSmrMNDexQIh2g3gTnZRHubZJugZraC5JnL+UZp62okC5ziSrDJLACBEiMYlN5sADoqgYIr9dBGqt3XSouwW2RAN/W6TPI4EhsEXprRAWFcT27UosUD1yubZ2nAISwwrBUVwpTLfiHDt7cCSdMghynuL3LfVs3+ShfURj5OSgSscPMcF06XDmhpAMR+T7lgDgza4zie4JM0ctnXOlYzE/FZ5l90ONZYjYhGzYJNwsdgEP/VzDRih5zXBpdaEj3UtKGXfRILF1mTFdU06SltBUd3SYiYxbULfjxKUwdSVRLVtVawaSrcyBruoq6fJyeTK1tDWsWrFcM6+mygUL0shAlS8fxM3ZLMbJrnwg52tz49QoKcD+1BDAB0ItYIBCorG2vUQCLpM+z4cLc3doidQnItmOeh4hvM+LOLHI2qT3c4a4eZg8RIE4WlNju50AgC/15mIgV4FJk03vQdr1sbtOtB8UsU8KbENdzXHYF8DECmmooLrnrje9z2zvd3l2B6rZZ7jfdm2z5tu1qXXRyQKX85We9tQpYjVuGLzbXVPS4ykH+cZ3vXOGnFbrPgc5jmTsq/+Y8N/oIaN4Mai/E5j5mum2RHvWh/5zqJLf6rIrO9U46nS4NR/fCtZ6CsLME6l0fu9k1vPS3m/bMbRfG1wsi7bvjPe/hmEzLi/BHyumV0L0evCWINoe+H+Ggjfi7LtC+EVoSPvK2VBrim1B5FjC+knWPkuQ7b2jK10/JwhmQwa+ZKdqIyJlqbnYQebrn5hXAt5UK9nbDunkzeT73r46XAUJfnnP6JwH0/FUgBK569yHHuNd2QJbxh5b9dcjaaYmtKRyvG1rrPvuaAD0jzBOFCAy4GuN6zjgPikFhy1YY6JqPjL0lQsao2xbWlwv2tW9/GCytdOFZHoWxsAeBNR35Gf9fzOhQZ+ibgl0bEGmBEKHYvu2YKMwffgje/d1fxYQLg2xBF9QOA4DGd/FUsZSf6nkRx9GXIYyRX+wbwZSg5sHdUngaBTpaBJYLoajIcUHg7W0JDNqfDNog6ShS+jUeDhqK3hFhERbh3Ala4JVdyC0hEjadENYL1vWcE5qADGaG2h2E1MUXFR5dCz6W13mhzlmhFhoBGdYcFs4cFN6DGT6d3LXdGKLhQLDhqnFhFaphvkjhHe4MHLrhF7IdF/LhH05hztUh3YXhZikd0THDHPQgNDRiY/xCIBIiE+ahXz2BCbxUfo2cJ2ReCjyiCoyWJDbhII5i9bUcsaCYKXQiCnz/ol5Eoh66wxymXR/Clcz8C2zcwR/swR1gExZkkBlwy/EkTzxlkAoxwOv1yxvAU8EYV3ghY/KNwAMkRnSFIixyTCUqoinKwXKcExgZS2LA1Hosh/7JkwKhwnfEBoM0n2ooB0Ixi5xpwfKtowHUU39A2H1V4yHGXSIqIdjIDLGZSwNgUMn8Y8QYABiZRQLQBszEWI0VAgTU3gxqCvslwAG5gQIc0HqE2Cvqo3OhjREeITUUpI01lACchhfEDBkZCELCUGI4IHX4EMLIhh2QlAGWEXwkoH+IEAEgD3QQVT5mI9kJkg4SzQr1mQvt2QEQpEoepAuF0TUhQh+IATKWiQI8/9AKIqMUHdx8rBlHBiUlghIMWiESBJTSWOMhoQ1RCg0EGJxZduR7YcYLmtpY2t1ZThKZiWUhuoBd/kxa5mWgCI0oYuNMyGUMLsOtOIlggmFPFOalHSZdBl0/LiZhquWjbArIFBMd7FmHOBRnlgFMbeZk8CUnVRpIEiGtMBTIiFs0UlhNhoxJEhFrPhj1ddxXZp1QTiYTbAti+tMYbEqIKOQKCZQASNlvctzu+OEk3uZgKsK+dMudtMGWTYFLypmuSKdoviWH4VwpioLHPCdLwcaeEcelIMKIYIp4PiAgZadQ5GZl6WXEjCYp8WNyFqJizqd2cufc2ed2guV95pppAv9ogArogBJogWqDBQDdfuImKTKnGMan2LQnIuqlgvbng6rNexqibTLockaoqFEoh26of3qoheJSh3rke35oiJKo3mBoiq6oLciiU7Toi4ITf5qopLnoKLDGOpFmNBTTJrJAadDmrInCj+JOOA4Tip6OE0iGkXpCaYwbYJnCZyKpCWzBkKJAGRBVph0BsYSBlD2CkxqBkE4dErDHAUDAloqAmPpdlb7OjB4pHrDpI0ApW4nCFWDpcZhkEWhpKnXpGnBLWzbCnLYAmW5hERgpC9EmoWKem56Pkh6pGjCAkc4YsLzTpTQpcZaBbXzKASRTGJTewx1qKOBpGaUKbIBIBID/SOzt26meAYgwVaj9qcG9FGhwwRY0QKXaxqU6AQEMVxhEQDF9hqWap3AVK2rkaRuOKXGm6eaEAQQI66au6cPxqqeuiHetqjWlhgAkhq6WKaQewRsUB3HCFLEY3HgkAJQ2wAGAhpGWQUkpI2pIxhskhhqkp7LeKZPtG66EY59GI0ztax7sgb9G2qzG0wO8lMoAKroW03aVRmu5q1qoK7v+agSsK2gYahkiwY6aARTwaMRaGLfmgaqK28VaCpA+LLGUE7eaq0YeJ5FO6JK+UK9+ynj16RUEazjiaQTQl8HVKYgw6ah6Qqnum21E7Gn403gVLQAcrZ8agZeOD0BRz4pU/wMEcCxJEayR4unNihvXkmyyit0RhMYWEECdTuse4GmdFhMEeK24ftmmQMAbcCq31qzIaiychms4ZmaVCaq8mqzWqkUZGEDLlkYcvEFE3u0oEC2wHC2xIBC9Lm3E3qtcbSygctfUtqwJNOzDjgDgMl/JUuzEYiyTCW2Q6g66ym3n6qxa0OvIiu7JjoDjrggETNfsZu7N1afMTkE4VipM8SpGMu3qhuzLGJxUhqrKlO4jUCkBRG6/7inxcGvz7lSsfpXBXq4akZMeZOuvMqnn/q6xmoFkZCxUGEHZpkZMPavnBi8X7MH3XisJQG9iZOYVdOumAOkZ4q1kimhZXcQWvP/st8bsel7J/kLDQlIvYuUvfTYoewqiE+aohrpnAyPhA5OAAvyPOliBCOFuIyTSFDlCBk9u8j7CeERpIxSu0wYwBJdAMS3SxYpCM7EAsdhR4j4CGwgIDJdAwgLrCsiwrIrCvqlH2VKfDgftCvwLCuduGHaB6k7tkybCFVweaoTwLD4CGDDVAzxxyR3cnhJBaUwxERTGZwiIA1xBAbSwE6jpWSAcl4Kr/oKioy4A9qrusDJAadQkGU/TveKsh/TbOn3H/eLvI7zBau3xilUtCRgPt5DPH1evKCzAxPDsGrTvIZPAu/pHuhzCDDdyCrtxCnzHccax5jovAnxHh1DsdO3/23j9Bh5UsLiNB8EQywHDbCOMh4ptQRakst2KwBVwHM6+sgjE8iZ3wiEgbhmR7i6vcfC2WJUuccG2sQKzwCeXQCivsPM2QNG2bMKq6Y66prM+QDOnhSzL6AjLGTcnK5vKLTgHs50OM/qNQCRDo+p6l8qK8QiAsw9zMjRD4shRMwkc7dKesuXGrpudwPaMACOLcN7CMkGbgKoiM/UZ9GsCckI3p4rgsRm/M/mUKvyyl6hoMjvXIQUzkaBmZq/6szUvLR4Tp4pB7fhU84lJMQDPlt22NI+SDi++bDHBtBcLcyfUsxw8APWxERa8bCrDazL3NCBSFgtPg5j2sEw3gg1z7YJT27RgjQIQN0LAGgtM43MSq3AJWPAXp0IcCwgIb7AidDAnkLUImHVScwIJK8IWLNIJI9ozR7ByquiCOjCNvikB42dI8/Wj2qhfp1pgG84C72M+33V+dnKFTrBhwyhin6hiSyhj6/Ng77UA8y9m6/Vja7ZidbZj6ydkXxJhDzBlJ7ZlL7Zk4yhpZw5r/7VSf7a5mfZmF2IFRAUF4IhuDwZv34dvY2hwC/dwE3dxG/dxI3dyK/dyM3dzO/dzQ3d0S/d0U3d1W/d1Y3d2a/d2c3d3e/d3g3d4i/d4k3d5m/d5o3d6q/d6s3d7O2EIAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38382=[""].join("\n");
var outline_f37_30_38382=null;
var title_f37_30_38383="Evaluation of postnatal microcephaly";
var content_f37_30_38383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Evaluation of postnatal-onset microcephaly",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 478px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Practice Committee of the Child Neurology Society. Practice parameter: Evaluation of the child with microcephaly (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2009; 73:887. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_30_38383=[""].join("\n");
var outline_f37_30_38383=null;
